var title_f18_14_18656="AED for primary generalized tonic-clonic seizures";
var content_f18_14_18656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61530%7ENEURO%2F79951%7ENEURO%2F68910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61530%7ENEURO%2F79951%7ENEURO%2F68910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of primary generalized tonic-clonic seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drugs",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily adult dosage*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily pediatric dosage*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Usual dosing interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Primary generalized tonic-clonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Drugs of choice:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Valproate",
"        <sup>",
"         &bull;,&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3500 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        15-60 mg/kg",
"       </td>",
"       <td>",
"        Once/bid/tid",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Lamotrigine",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        12.5-50 mg",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        100-700 mg",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        0.15-0.6 mg/kg",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        1-15 mg/kg",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Levetiracetam",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3000 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        40-60 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Some alternatives:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Carbamazepine",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        800-1800 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        10-30 mg/kg",
"       </td>",
"       <td>",
"        Bid/tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Topiramate",
"       </td>",
"       <td>",
"        25-50 mg",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        1-3 mg/kg",
"       </td>",
"       <td>",
"        5-9 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Zonisamide",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        100-600 mg",
"       </td>",
"       <td>",
"        1-2 mg/kg**",
"       </td>",
"       <td>",
"        6-8 mg/kg**",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Oxcarbazepine",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        300-600 mg",
"       </td>",
"       <td>",
"        900-2400 mg",
"       </td>",
"       <td>",
"        8-10 mg/kg",
"       </td>",
"       <td>",
"        6-51 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Phenytoin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        300-400 mg",
"       </td>",
"       <td>",
"        300-400 mg",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        5 mg/kg",
"       </td>",
"       <td>",
"        4-8 mg/kg",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dosage may need to be adjusted for renal or hepatic impairment, or concomitant use of other drugs.",
"     <br>",
"      &bull; Measurement of serum concentrations may be useful to guide therapy. Usual therapeutic serum concentrations are: carbamazepine 6-12 mcg/mL, phenobarbital 15-35 mcg/mL, phenytoin 10-20 mcg/mL, valproate 50-120 mcg/mL. Some patients achieve complete seizure control at lower concentrations, and occasional patients need higher concentrations.",
"      <br>",
"       &Delta; Not FDA-approved unless absence is involved.",
"       <br>",
"        &loz; Once daily for the extended-release formulation (Depakote ER).",
"        <br>",
"         &sect; FDA-approved for adjunctive therapy in adults and children &ge;2 years old with partial seizures, with Lennox-Gastaut syndrome or with primary generalized seizures, and as monotherapy in adults with partial seizures as a substitute for carbamazepine, phenytoin, phenobarbital or valproate.",
"         <br>",
"          &yen; Starting dosage is 25 mg every other day and maintenance dosage is 100 to 400 mg daily when given with valproate.",
"          <br>",
"           &Dagger; Starting dosage is 0.15 mg/kg daily and maintenance dosage is 1 to 5 mg/kg daily when given with valproate.",
"           <br>",
"            &dagger; Not FDA-approved for this indication.",
"            <br>",
"             ** Not FDA-approved for pediatric use.",
"             <br>",
"              &bull;&bull; Adjustments in maintenance dosage above 300 mg/day for adults should usually be made in 25- or 30-mg increments because metabolism becomes saturated.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drugs for Epilepsy. Treatment guidelines from The Medical Letter 2008; 6(70): 37-46. Copyright &copy;2008 The Medical Letter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of partial seizures including secondarily generalized",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drugs",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily adult dosage*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily pediatric dosage*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Usual dosing interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Partial, including secondarily generalized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Drugs of choice:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Carbamazepine",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        800-1800 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        10-30 mg/kg",
"       </td>",
"       <td>",
"        Bid/tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Lamotrigine",
"       </td>",
"       <td>",
"        12.5-50 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        100-700 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.15-0.6 mg/kg",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1-15 mg/kg",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Oxcarbazepine",
"       </td>",
"       <td>",
"        300-600 mg",
"       </td>",
"       <td>",
"        900-2400 mg",
"       </td>",
"       <td>",
"        8-10 mg/kg",
"       </td>",
"       <td>",
"        6-51 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Levetiracetam",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3000 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        40-60 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Some alternatives:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Topiramate",
"       </td>",
"       <td>",
"        25-50 mg",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        1-3 mg/kg",
"       </td>",
"       <td>",
"        5-9 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Valproate",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3500 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        15-60 mg/kg",
"       </td>",
"       <td>",
"        Once/bid/tid&yen;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Gabapentin",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        900-1200 mg",
"       </td>",
"       <td>",
"        1800-6400 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        25-40 mg/kg",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Zonisamide",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        100-600 mg",
"       </td>",
"       <td>",
"        1-2 mg/kg",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        6-8 mg/kg",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Phenytoin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        300-400 mg",
"       </td>",
"       <td>",
"        300-400 mg**",
"       </td>",
"       <td>",
"        5 mg/kg",
"       </td>",
"       <td>",
"        4-8 mg/kg",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pregabalin",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        150 mg",
"       </td>",
"       <td>",
"        150-600 mg",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Bid/tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Absence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Drugs of choice:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Ethosuximide",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        750-1500 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        20-40 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Valproate",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3500 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        15-60 mg/kg",
"       </td>",
"       <td>",
"        Once/bid/tid",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Alternatives:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lamotrigine",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        12.5-50 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        100-700 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.15-0.6 mg/kg",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1-15 mg/kg",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Clonazepam",
"       </td>",
"       <td>",
"        1.5 mg",
"       </td>",
"       <td>",
"        1.5-8 mg",
"       </td>",
"       <td>",
"        0.01-0.03 mg/kg",
"       </td>",
"       <td>",
"        0.05-0.2 mg/kg",
"       </td>",
"       <td>",
"        Bid/tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Zonisamide",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        100-600 mg",
"       </td>",
"       <td>",
"        1-2 mg/kg",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        6-8 mg/kg",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Levetiracetam",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3000 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        40-60 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dosage may need to be adjusted for renal or hepatic impairment, or concomitant use of other drugs.",
"     <br>",
"      &bull; Measurement of serum concentrations may be useful to guide therapy. Usual therapeutic serum concentrations are: carbamazepine 6-12 mcg/mL, phenobarbital 15-35 mcg/mL, phenytoin 10-20 mcg/mL, valproate 50-120 mcg/mL. Some patients achieve complete seizure control at lower concentrations, and occasional patients need higher concentrations.",
"      <br>",
"       &Delta; Starting dosage is 25 mg every other day and maintenance dosage is 100 to 400 mg daily when given with valproate.",
"       <br>",
"        &loz; Starting dosage is 0.15 mg/kg daily and maintenance dosage is 1 to 5 mg/kg daily when given with valproate.",
"        <br>",
"         &sect; Only FDA-approved for adjunctive therapy.",
"         <br>",
"          &yen; Once daily for the extended-release formulation (Depakote ER).",
"          <br>",
"           &Dagger; For children more than 5 years old, 25 to 35 mg/kg/day. For children 3-4 years old, 40 mg/kg/day.",
"           <br>",
"            &dagger; Not FDA-approved for pediatric use.",
"            <br>",
"             ** Adjustments in maintenance dosage above 300 mg/day for adults should usually be made in 25- or 30-mg increments because metabolism becomes saturated.",
"             <br>",
"              &bull;&bull; Not FDA-approved for this indication.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drugs for Epilepsy. Treatment guidelines from The Medical Letter 2008; 6(70): 37-46. Copyright &copy;2008 The Medical Letter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of atypical absence, myoclonic, atonic seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drugs",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily adult dosage*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily pediatric dosage*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Usual dosing interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Atypical absence, myoclonic, atonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Drugs of choice:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Valproate",
"        <sup>",
"         &bull;,&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3500 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        15-60 mg/kg",
"       </td>",
"       <td>",
"        Once/bid/tid",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Lamotrigine",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        12.5-50 mg",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        100-700 mg",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        0.15-0.6 mg/kg",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        1-15 mg/kg",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Levetiracetam",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3000 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        40-60 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Alternatives:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Topiramate**",
"       </td>",
"       <td>",
"        25-50 mg",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        1-3 mg/kg",
"       </td>",
"       <td>",
"        5-9 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Zonisamide",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        100-600 mg",
"       </td>",
"       <td>",
"        1-2 mg/kg",
"        <sup>",
"         &Delta;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6-8 mg/kg",
"        <sup>",
"         &Delta;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Clonazepam",
"       </td>",
"       <td>",
"        1.5 mg",
"       </td>",
"       <td>",
"        1.5-8 mg",
"       </td>",
"       <td>",
"        0.01-0.03 mg/kg",
"       </td>",
"       <td>",
"        0.05-0.2 mg/kg",
"       </td>",
"       <td>",
"        Bid/tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Felbamate**",
"       </td>",
"       <td>",
"        600-800 mg",
"       </td>",
"       <td>",
"        2400-4800 mg",
"       </td>",
"       <td>",
"        15 mg/kg",
"       </td>",
"       <td>",
"        15-60 mg/kg",
"       </td>",
"       <td>",
"        Bid/qid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dosage may need to be adjusted for renal or hepatic impairment, or concomitant use of other drugs.",
"     <br>",
"      &bull; Measurement of serum concentrations may be useful to guide therapy. Usual therapeutic serum concentrations are: carbamazepine 6-12 mcg/mL, phenobarbital 15-35 mcg/mL, phenytoin 10-20 mcg/mL, valproate 50-120 mcg/mL. Some patients achieve complete seizure control at lower concentrations, and occasional patients need higher concentrations.",
"      <br>",
"       &Delta; Not FDA-approved unless absence is involved.",
"       <br>",
"        &loz; Once daily for the extended-release formulation (Depakote ER).",
"        <br>",
"         &sect; FDA-approved for adjunctive therapy in adults and children &ge;2 years old with partial seizures, with Lennox-Gastaut syndrome or with primary generalized seizures, and as monotherapy in adults with partial seizures as a substitute for carbamazepine, phenytoin, phenobarbital or valproate.",
"         <br>",
"          &yen; Starting dosage is 25 mg every other day and maintenance dosage is 100 to 400 mg daily when given with valproate.",
"          <br>",
"           &Dagger; Starting dosage is 0.15 mg/kg daily and maintenance dosage is 1 to 5 mg/kg daily when given with valproate.",
"           <br>",
"            &dagger; FDA-approved as adjunctive therapy for patients 12 years and older with myoclonic seizures.",
"            <br>",
"             ** FDA-approved as adjunctive therapy for patients with Lennox-Gastaut syndrome.",
"             <br>",
"              &bull;&bull; Not FDA-approved for this indication.",
"              <br>",
"               &Delta;&Delta; Not FDA-approved for pediatric use.",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drugs for Epilepsy. Treatment guidelines from The Medical Letter 2008; 6(70): 37-46. Copyright &copy;2008 The Medical Letter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18656=[""].join("\n");
var outline_f18_14_18656=null;
var title_f18_14_18657="Small bowel leiomyoma Light";
var content_f18_14_18657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Small intestinal leiomyoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 202px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left panel demonstrates the submucosal location of leiomyomas that arise in the small bowel. In the right panel, high power magnification reveals bland appearing spindle shaped cells and an absence of mitotic figures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Saint Aufranc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18657=[""].join("\n");
var outline_f18_14_18657=null;
var title_f18_14_18658="Bipolar sterilization C";
var content_f18_14_18658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Bipolar elecrodesiccation of laproscopic sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 332px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFMAckDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorxG28ZeIvh/wDFhfD/AMQtaOpeG9bXGjanJbRQmGUEfu5fLVR/EFLYIzsPygtt9uoAKKKKACiiigAooooAKKKKACiiigCnrGoQaRpF9qV4WFrZwPcSlRkhEUscDucA1crL8U6fHq3hjV9OuLgW0N5ZzW7zkDESuhUtzjoDn8K1KACiiigAooooAKKKKACiiigArD8a6jcaZ4duJrFgt9K8VrbsV3YllkWNDjvguD+FblZ2r6VHqkunNNI6rZ3S3WxcYkKqwUH2BYN9VFAGjRRRQAUUUUAFFFFABRXi3x/8YeINF8T+A9A8Ka2NKu9cvTbTyC2iuNiM8SKxVwehdsYxnB54rU/4Qn4n/wDRXP8Ay2rX/wCKoA9VorxrUPB3xjjRzp3xQsZ3H3RPosEQP1IRsfrWZbeFPj4zgXXxB0GNO5js43P5G3FAHvFFeAz+HfjzamSW7+InhuCyTlpnto1wPUg2wA/OuGsfFHxhvYjcQ/EHQls5dX/sWyne2iK305YKDFtt2ynP3jgUAfW9FfLfje5+O/g+LSW1Dxpo1zJqmoRabbRWttEzmWTO0kNbr8vHJ9xxX1BbJJHbxJPL5sqoA8m3bvOOTgdM+lAElFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHG/FvwNa/EPwReaHcOIpyRPaTn/AJYzrnax9iCVPsxxziuO/Zy8a32q6Re+EPFW+LxX4bb7NOkzqXmiB2q4x97bgKWGQfkbcS9ex187ftD6dqPgbxpovxV8NRlmgItNVi3fLIh+VCR6EEoTngiMgZ5oA+iaKpaJqVtrWjWGqWLM1pe28dzCzLtJR1DKSO3BFXaACiiigAooooAKKKKACiiigDmvib/yTbxZ/wBgm7/9EvXS1l+KZLCLwxq8msxmTS0s5mu0AJLQhDvHHP3c9K1KACiiigAooooAKKKKACiiigArPsdVhvdT1OyiSTfYOkcrkDaWZA+B9FZSf94VoVzvge1ni0+/uryKSG6v9QuLl0kXDBd5SPP/AGzSOgDoqKKKACiiigAoorjfjF4mbwf8M/EGtQl1uYLYx27IASs0hEcbYPBAZ1J9getAHj/h+CH4jftW6prKFbvRfCsCwxu0e+MzqCqr83QiRpnVhnmIEdQa+kq8h/Zd8IL4X+FdjdzJjUNaxqE7EhvkYfugCO2za2Dkgu30r16gAoopk0scMLyzOscUalndzgKByST2FAHzJ+134hl1bVdA8Babaz3UzuNRuVtkLzEAOqqig8nb5jEH/Z6V03w48G2l147020kghm0zwHpkNgAtuPIk1eTDzzxtj5mAEZOeQzKeCMngtJmaw8c/ELx5ryW+sXekzLJpbRP9oimlmJSzSB1PzIAWDAcjC8ZU16nYwxfA34DXVzdSJLrKRNcTO5L/AGjUJcAA8gsA21SRglUJ65oAp2MsXxA/aOuLhD52jeB7UwLkgqb+UkMcEdgrDPZoQfSvbq8++BXg9vBnw4060vEYavdg32oO+d7TyckNknlRtQ+u3Pc16DQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUNf0iy1/Rb3SdVgWexvImhmjPdSMcHsR1BHIIBFX6KAPAP2dL288GeJPEHws8RSn7RYStd6VLJ8ouYGOW2DJAB4kCgkgtJn7pr3+vB/wBpDTrnw9r3hP4naXExfQbhYNSMbYd7V3ACgE7cfPIhwM/vh2HHtuk6ha6vpVlqWny+dZXkKXEEm0rvjdQynBAIyCOCAaALdFFFABRRRQAUUUUAFFFFAHN/EtWf4ceKlQFmOlXYAHJJ8lq6SsrxZqb6J4W1nVYo1lksbOa6WNjgMUQsAfY4rVoAKKKKACiiigAooooAKKKKACiuY8ZO1xf+G9MjZgbrUUmkx/zzgVpufbekY/4FXT0AFFFFABRRRQAV87fH0nx/8VvBvw2tZd1qkn9o6pscEKuDgHGSjiMSYzjPnJ6ivoS6uIbS2luLqVIbeFDJJJIwVUUDJJJ6ADvXgP7NST+LvGfjj4lXyOP7RufsNjvIDJAuGKMoAU4VbdQ3Jyje5IB9AxosaKkahUUAKqjAAHYU6iigArw/9qLxJFD4X/4RxDcOlwqXuri0K+dBp6yqhkUMRkmVoxjuA4OBlh7VeXUFjZz3d5NHBawRtLLLIwVY0UZLEnoAASTXy/JdaTrvxN1rxx4iu7n+ydANtqbSRxFmgQMTp8cJ3k+VcRyiZ12jDqQ2zNAG38M/AtrD4j0Hwg7DZ4N2a1rSIW2XGqTqDBg8ZEaKTkcHgYOWx0Hitrjx38ftD8Owu40Pwkqazfsm4Brs8woTgjIyrAHBKmX0ro/Dir8M/hvrHiDxdK7X9xLLrOqrEwYC4l2jyYsnGBhI1GccdcVB+z54cutJ8Gza3rUJj8Q+JLmTVr/KgbTIxKKAPujad208guw9gAen0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBl+KtEtvEvhvU9Fvsi2v7Z7d2CglNykblyCNwOCPQgV49+y1rF7Ba+KPAupSRzyeFb5raG4Vj+8QySKQFPOFaMkHPRwMDHPuteAajYv4a/a80e7tYjDZ+JdNlSaQcLJIkbFh9f3UJOO7A9TQB7/RRRQAUUUUAFFFFABRRRQBieOLC41XwXr+nWSh7q70+4t4VJABd42VRk8DkitusHx/dz2HgTxJeWcrQ3VvptzLFIvVHWJiCPoQDW9QAUUUUAFFFFABRRRQAUUUUAVJdPt5dUt9QkQm6t4pIYm3HCq5Qtx0yfLXnr19TVusrw3qp1mxnu/KEcS3U9vEc53rHI0e/2yVJ+mK1aACiiigAooooA8e/al8SSaP8M5NI04yPq/iCZdPtoYGzK6kgybU6sCv7s47yr61o+EtJfwjH4I8B6TNLbzWVs2o6jNCm+KdQCsiEtyN80u4dMBO3ArgNQmHxG/antbdZGk0LwZEZZDuPli4Qgk56BvNKKfUQn0r1/wCHt5b+Il1HxTbqrx38zQWsyk4ktoXZUYA8jcd7duo9qAOwooooA8z+O3jYeE/CF0bOYfb1CSsEVZTCmWKGWPr5UskYgLcAeZ1yMVxXw+8HpLd6L4fRktJbC+XxZr9vZnyBZXsoVrazWPLDywoYFeTiMHK7gDQ8Zalpfiz40WmmSpPEdFmbVdZvLlVQWVjbqrfZWGcSxPKiSk/NjzhjowHpPwqLWfg7U/GPiORrebWZJdXnNzgtZ2uCY4S45ZI0BIOBwx4HSgDmPjdeQ+L/AB54Q+GCSusN9ONR1XY7KGtoldhCdp/j2MefulYz6V7dXiP7PGny+ItT8S/FDUlxdeIbh4LFDgtDaRtsCkjgkmNVPH/LIH+KvbqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOZ+Itx4ptPC89z4Gt7C61mFlcW96rFZkH3lXDLhumMnHUdwR88fHXxeuu+H/AIYfETScxpp2oOlzD/Fb3OY3MTA85BhfqORg9CM/VtfN/wC0n4L1DQvCXijVvCabtJ1t4pNcscZEbpKHF3HzwSwCuBnIbcRxlQD6Mt5orm3int5UlglUPHJGwZXUjIII4II71JXm37OWqx6t8GfDUkbMWt4DauGbcVMbFP5AEDsCK9JoAKKKKACiiigAooooAy/FOnx6t4Y1fTri4FtDeWc1u85AxEroVLc46A5/CtSua+Jv/JNvFn/YJu//AES9dLQAUUUUAFFFFABRRRQAVDevNHZzvaxiW4WNjHGSBubHAyemTU1RyTRRPEkkqI8rFI1ZgC7YLYHqcAn6A0AZvhLTG0bwxpWnSkNNbW0ccrf35Ao3t+LZP41rUUUAFFFFABXNfEjxTD4L8Daxr8+0mzgLRIwJEkp+WNDjnBcqCewOe1dLXzl+1NdXPifxP4L+G+mMVm1K5W8uW8snYhJjRsg8qB57MP8AZU8UAYPgLSdX0b4FXuo28k0vi/4gXy26TSORIEkZlDnceSVM0m4Y/wBYPTNfTPhrR7fw/wCHtN0iyH+j2NvHbocAZCqBk+5xk+5rgtFFrqXxWXRdNgQaJ4L02KFABxFdSqQqDP3gsKjnsTXp9ABXCfGTxdF4U8IzFHJ1K8DQ2kSlQXIGWOWIAAXq3YkdyK7uvmn4/wCsR+JPiNYeEnv4bTS7CM3OrPLEyFIMK7/vMZwwKrhe496AOe8H2ep+HfCuieGo7YL4v8faiLq5SZdzW2mxkZWUMdxBUSEDH3WcZBHPqP7RGqzy6PpPw78NNDHrPiaRbZVWTyxb2qkF2IHRSBtxjlQ4AOMVS/Z709/FWta38UNTtjbyamxsdLtt25YLOPanHPUlNp4HKMejUvwpa48efGPxX48mZX0TTgdD0YjZIjhTmSVG4IzjdnHInK7iFIoA9g8NaLZeHPD+n6Npcfl2VjCsEQIGSAMbmwBlicknuSTWlRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXJ3/AIfvIPiDYeIdISJlnt2stSWe5dQIh8yPGgBUuGGDnHB/EdZQc4460AFRXdtBeWk1reQxT20yNHLFKgZJEIwVYHgggkEGuM+GvjqTxVLq2maxpraN4k0mfyrvT3k3/KfuSo2BuRh0OP0IJ7igDwT9muSz8JeIPG3w4eST7Zp+ovfW7Srhp7dljTdwMZAEZ99/HAOPe6+bP2jrefwL8S/CPxO0+JDDHKtlfJHhXlOH/MtF5i5PTYvtX0jHIksaSROrxuAyspyGB6EGgB1FFFABRRRQAUUUUAZfimSwi8MavJrMZk0tLOZrtACS0IQ7xxz93PStSub+Jas/w48VKgLMdKuwAOST5LV0lAFXUtQstLtWudSvLeztl+9LcSrGg+pJArDbx94S/wCWXiTSbh+0dtdJM5+ioST+VXLbwroNtqcupR6RZHUpZGle7eIPMWJyfnbLAegBwOgAraoA5f8A4TCOY40zQvEF/kjBWxNuDnuDOYxj3p//AAkeqf8AQl+IP+/1h/8AJNdLRQBzX/CR6p/0JfiD/v8AWH/yTR/wkeqf9CX4g/7/AFh/8k10tFAHNf8ACSakvL+DfECr3PmWTY/AXBP5CubvfFtlcePNM+3WWsWkWm2c07pLp0zlZJSqRsdisANqTjJOCTgcg16TUMdrBHdy3SQotxKqpJIB8zKudoJ9BubH1NAGPY+MfDl9crbW2tWBum6QPMEkP0RsH9K3qr39haajbNb6hawXVu3WKeMOp/A8Vzc3hFtOIn8IX0mkzL/y6uWms5P9loSfk+sZU+uelAHWUV83eO/jvrWgeObXTRp9tHBprmPU4I5RKLhj1CSEAgAEEcA7sg8Cvf8Aw5rdh4j0W11XSJxPZXKbkYcEeoI7EHgigDRdlRGd2CooySTgAV8sfCDVLfxB8SfiF8XdZUnR9LikWzZ4QG27cLt5wJFhQKR3M3vz6b+1F4rPhj4S6jFCf9L1dv7Mj4BwrqTISD28tXXIzgstcGPCh0f4f/D74WR5t9U8SXQ1DWhtAIhQebMrYJw3EcanofLIoA9M/Z90iay+H8er6gzyan4infWLp365lwVA74CBfxJr0umxRpDEkcSKkaAKqKMBQOgA7CnUAU9a1KDR9IvdRu9xgtYmmcIAWIUZwM9z0HvXxrbQw+P/AO2b7XDP/aXi7VrfSdGVpDNd2MCSCSSVoztDQhdgJzwQenWvW/2pvEl1NZ6L4B0Pa2qeIrhI3bzMeWm9QobHIDMRzjopro/AHhiwXxyxtmNzY+ELRdIszPBiSO4dA8rCTJ3ZR1HbG8jHcgEPxr1qD4a/B+PRvDcbJe3SJo+lwRrufJGGbAOSQobkA/Oy5612/wANPCdv4I8EaToNtsZrWEefIg4lmPMj+vLE4z0GB2ry3TzF8Uv2g7m6kaO48OeBgEtdhIEl85GWORkhWjbocZiQ8hjn3mgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4L4ieBrvWdQs/EXhS/XSfF1ghjhuGH7m6iJBMFwAMtGSOOuCcgVm/Cv4r23iq8k8PeI7YaH40tCY7nTZTgSsoyzQ56jALbckgc5YDcfT68x+M3wutvGtmmraSx0/wAY6aBNp1/CdrM6Hcsb/wCyT0bqp5HGVYAs/tBeGV8U/CfXbVLRrq8tovtlqqDLiSPn5R3JXcuBydxHesz9l7xAuvfBvR0e6a4u9NMlhPuUgx7GJjX3AiaPkfTqDWr8FPiAfHXhuZdSgaz8R6TJ9j1W0cAMkwyN4XqAxVuCBgqy84yfNv2W4ZvB3i7xz8P9Ub/TrKdLuHjiWLhTJ7Aq0LYz/H7GgD6MooooAKKKKACiiigDK8Wam+ieFtZ1WKNZZLGzmuljY4DFELAH2OK1axPHFhcar4L1/TrJQ91d6fcW8KkgAu8bKoyeByRW3QAUUUUAFFFFABRRRQBBf3UVjY3F3cttggjaWRvRVGSfyFUvC9zeXnhvS7rVFRb6e2jlmVBgK7KCQPpnH4Uzxdpc2t+HL/TLeVYjdp5Ls2ceWxAccdym4D3Na4AUAAYA6AUAFFFFAHC+IPhN4J1+7nu9S0OJrudzLJNFLJEzMTkk7WGSc96s+Avh9pfgaS7Gg3eorZ3OGezmlWSIP/fX5dwOOOuD3HAx2NY3jLXY/DHhPWNcmjWVdPtJLkRM+wSMqkhN2DjccDOD16GgD50+Ihf4nftQaF4agC3Gj+Hdsl2rKJoTtIlm3AdA37uEg9GH4V6d8OZLbxj8T/FvjFPLkg01h4csGUhsiM+ZM/8AwJpF2kdgfWvG/hNf3HhH4M+NfiVfSXL+ItbuXtrRpHVRcOzACVFxlmErysQOoiOAME19I/C7wxH4O8A6JoqQRQz29sn2ryzkPOQDI2e+WJ/DFAHU1HczxWtvLcXMqRQRIZJJHYKqKBkkk9ABUleHftaeNv8AhG/h42jWkhXUdcJt/lcApbjBlOO4YYTHHDnnjBAPMNB8Tf294/8AGPxcexa4s9LgFppNo53v9scJFAuwYyDucnByN2fSvY9evX+DHwKuZrm9jutdVHAuGIzcX07E7hu5cKWJwedkftXI/C7wmJtY8K+EbpWFr4KtotY1WJztLapc5khjIHXyl3EOCQeFIrS8biH4m/HjRfCixyvo3hMHUtUJIaGeU7DHEVIIOOAc8kNIABtyQDtPgH4Lk8EfDews71CurXhN7fFvvCV8fKfdVCqfcE969FoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDxf41+HLzw3qsHxR8II6atpe3+2LaJiv9o2QK71bgjKqvUrwBu6otedaF8QfDWo/tRaJr3hm+lWz8Q6elnqQuYmUpcFCqRc990duPlyuc4Y5OPq2vhL4h+ELb4RfHbRJ/nXw6L+21S2YBnMcKzAvHz95k2kYySRtJOTQB920VBp95b6hY217ZTJPaXMazQyocq6MAVYexBBqegAooooAKKKKAMHx/dz2HgTxJeWcrQ3VvptzLFIvVHWJiCPoQDW9WX4p0+PVvDGr6dcXAtobyzmt3nIGIldCpbnHQHP4VqUAFFFFABRRRQAUUUUAVjfWw1JdPMo+2NCZxHg52BgpbPTqQKs1y/h8/bvGnia/6pbeRpkZ9NiGV8fjOAf9z2rqKACiiigAr5z/AGy/Fv2PwnZeFbN2N1qMi3V2iYO23jb5dw6gNLtwf+mZFfRlfKnh3WbXxx+0P4h8Vz3d1H4d8P2LTszIXQQQgoYXH3QHffOOvCnAzkqAdPpGgG8+IPgfwBCFOkeBrGDVNUNqrLE2okZjyxA5LEyj+8HfPQ4+hK8t+ANpe3ehax4v1i38rUPFN++oRhyTIlpgLbxsSBkKoJXHG1h9K9SoAK+PfE+vWXiz42eJ/Fmsq934Q8GRKojZBtmdG2RQZTIIluSXBbI2jnAGB7z+0N4obwr8KtXmt544b6+Q2Ns0m4De6sWwRjDCNZCp/vBRznFeG/CLwU1xc+GvB01tBNbSrF4o8RuCG+XBFnZSDGMYKyNG458wkcLkgHtngmzi+GPw01bxF4tlxqd20ut6wRsU/aJACYI/m25BwijdgseMbsVR/Zj0Sa0+HreIdVVm1zxLdS6neTSQiN3DMdnQDKkZkHb96ccGsH4/Tjxj4/8AA/w4s5VniuLz7fq9ujFWWBOQC44GU847euQh4yM+8xRpDEkcSKkaAKqKMBQOgA7CgB1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUdU1OLTpLBJYriQ3lyLVPKjLhGKs2W9Fwp59xV6igAormvC3jPTPEuueItJsY7yK90K5W2uluIdgJbO10OeVO1sHg8ZxggnpaACiiigArzX48fDOH4leERbQusOtWJaawmb7u4gbo2/2WAHI6EKecEH0qigD55/Za8dXMcM/w48TwPaa5o/mfZxMx3SRhstGcnlkLcY4KYwMKSfoavOfi/wDDOHxvb22paTdf2V4u0z59O1OPKkEHIjkI5KE555KkkgEFlbi/B3xp1Lw/rEHhb4y6a2i6uxSOHVAgFrOMY3uwO0ZOMunyAschApoA96opsUiTRJJE6vG4DK6nIYHoQe4p1ABRRRQBzXxN/wCSbeLP+wTd/wDol66WsvxTJYReGNXk1mMyaWlnM12gBJaEId445+7npWpQAUUUUAFFFFABRRWB48v7jT/Cl/JYy+VfTBbW1cDJWaVxFGQO5DOD+FAG8ABnAAzycUtIowoGSccZNLQAUUUUAeefH/xKPCvwm1+9jlRLqeIWduPO8p2eU7CYz13qpdxj+4T0Br5+8G+G4NO+Dmh+HFhuo/EXxH1GFZSm8yQ6fFLuMwXG3aEy3JG5ZSckLga37SuoTeOvi74Z+HljMwginiS58u3Znikl2kydcMqxMG4xj5sn0734Sacmr/FnxNq1v9pj0TwrBH4W0mKTbgCIATcjJJDKCGPJWQZ6YAB7ZaW0FnaQ2tnDFBbQoscUUSBUjQDAVQOAAAAAKlornviD4ng8G+DNW1+6TzEsoS6x5x5jkhUXPbLEDPvQB4D8cvEum+JfiO+i6u0reFfC1o+qapHBfDZfsAixRBVB2t5sixnJzhyflwDXqHwv0+Twn4H1fxj4yZ01zVlfWdXdlctBGELJAFYbwI4+AhyVO4AkYr59+DPhdfEfirw3o15aq00bnxNrs00IWU/N/o9ucrgowMcpHQic9Nteq/tSa3d6qmhfDXQFWTVvEU8bzAgkRwK/ylsKSFLqWLDosTZGDQBc/Ztt5PEtx4n+JWrW0kWpa9evDa7yrCOzj2hURgBnBXYSQM+SpxnOfcKz/D2kWmgaFp+kachSzsYEt4geTtUAAk9ycZJ7mtCgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5b4keLLXwH4TvfEd3ZS3UFu8SypBgOQzhAcn0Ld66DTL631PTbS/sZBLaXUKTwyDo6MAyn8QRVPxXoVh4m8O6ho2rw+dY3kRjkXv6gj3BAI9wK8Y/Ze8Y3iWN18PvFiTWfiLRc/Z4LhCrtbYBC89SuePVGUjIBNAHvlFFFABRRRQAVj+KvDWj+LNHk0vxDYQX1k+SElXJRsEb0PVWAY4YYIya2KKAPlK1bxF+zb4thi1G5vNZ+HWpN5aOv/Lu/3vunhJB83AIEi5PVcJ9N+Hdd0zxJpFvqmhXsN9YTjKTRNkfQjqpHdTgg8ECjxJoen+JdCvdH1m3W50+8jMcsbdx1BHoQQCD1BAI6V8m/DbwT4l8JeJvF+g+EfEc1n460srcLZSRKbLVbL5SpychZPnHXpv2gjLsoB9iUV4t8OvjpY6hfT6B8Q4IvC3ii1YpKly3lW8nGflZj8h9mJBGCrNnA9poA5v4lqz/DjxUqAsx0q7AA5JPktXSVl+J4NNuPD99Hrk6W2mmMmad5vJEQHO/fkbSCAc54xXzT4n/aUl0XS7jSPDXl+IL+3ZkTW542jiMXybXMeAWfllJ+VdyhhuDYAB9R3t3bWFrJdX1xDbW0Q3PLM4REHqSeBXND4k+BzJ5Y8Y+Hd2M/8hKHH57sV8oaH4Y1T4neN/CEXjnxXqep2Wv2c98HtQdlu6bwYV3DZGw2fNhMAkAZyGr0DQP2XLW0tvFEOr3ltqDzw7NFuA0sTW8m1vnlUHb94qMfNkAnjOKAPXvG3xc8GeENLF5f61bXbuAYrWwlSeaUHOCqhsBeD8zELxjOcCuN8OftLeCtX1a0sbuDVdJF0+2O6voo1gHJALMrkqCRjONo7kAE187+HvhvqFx4H1fWNAi1Oz8ZeGp3j1SxuVADQMjfPCNgIcLuypJJA3KQSqn2K48NR658L/hV4U0zTJ7rwneBrzVL+VCJLErh3O8/LGS0kwyQeBgZFAHsNt8VPAdxezWsXi7RPNiALF7tEQ5/uuSFb8Cas+Op1Gk6XqkcUt7YWd7FeTLa4dniAbDKP4sMyPgcnbxmvnb4weEdN8Npd2H/AAgtjN4Uu7dYfD2p6Mm+9F86Dy0mcvukQtv6hsgrt54ryiLwxr58ZaZ8P/Hl/qOl8CGzjkm8+C1eT5kIVSVKM3ykqRtzkn5CpAP0D0+9ttSsYLywnjuLWdBJFLG2VdT0INWK+LPhZ4k+NFrYLZ+ErOXUtL0lC8ltc20XlNuy+0OdruTndhHJOfQivX7P9oa3s7W1ufGHgrxNoNncSLCLx7YvAHOc/MwUkAAn5QWwDxxQB7pVLW9Tt9F0W/1S+LLaWNvJczFVyQiKWbA7nANJomrafrulW2paPeQ3thcLuinhbcrDODz6gggjqCCDyK8c/bA1u60r4Ura2hlRdTvY7WaRDgCMKzlSfcoBjuM/QgHjnw21XUdZ1P4kfFvUU/0+ws5FsMqdsdzMpjj2NwD5aAJtOSQ698V9LfAvwk/g34aaVYXaFdTuAb2+LfeM8nzENyeVG1M99ma8J0Pwq1v4e+DPgyOeD7N4hu5PEGrRoWbz1RY5Yw3OQPK+TjA3LnkjNfWlABXzX+0N4oXXPHum+C9xn8Paaq6t4hiU7cwxZkaPcpBBMfQZGWaPBBr33xdr1r4X8MaprmoEfZrC3edl3BS5A4QE8bmOFHqSK+L/AATbXnjPV7cX7mXxF421FvtThAoj0yM5mdcdNzI6gcf6jg80Ae+/s77p9D8U/EDXETT0128e4ia4lXEFjCpWMFuAFQB1yQOEB6Yrm/gQJfiL8YPFnxJvI82Fsx0/Sg6HCjAGVyx2sIgNwHBM7EY6Vv8A7SviB/DvgLTfBnhe3Cal4gZdLtLaBQoS3G1GVR0GdyRgccOcdK9J+GnhWDwV4G0fQYFjD2kCid4ySskx5kcE84LliM9BgcAYoA6aiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+bf2oPCFxpmsWvxK0fWo9K1CwijhRdhLTTqxK4OCOULA7uDtAPBNfSVcd8XPDE/jDwBqWiWkVvJcXHl7BcOUQFZFYkkc9Ace9AGF8DfizYfEzRGWRY7PxDaIPttmCdpHTzYs8lCe3JU8HPys3p1fm/wCL9P1n4a/Eu9hsjc6VfWFyz2ksbkHyyTtZW/iUqce4yD3r6q8I/GjU9BXR9L+Mmi3OgXt9Aj22qFP3FwO5lUf6pxlNy84LZYRjFAHu1FQ2d1b31pDdWU8VxazIJIponDpIpGQysOCCO4qagAooooAKr/YbT+0ft/2WD7d5XkfafLHmeXnds3dduecdM1YooA87+Kvwi8OfEqSzn1o3dre2iNHHc2bIrsh5CPuVtyg5IHbJweTXz7p3w3+NXhTT0fRtQufKu8Wi2UOoL58cYztALApHgDqrcV9jVX1CdraymnUxDy1LkzOUQKOSScHGBntQB8H3PgjxfqXjOx8M33iqLVtV1kj+0ra21KS7a1MZGVuz93chB4DMV2E/3c+9eEfEvgrRPFqfCDT/AA7HfaUrGG91C48qaGa6xvAkUAhjlQuSQVZQm3C8dUdD8GaVb+KPid4cuIRNqGmzs15BN+4yBlnUL0cugyeTuz3JzynwN8QaB8Pv2dNG1zUorhIr26mab7PC8zzT+a6A4HC/JEoycD5Rzk8gHoXxG1XVfBPhS1i8D+E21MOxtI7TTx5X2XcDtkCqhGwHOeAORyKd4H8G6zpXw9fQfEfivVNR1Ocsz6lHMRNDux8scjZbAxwWz1PAGAH6Bq/jDX/ht/akWm6ZpfiO7QyWltePJ5UaEjaZcLuDbcnAHXHTnG/4QtdasvDtnb+KNRg1LWEU+fdQQiJHOTjCjjgYGcDOOgoA8j+Inh/4m6V8XrPxd4ISPXLB7NbSawmuI4QqL1RgzKDliXVl5DZBGBhuw8G/EbSPG3gDW9V1HT5LGPTkng1bT7rDeVsQmRSSBuXbnqB3BArnPjh8QdU8L+NvBWk24m03Rbm/gn1DV5FIhMXmFWg3YwPlBLZ6Aqema6jw34B8PvoPiaK1vTqGj+Kb6TUpWgkCqyybSyLIhyUOD36MRQBx/wAJPEml+Bvgd/wkuu6m40W5upriytVUsbZGchLWMEksQyt3wMnOACayG+JGv+KfgD4v8U69osNhaFTHpj2bljMjSCMhwTnaG4ZuNy7sAY53NT+H2pxfF/QbfSNPtT8OodNZLrTrgB7NJC0m4JCeBIxZDuxz82T1B9F8N3eg6ppE1r4OmsUtNNuJLRre1iEcMUq5DRsgA4y2eOvUZoA85+Hfx40bWz4e0S60fWodbu7VGdIbHdCMLy6hTuMZALAhSAPpVPVPjd4T8ReGvEkuteGtTu/BUMi2P2xo1K3kx58tYyVKtgbwc5AAJ2MVB9ztfO+zxG7EX2jb8/l52574zzivGfEnw10Twf8AD/4pXE16JrLW45b1LW8ZY7e2mAdognI58xlAPBO1B1HIB89+FvizbfDfxlMfh9Lqc/gu8kjmudM1aNd8bcB/LKufm2jAfjPAYNsDH6R+OSw+Pv2f9Tv/AA0wvoZYIr+3MeMsiOrPx2YKHyvXIx14ryXUtR8Vj4b6LpGp6PoHivxJqtqg0+yh0v7Q9npZTb5hki2hDv8AKwR8q7c5J+7yXhfw/wCOPDvxF17wR8LtbF6DshvtSgVVgVWRdxckuEKFnXK/vMhgOfloA2v2dfFUvin4yeFhqsMcc2kaA2lWphBAdYg21nyTzsZgcdwPWvsuvk7W/gf4s+F8mneKPhlqk+pahaQkX1v5Y3yn+Ly4xw8ZH8BywKggsSNva/Dv9pXw3q9qtt4zB0DVkKxufLeS3lbgEqQCY+c5D8AY+Y84AKP7YN1rN7a+D/CmkEiLXL10kUEjzZFMaxIxHG3dIWwQeVU/w1ofs9+ArzRPEviHWNbtJrUab/xItLW4jKH7PGdzzDIAIkbDBhxkvg4Nel3vxI8C21uLm48W+HyiDepS+ikY9RlQpJPccD1rxn4lfF+5+ITx+Cfg+txe3Wori61ERvCIoujBdwBUc/M5AwDgZJ4AGfCi5k+LHx/1nxtcKsmh6BEbTSzs2g5LCM4K5PymWQ55VnXsBj6YrjvhN4Fs/h34LtdDs3Ms2TPdzn/ltOwAZgOw4CgeijOTknsaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArivhZ44PjbTdTa6sW07U9Mv5bG7s2bcY2U/Kc+4/UGu1rxK48fW//AAn+ka7pE62vh241aXwxrMc0ASR70ITA/HUZwNxPC5yPQA9tooooA+b/ANrv4fR32jz+PEv5o7rS7e3tfswUbWUzkbt3UHM36Ve8Kf2R8cp9Kl1fVX1fTdO0SFNY00rJBGmov0lXG0buJhuXIAGBwxr3y8tbe+tJrW9giuLWZDHLDKgdJFIwVZTwQR2NfLfwT1LQvAHxP+KXhfUXWysXLy27lyUSCAynYSeS3lyg/wDADznGQCHwn4M+KXg6xutW+GGtW2q+GTeSGz0ye4WU3FusrAMVZQikgfNsZWPbnAHa+Cf2mPDWqyW1n4psbvQL6VirSuPMtgc4yX4ZckEcrgd26msySSfwb+xrAiu1zNeWAVDCSuwXcpbBPX5RKQfU8dDXW/EvwfFc/D3wT4Nu5NHaM3Vlp0tzqD7ZdkafN9nPXzmCYGOoJHfIAPWNN1Cy1WxivdMu7e9s5QTHPbyLJG4BwcMpIPII/CrNfHvxi8I6t8KvGuiR/CS/1y3/ALYEky6RZySTkSRYJOznzFKnOGDY2tk4wB0Xgr4w/E2fw1B4ibRdJ8WaUS8dza6YzJe2jDhTKqhtobBYYRhgdV4yAfUFFeKeCv2i/DHirU9P0u30rXY9Tu3WPylt1lVSep3K2So7naOB0r2ugArnryx1648XJIb2wPhQ2TRTWDwbpZZiTyWPATaen14OcibxnqmqaN4fuL7QtEfXL+MoEsUnEJkBYAncQcYBJ6dqf4g1W9sbG+Ok6RPqeowW4nitt4hSckkbBKQVDcE4+nrQB4L8KTr+u+Gtfk8f6ho+j+CdJkudN1Dw7DpsUMeAhLnemGiwzggqSSQcY4J9W+C+g2vhzwTDZaTrS6voUs0l1pUnlhGjtpDvEZP8RDM2WODk9B0GJZHQtB8etpGp2Os3GqePIvtV1p9yUurK1MUZ8xCTgYOSpxvB2r90Yrj/AAroWnz/ALTPxB0q2K2Fknh+OxS2tT5RSOSO3yYgOEC+w4LA0Aew6d4wtNZt9Ku/D1pearpt9O8DXcKBFttoOWdZCrYyMcA/yzzHww8cat4u8eePbK6Szh0nQ70WFtGhzMWVpFZ256NsyOB6DOCa4fXviF4p+FE1pp/iDXfDXiqwtZY4rvyyYdUhhYDDvEGIwAyYPJORnruEMngr4m+CviZ4i8c6DBo+t2uoTOJdLhnaKSaDcCrYKhRIAo5BY5LYByaAPWPjRaWt58JvF8d9FFLGml3EqiQZAkSNmRh7hgpHuBXkP7KNxLd6LHcXXjSG5v1spLOw8OrMqpaRJJnzZIVwWctj58Z2scsc4XlfHv8Awt/4zT3Nnb+GdQ8P+H4UQnT7tvIWVxzlnkVDKSRwANq4XgH5jr/Cn4nfDPQNcA1HwpN4S8VJb/2ddPHC7w7kYLswCWDsyjJKZyPmY9SAeva7qfjzwx4E0yYWemeINdjnJ1KcOLaCO3BdjIASOiBR35ycHpXhOnW954m8aeJPiR4c8L6ne6DLfww2GlWjNbpqU3KtcyleiqwMhO377jJ4c16V4i+IfirWU1RI/hrqcvgqENBqTXe6O6vLZxsYwR8HOGLcEggYypORtfCPx/4L8Q2T+EfAUd3pMthZNJFbzWpBgXcAW5JDMHcE5JJJzzzQBs+MPFOiaprr/D+z8TT6V4quo1kja0RmeLb+92lsbVLIp4JB2n3GfPtcude+I3jFfDXj7w7deHPB+ixy3+qTfaWNrqAQDy/9IwgVBkvgMfunOCuV35vg9oeleAfEI1HUDLr95FJdXfiW4PlTLIreaH3ZJjRWVSQp5C85r5d8MS+NPjDqmi+ELvxBqN/bCdriU3IMwtEVQpmZs5bCkgBmHzNjgvkgHVfA3wNrvjrxLqeoeHNc1nw54Pt7loA0N3IJjCW3i3Ug4yFK5JyASDhulew6l4htfDUOo+BPgxZaZYyaahl1TW7qULY6W5OCZZG3eZN8uMHOMY52Mq7XxI123+HvhTTfBXgRbOx1a5gMds0rbIdOthnzbyZuwHzHccksScMQQfNfht8MLT4gWdhGr3tr8M9Lm329uwMUutXQ4kupMcqpxsHOVUbV2ncaALH7NfxR1vW/iLqfhzWNek1rTpoZLi0uLqERSmRSudgB4UqWO05xtBG3kH0/4ifA3wb45vm1C9trjT9SkcNNdWDiNpvXcpBUk/3sZ6cnpXh3h3wlo+q/tbXln4ZdbDStEmjuxHaRHaHgWJZIzyNoMu5Seh5HOa+t9Y1G20jSb3Ur9zHZ2cD3EzgE7URSzHA5PANAH5m+L9PtNK8VazYaZLNPYWl5LBDLMu12RXIBYYHOB6D6DpX3j+z5p/hZPhvpWr+EtGTTU1GHNwWO+V5EZkcNIeWAdXx0GDkAZxXxBp+n6p8QvHDIbuz/ALW1eSe7eSeTyow+HkYE4wudpwOnK9K9b/ZZ+LEvhzVrTwbqcRm0vU7sLbS7jutppMKBjujNt4GMEk85NAH2hRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfPXxb0XQfEniTxBbwagLeC6NtpWusU4sLo4ezu8EchjiBiCPlfqME19C14L8SrfRL+S58WSCX/hGdUeTwz4khIVDAUuDFFfYPHmRyogBYMQjLgDBFAHZ/AfxRfeIvBJtPEDH/hJNDuZNK1NWZWYyxHAbIZt2VxluhYPjivR6+ZfD/iqXwD8RGvvEN0zG5uI/D3iWWUhds0Uf+g33zMW2ywqxbsMOTztFfTVABXy38a/h1LdeHPiNqX9kW1peQapHrFpJAQZbu3ESLMWyeEXe8h9G3euT9SV5j+0np73/AMG/EK2ywC72QqkssqRBUNxCzje5AAIUZBPOB7UAcsNfPivwP8JbzweiJZx63ZQXlpCc/ZhFGweM9wqhTjOMgoehFdP8QJZH+NXwvsmijmtH/tKd1Zd2x0gXZJ7EE4B/2vXFeV+F9Otfhb+1TeWkqSWWieII3j08iILEzysjiNQoAAWQFAAOPlzwc17LBqQ/4X1eaY6Ln/hG4biNivOBcyK+D6HKce1AFfQbM33x18UauLklNO0u10owkdGcmfOfYEf99GqnxH+Eugaxd3HifT7+58LeI4FaZtZsZCmAFIYyLkAjaTkgqT3JHFb3gpi3jj4hAxMoXUbYCTacN/oNucZ7kZ/UVe+Jet2fhzwDruqanG8tpDauHjQZL7vkC/iWA/GgDw/RPHvjvw74OvfHl/4f0DxBpE37s6pAosr65iSTy4pplCkFOeFAyoznA5rXsf2m9Bs9Pgj8WaHrWm63tQz2kUKuoDKGV1LMp2lSrYIz83Gep9Gm+HNi3w/0bwfFdSLpNjJbmdWQN9sjjcO0bjjAcjnHrXQeIfC2g+JIwniDRtP1IKpRDdW6yMgPXaxGV+oxQB5z4m+N/hTRNV0u9j8TWWo6ReQBPsOnw+fcrIzKRK7bgI1CnBRhuz0B5xt3fxU0WKzutUhurKbRrZ7qzLC5UTzX0TqqwRJ0fepLBgem0nAOa8o8W/AzwJqHxI0nwpoCXuk3H2R9WvykzSA2oYRKsZk3fOZPXgDcTn5RWH8TPgD4e8M6ZY2Ph6fVdT8Ta1epZ2EVxMm2BNwZ53RE3FEQbWb7q+YCQOKAOvm+L9zoeva8vi2I6h4FuNYn0cTN5a3VhKq5lieNf9bEN2Ay7iFHViQp4PxB4n8I6NdeHvH/AIIuLOePQ7p9IHh4ExCSzzK6TYI3qdzlizhgXZTwV2nqfG37P3g7wn4ZuprBNW1TVL+SHTdPF7dqkcFxPII0lYxovClgSDuB6Y5yO+0z9nz4frpWnx6voUV3qMVrDDcXEVzPCs0iRqrPsWQAbiMnjqcnmgD5v8X+JtG+LL+IDbaRY6b4on1G1bRYre3c3OoqxaOSOaTcYwQvlvn5eQQM5zWr8KPEEvw4u7aTxf4muH0bTtZuNLk0S1vC7QSouRciMH54NzybtuMtg4c8V6J8Qv2fvBWm6PYWWjJqkOr6rqEVja3bO1wsJIZ2LoMfJsjk57EjOBkjNm/Z28OwfE7SNK06a/1HRRZzy6us9ygltSyMtuwKBeWc5AIwfKJ5GRQB0fjP462XhHR7GTwx4ZuLu41OzTWrnzZv3doLhvlMhXd8zN2+UfMuOuK8lmGo6L+0hoGu+LNEtnm1OWPV30y03u1mkgYBpF2Z8yLb5rDHJTPGcjQ+IX7OuqeFLKefQvEkNzaX11BYxWc2YJZzLMixxkg7XIYqxzgfJuwMYCRfBHW5PiO+kaP4qlPiOx0VNRv9TV3ZIr6SRlW3Mi/PHmMggtlmALbcHCgHc+FPiRb6h8R/EXiLX/iTBb6Bo0zLaaZEjCG7tJA2xtnDPIpZAcKzBlx0Ir2jQ9ZguL2bW7uXRIdF1MWiaLfBjHcXSyIDsk3gfMXPyqOeeRmvjO9+FXjfwl47tPC9lb6Pqur6laG6TbDFcRBFL5y1xGAhG088ZyoyTxXQeOfiEbPyrfxT4Z1DSvHGhR2S6ZBFcY0+3eFy4mEAwq5UgADepAGCvcA9g+KHxVeD4Z+L4fEfh270Ka8SbSdLgu5h5t+WUpJKqBflRAwbdyrZADZIq34B03TfgT8EJdX1u3RdWkiFzerwJJp2/wBVb55Py7gvcA726E15x4H0ifxp8dPD0ni61vD4r02KbV9chu5NsUK/IbOKBVPATfE5Vj1Zg2SCtbfxs+Itp/wnk9wAt3pfgpVeGMHdFca1LnyUfa3KxKkj/wAJDRSKTkgEA8p+Kd3rF5rE1lqk8Nx4q1mS3fWypEFvYjBa309ZGIAAXDSbiQXjj5LRsx+m/FfxBXwf8DoPEEWiPod9JbJa2Oj3EewwTsNqx7cD5VCs+MKSq9FJwPOPgVpXhqI6n4c+JWiJZeNr1M3DatcFm1aG4dZVIDOQ0isi5AG5WXIO4vjuvGFu3jP4+eGNEeB/7L8LW7a1dM0zBJpnIWABV/iRlDAk8guMY+8AdF8E/An/AAg/g+NL/wDfeI9RP2vVrtzullnbJ2s+TuCbiM5wTubgsa8z/az+J6aTok3gvRJkfUr6MHUXRiTa25xhDjo0mQCD/Aenzqa9h+KXi6HwN4E1bXpTGZreIrbRvyJJ24jXGQSNxBODnaCe1fKdhZaC/wASbF/iteGHV9PtzrfiG4vm837ZM5jNvZpFt4CRum5FBz86AbUUgA5fTvhI0emR3XiLWLbTln0631y3dQ0gmsSrGcKMDM6bofkyM7jgkc1gaNpep+BvFuk67rNhK2n6TrMImkgZXV2ikDlVOcHcEbaejbWwflOPr74X+KPAmveJbrQNCS/nmtJn1yxbUYCsaiYfMbUMAUjXzOFIH3yRkAmrvj/4VWmrW2lxaJGYbaK2j0a6szMTFJYfMqttbIM0HmNJGx53Zzk4oA9F0LV7DXtItdU0e6iu9PukEkM0ZyGH8wQcgg8ggg4Iq9XxX4E8W63+z98Q7/wv4minl8OzTmR/3fLoflS6i5xyFGRk9Cp+ZePsfRdVsdc0m11PSbmO6sLqMSQzRnhlP8j2IPIPB5oAu0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeSeM9PsfCninUNV1OM3Hg7xfs0/W1c4jsp9vlxTkjhI3GUdjjDbDu7V63XjnxB0u20Hxdf3OuRy33g7xsIdM1QSEEafcqojglXsqMOCxGVcK24cCgDzzxR4dEsOq6LrEIku9ORdK1W6k+QSWTDNhqzngO0GwxvjJwXBYAkH0b9nT4g3PibQZvDviYS2/i3QwILmK5YieeMYAlYN824cK/XnBJG8CuXM2prp9zH4kePUNX8Fefp2uJLId2qaFPGGM5AyTIVRWCl+qNuOWAriPFug614Q1+DxPY6kt14u01TciYRMx1qJI/NuLmT5wsdusBjjG05d1kH3iDQB9f1BfWdrqFpJa39tDdWsgw8MyB0YZzyp4PNeefBD4q2fxQ0a8ljsnsNSsGRbu3Lb0G/dsZGwMg7G4IyMY54J9KoA8V/aS+HPiLxxDoGpeE7qGG/wBC+0XCqZXildyI2TymUcPmLjJXkjkVyXwG8dy/ET4yJq15CYNRs/Cf2C7BxiWVbtWMigdAQwOMcEkcgAn6Xr5Ll+HWt/DLwvo/jLRbCSPXvCl5cQ6oqqCuq2RlYiZcFsL5b7SSu4DJ48sZAPf9V+Iug6U3jJblpIJfDKwPemRQquZow0W1gTndwnODkemCanxF0DWPE/wV1HSLxYX1+401DKkGdjXKBXZU9i6kD6iuS+LV5pnjf9nTXtf8MwRj+1oLe4d/LCSuYp48rIR1ZdjL1I44OK9i1i6msdJvLq0s5b64gheSO1iYK0zAEhATwCTxQA6xguITc/abo3PmTM8eYwvlocYTjrjnnrzVmmxMzxIzoY3IBKEglT6cVW1e/i0vSr3ULkMYLSB55AoydqKWOPfAoA85+GUaa98R/Hfi9XM9o08Wi6e0qnfFHAg88LnpG0pzjuVyas6HcP4k+NOvzXMTLaeFbaOysZEyUmkuVDzsT03L5aJgdOc8kY1vhFPYX/gSy1bS7U2sWrSTai8RbdtklkZ3GfYkgewrC+BNvLHB46uZFbyrzxZqM0Eh6SRblUMp7rlWwaANnxxJf3Xi/wAGaMmkvd6Hd3Ut1f3Qjci1e2VZrfLLwuZVXr1247mu2qol6j6nJZIjM8cQkdwRtXJwFPOQTgn6VboA5KX+2m+LFviQnw7Hoku6NSPlumnTazDryisFPs9UPhzf6fr/AIm8ba3ZW89vcxaj/YdwsjArIbTOJFx0z5x/ACujtNJlg8WajqhlRoLq2hhCc7kZC+fbBDCuH+BkRt7n4jQtnf8A8JdfS/g6xkUAdt4t0CPxDZ2MMjiNrTULW/jcrnDQzLJj8QpX/gVUfDVvoMfjLxhNpbO+uSz239qbwRtIt0EKqcAFdnPGeWbJ6AdTXK/Di21u30S6bxLe2t9dzXs8sVzb4w8Bb93nAHRcD2GB2oAyNXtEHx18N3ZcK76HfRhT/FtmgOB/32T+FbvjXwP4b8a2L23iTSba8ymxJymJohkH5JB8y8gdDg9DkEiug8uGSdZtkbTRhkV8AsoOCQD2zhcj2FSUAfOPwZaHwhH8Y9VaO61DUdCuJoklvpi0sttbRyeTGXIyMqgGQMY28YAr5R+0xXmuz3XiO6urlLovc3MtqytI8rqWBO7jO9hu/wCBYr7A1O6j8F/FnxVpPjB1h8GeOIA0N+3ypDOY/LeJ5CAFyN3qANh4y2PlbStZl8A+LdYg086PrVruksJGubdbq1u4VmVg4UkggmJGBz+NAH138Eby21jwOtx8RJBdeJ/DNzNLdNrcKLPpgPzq4LAMqFAGDnqVODhBh37M8n9vWPi/xpcWl1Hda9rUzRTXLszNaIB5SKTwVQtImV/u4/hAB8TdQ8Ppo3jnUbnSriLV4/DMlo2vratHaXq3CKEjjcMQ5LmMDOdvQNjNO+AOqx6D+zPp2rzRtLFp9pf3bopwWEc87EA++KAPPP2qfiEdE+JXhK206G0vZ9BDai8M8rPD5748sSRoykOgQOMn/loOMHl3w70Ow0690bWNU0uHXtW1OCSPxSMPPiO+ZZ4LwKVKNGqbkkZMKCW64Jrx7wRan4ofFS/u9akim1G6MmoQ2EspRL+VWDC08z/lmpTcAewUDjqPrf4NW7WEH2fR4Wbw0fNCWs8gNxodyHHnWb5+Z1LEsp7be4KtQB1vgfwv/wAIxo1tp815/aJsla3s7iWBUlhtcjZAWH3goVRnjO0HFdJRRQBxvxE+Gvhn4gx2w8SWTyy2qusM0UrRum8YPI64OGAORkehIPgnhW7139njx0NG8TT3l/4C1ErHDfhG8qBzkh1XJCEHdvQHJUbhuwAfq2sTxn4Y0vxh4cvNE1yDzrO5XBI4eNuzoezA8g/nkZFAGzFIk0SSROrxuAyupyGB6EHuKdXgXwi13W/h14yX4X+OruO4tWj3+H9SIIEydocn8cKTlSCgLAx177QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxnxS1PQrfRLfSPFdvO+k69ONLeZVBjgeQHYzkn5OQMNg4ODxiuzrL8U6DYeJ/D1/ourxebY3sRikXuO4YejAgEHsQKAPDIBq3h6e3vNRWS813wWJLK/QSIjazoz8RzsMnPljDYJPzK2TluHXWh6fl/C+ombUNOtYrRFeGZZ7zWdHkkYwhCjb1SCYkuVAyiDsRWtpMV7o+kPJrVrLqfirwbA1nOIFXOraZJ03bsBsIA+Mkh4znliDQgTWLLybPwpf293qFowvvC91IkIXVNLIUyacrk8BPkyxO7AUgDGQAfNvhjS9U8O/GRNC8N+Kbey1FLxrK11SBmaGVz/AKtGChsq7hFIIYAnkEA19aeA/ineQ3Nt4e+Kumt4b8SySNFBPIhWyv8AABzHLkoGwQCNxBJGDltg+d/iToek+OPjvFpfw7Q2F5cQMZ4fINsIL6FJGdNpC7T+7XLD+Isea+m/gz4vTx54LkstfgU6/pT/ANn6xaXIVm85ON7LjoxUnoAGDAZ25oA9JoqppOnWuk6fFZafEYrWLOxN5bbkknkknqT9Kt0AfJnxg0W8+E9r4sstPtLm48BeKLc+TDGyqmn35IIHc7cJnoMgqvOzJ9h17X/FMPwX8N6t4NjivtbuoLBsXC58xZEXccEjkkj8Ca7jxn4dsPFvhbUtC1ZWNnexGNypwyHqrj3VgGGeMgV8uapr+pW3wh8ReGzr8Tax4A1G0n0+/s7hMXluZNkYPzHOwNyo6YjUgkHIB9e1zPxO1NNH+HniO/ki81IbGUlOOcqR/WtjQtRj1fRNP1KD/U3lvHcJzn5XUMP0Nc18aLNr74TeLYIwS39mzuAO+1C3/stAF74aaTBofw/8PadaktFBZRYYnOSVDE/iSa5L9miJ7X4RabZyyNJLa3N1C7FSORO+ev1rd8O31xY/BfTL+1xJdQeH4p4938TrbBhn8RR8HtRN/wDCnw7qDrulmshLIEXlpOS+B6ls/nQBQ+HWmyJ4/wDiFrUV5Hd6dqF3bww7Gz5ckCMkqEHoQxx6V6JXFfCBI5PBUWpLps2mXGrXM+o3FrKCGjlkkYsMHoOBj2rtaAOdtfEjS+O77w3JYXMZgs0vY7vy28qRS20ruxjcD2zzz6VJ4b0RdI1DXpkQKuoXv2vIx8xKKD+orD0z/hOV+L2rrf8AkN4DayRrJh5e5JwIwVOP3mSfMPOVxjBB4ruqAM/xEJG8P6msJYSm1lCFOoOw4x71xX7PFxJdfBnwxLMztJ5MisXznKyuvf6V6LWRNJY+GfC9zc2sASwsbaS5EUYx8qguQPrzQBnfDPVdS1vwVYX+uQeRqMrTCVOONsrqP0ArqKyPCWt23iTw1p2s2KMltfQidFYYIB9a16AOO+Lt5Bp/w/1S7vfD8fiKzi8sz6c4z5kfmKGYDaeVB3D/AHeo614h4n/Zl0jxDaRaz4E1SXSYbu2SeHTr+J3UFlBALk70GDyCHIOfoPqCigD4S1zxL4v8H/DLXPhr450a9WKVYTp9w5GIAsyyFQ4BWRDt4Ib5SCP9307QNct4/wBjC/j0G8kN1Z28ltdKmDJE0tz86kY4UpIef7p65Bx9Ganf6Wb630PUXhkn1KKXZaSpvE8ageYCMYxhhkHrnvXyZ8U/hdb/AAz8WXWvJ4Zm8TeBLxGaayW5lt/sTlshS8RzsUgbWYEYbafmwxAPO/hLc6b4a+JA0nxjBCbOaUW0lzBKkj2NwrAxTxSoSAVcAEgkYJyDjFfaOmP/AGJrUN3qGkCDUtVl+yahfRSbYWMe4QSEdCXGBxyucHoK+AG0PWYbR9cs9F1aHRlbdHdyQO0aqTgBpQoU+meAfTtX2f8ADa5074x/BJ9L1N7ePbi1MVqzB7MxkGInJzkbQQehHHrQB7TRXAfC3xjPqyXPh3xOI7TxjpPyXdrkgzxg4W4jz95GGMkZwTzjIrv6ACiiigDjvij4C0/4geHfsF5JJa31u/n2F/CcSWsw6MMdR6r3HTBCsPBPh/8AHTx7p1/qeieKfDcniG40gn7a9piO7gRZNsjlFBWQLkD5QvYluc19WV5l8Tfh1c6pqdv4r8DzW2k+N7Rl23TjbFdx4CtHNgHd8vAJBPAHAwQAdD4B+IXhrx5YLceHNSimlCB5bRzsuIemQ6HngnG4ZUnoTXWV5D4u+Cel+Kbe11cNH4b8bgJNNqmi71j+0dZGCZUsCxYhvlc8ZbqDz9t8TPGXwy1K10v4wafFd6NMyQweI9OUsu4gk+YoHJ9gqNhGID9aAPfqKp6RqdlrOmW2o6VdRXdlcIHimibcrj2P+cVcoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs7xHp82q6Fe2VrdzWdxNGRFcRMVaJ+qsCPQgfhWjUV00qWsz20YlnVCY0LbQzY4Ge2TQB5XHqKyWtr4wupon8R+F45dP1+K1Od0PWUbcc4KrKvQcEfTMFhbaZPBoHhx7dLpw+t+EL6VUEAVirS2cbdcMpY4Gfkkz/CKu2N/Z3t5H8QtBjmSyuQ+n+IdKIUszowQMy9N8Z4OeqN27zeG9H03RvG6eD9ahsZrSzkOseFgc+bAp3ebHngfIzHaOflwT90YAOW0DUY9Y/a0uHi0h9PvLPQBHqCOF3edlG3ll+98skaBu4A7Yqj4xu77wP40b4n6bpUulaU+ovpPiCxkkBN5GJNqXcScAk9eCDkDqGkY7HwuZNc/aV+Jeu2sTLb2cMWlszLgmRdiN+tu34YrM+IMN9458GfEHRLt2uJtH8RRyRO/BhtyV+51ztQv1wOTQB9CWN3b39lb3llMk9rcRrLFLGcq6MMqwPcEEGp6+fvBniWb4L+I08CeO9QuZ/D9yUOg6zLCFiRCDvjlfd8oViijrt3ZO1CMfQNADZEWRGSRQyMCGVhkEHsa+OP2lPgjbeE7V/FXhJfL0TeqXlkzE/ZWYhVdCeqEkAqeVJGMg4T7Jqtqlha6rpt1p+oQrPZ3UTQzRN0dGGCD9QaAMH4beItB8T+DNNv8AwoyjSliWCODGGtiigeU69mUYHcEYIJBBOh4xsZtT8I63YWiB7i6sZ4I1LbQzNGygZ7cmvBr/AMHap8A9VbxP4Mku9U8HTuo1nTJFEk8MYz+9QgDIUFuTjHG7IJK+/wDhzW9O8R6HZ6votyl1p92nmRSp3HQgjsQQQQeQQQeRQB578ENRm1j4NW9nrul3OjNp8D6ZOt4hjDrGgBkG7BC4POehVh2o+HcV1pf7PljHoVwqXqadL9jmuMBTIzOUJ7YJIx9RXT/FqET/AAv8WRkkD+y7knGc8Rse30ri57Wx174EeCtJk1BtLk1K20yGzdW581VRwvvwhFAHquji6Gk2Q1Fg16IE88gYBk2jd+uat0Vk+LZdWh8M6nL4bS3k1hIGa1S4BMbOBwDgj+dAGH4L8RXniDxT4tVWX+xtMu10+AFAH85EBm5zyMsMZrsq8B/ZMubu9h8cXeq/Lqtzqvn3aBNgEjqWOB25Jr36gCnrEpg0i+lEhjMcDvvHVcKTmuf8Iz23ib4Z2DxXDzW1/p/l+bIu0kMpU5H51017ALmzngbGJY2Q55HIxXlPglp9D/ZpkcsBcWOkXrBkHQp5uMfkKAOz+FuizeHfh7oWk3JBltbYISDkdSev0NdTWN4Lvl1PwdoV9GHCXNhBMA4ww3RqcH35rZoAKKKzPEuu6b4Z0O71jW7kWunWqhpZSpbbkhRwASckgfjQBheJdMil+Ifg7VHMayW4vIFJOC2+IHA/74Jq58SovP8Ah14oi3Ou/S7oZRtpH7puh7VX17xBp0Nz4PvVhF5Bql4sFpcp0TzYJGVxnHBC4+hNbfiS2mvfDuqWtqIzcT2ssUYkXcu5kIGR3GTyKAOY+Dxj1P4P+F1uw1zFNpcUcq3P7zeNm1g2eo6jB7V498QPB938I/Ek3jH4VybrSJVm1rw+su4JBz+8Cct5fDc8lCSR8oIX2T4Laqdb+Fnhy+aCCBmtvLaOCPYisjFDhewyppV0+CH4xtfRwhZ7jQyjyhvvbZ1wCPx60AcVdR6X8YNC03xv4Avk0/xlpQxbTPjdG3O62uF7o25sH/aJHBYHtPh/46j8RmbStYtv7I8WWQxfaVKwLKf+ekZ6PGeCGGeo9ifFfiT4XPw++JNnffB6doPFF5E93c+HY490M9suSzKpwApKEeWDn+5tKgV03g/xj4O+OOn21tqaHRfGtmS0RhkMdzCy8iSCXHzLySUPTByCAGIB7zRXnVj4m8QeFbxNN8b2T3tgXCW/iCzUFHBOALiIYMbcclcryPevRQcjI6UAFFFFAHNeD9G1PQptUtru+fULCe6ku7ae4nZ5o/MOTEQRgKp6EHv0Fbmp2Frqmn3FjqNvHc2dwhjlhkXKup4IIqzRQB8mahfa1+zl8SmtdPgl1LwLrjmW3sBIWZW4BCE8iVCVHcOhXJ3YKfRPw88feH/iBpBv/Dl55vl7RPbSALNbsc4DrnjocEZBwcE4NR/FLwcPG/hOXToruax1CCRbuwu4ZCjQXKA+W+RzjJIOOcHjBwa808Q/CvxRai18aeErix034ipGf7SgsnIstUOfmyHCgM+AxBAXdySCN9AHvNFcF8JPiPafEHTLsG0n03W9NkEGo6dOCHgk5HfnGVYcgEFSCPXvaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDx7xNfWfgvxdF4ks7m2uPBviK5/s7W4ocOkF0QVS4yvABIKSZI6g4JxjX0i10y88TQaB4nBm13w1IdR0u7YMjNaN8obfxuxnY46EqDz1HLappdhpPjKeBntr34a+OC8FyscwMNpqGMB1YZx5hQrx/H1xtGa3izxHHa/CTxg/iC2ifxf4atpdGlktiysqXOIoZQx5Ksjo/JPIPQ0Aaf7Lf2jU/DHiLxTexxxz+INZuLwLHnaFyBgZ9G3jvwOuamOr/ANmeEfiR4r0rSLiHUW1CSCSC4T/WiHbFuAHXILkH1rb+F9hH4P8AgLpCTztbrb6S19NK42mEyK0z5Gf4S5/LtVL4TXGseIPgr4UuLC5g+1u4a5e/iZvOjSdg/AP3m28H3zzQAnxRfT/Fer2HgDxDpoFn4isJJ9Lvyu57W8iVmYlcjG1GQjB5yynhqofs+eMb+Y6p4A8Vyh/E3homHzQDtubZSFVwcAnGVGSASrIeSWra8Y2K6x8a/AaQXiJPo9rfahPCerRuI4l/8eJ+mK8k8S+GdfvPCcnj/S7dNO8b6Hrl3JNeSt9ma6tVdgMg4VuNiBScFAw5zggH1NRXDfCv4i2XjvTple2l0zXrLC3+l3AYS27EnB+YDIOM5xx0NdzQA2SNJY3jlRXjcFWVhkMD1BFfPOp2Go/ATxfJrekLLP8ADDVJlF/Yxq0jabMw2iRRnhSQo3ZwQdhGRGa+iKhvLW3vrSa1vYIri1mQxywyoHSRSMFWU8EEdjQBw/xf8Qw2nwY8RazpzLd28+nEQSQkMrLMAiuD3GHDfQVzGoeHTb6F8H/DcMglurG+trwzE4UrbwM0mPru4H0rhte0L/hChqnwt1nUryy8E+JmDaHq7t5gsJg6u9vICR8jMB0I+9k/fdl7jxda3Hh/xn8FbW4vZbqW0aewmnClfPY2yoXIycZIzjnrQB7NWb4jvJrDQ7y6tbF9QljTItkIDSDPIGfbJrSqjrul22t6Ne6ZfIZLW7iaGRQxUkEY6ggj8DQB5F8CL9r34jfFIyWz2jNdWU5gcqTHvif5SVJGRt7V7XXgf7GjRTfDbU5Ta20V4uqSQyyomJJVEcbLvPU43sB2/HJPvlAFLW9Qj0nRb/UZ/wDVWdvJcP8ARFLH+VcjbeJNC0r4QW2vyQE6E1jHK8QAOVkwCCCcdXOfxrovGdxZWvhLWZtWlSKwW0lE7v0CFSDn86858WWFr4d+Bmj+G9TxNb3bWWlO0PQCSVQSPoM0Aet26RR28SW6osCqBGsYAUKBwABxjFSU2NFjRUQYVRgD0FOoAK5X4peGk8X+ANZ0OSd7dbmIHzEXcQUZXAx7lcfjXVVxvxla9T4U+K5NLuGt7qLTppBKjYZVVSzYPY7QwoA4/wAX31jfeEvhXeeGp3k0tdfsBCyJkmJYpVKkduhB9DXpni3Vx4f8LaxrBj80afZzXfl5xu2IWx+OK4j9my4F78EfCsjRKmyOWMDr9yaRM/U4z+Nbfxjn1W3+GevtoGnnUdQeARLaiPf5iO6rINo6/Izn8KAF+DtpY2fww8NjSonhtZ7NLoI7biGlHmNk/wC8xrI8Qg2/x48ITkZS60q+tRgnIKmOTn2wK9A0+CO1sLa3ht1tooolRIUxiNQAAoxxgdK5XxNp5uviR4Ku0Uk2aXzNj+FWiVcn8dooAyLqbR9V+P1hZy2LnWNF0WW7ju8gDErrHt98At1/vGuB/aR+DVtrFnP4t8LrBYa1agy3MSARLdc535GMS5PU/e784rrXBt/2qUIQ7bnwkQW6ci76+/AA/Grn7Sth/aHwT8TJuKtFHHOD/uSoxH4gEUAeUeDvjf4n8Aana+GvjBpV0qhVC6iVzMEPR2wSsqjoWU7uD95uK+h9L1bw/wCN9BeTTL601XTZ0AfyZc4yM4YD5lb2OCKfdaTYeKPCK6drtsl7Y3tqomjl53ZUHOeoYHkMOQcEEGvir4ofC3xX8Itdm1jw9c6g2hoQYNWtXKSQhjjZNsOVOcLnhWyMYJ2gA+70UIiqowqjAFYGr+LNN0fxNpWiaiLmGfVAwtbgxEwPIP8Allv7ORyAevrnivmT4P8AxT+KPiKY6dpWseGtXu2GVh1r91MmMk7QhQv3PG7A9Ole7Q+JNe0XwzrurfFLRtNgtdK2TwyaUzXIn9SqMMqQ23BJA5JOAu4gHotFU9F1K21nR7DVLBmezvYI7mFmUqSjqGUkHpwRxVygAooooA8y+KPw2l1u7TxL4Lu10Txva4MV7GAq3QAA8ucYO8YAAJB6AEEcVJ8Hvija+OrW407U4k0zxdprNDqOmMcEMp2s8YJyUyMEclDwc/Kzek18zftieHNM0yx0jxrpvn2HiUX0dt9ptWKGUBHZXYjkOnlgKwOccHIC7QD6ZorwDS/FPjL4S21t/wAJ28/ifwVMUMWvRgm6tPMHCzox3EZ7kkjdgMThB7tpl/aarp9vfabcxXVncIJIpomDK6nuCKALNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUHgUU2VzHE7hGcqpO1erew96APnyPSfD1vd3OkR3KXXw38dTvFa7QwGn6orcIpyCN7IxAxw0YHA60fjHPqXiDwN4V8J+IJJdL1zUvEsGk3Exi2/boY8qblUz80e6SJsEj5vSrdvBpmt3lxdWGpjT/AAn45KmA/wCrm0fXI8YVRnCyOQ5OOWZOGGV3dRqcs3ib9pfRrW2kiFl4Q0ya6nYISxnul8vyic4HyGNxx2b1GAD0nxJ4fsfEHhm90G9EqWF3AbdxA+xlXGPlP+R65qzoOlWuh6Jp+laepWzsYEtoQxydiKFGT3OBya5nxF4nvLf4leFfDOlCKX7VHcXuprjLw2yoVjf2BlIGe5GPWt3xfrtr4Y8M6lrOoOyW1nCZGZULn0HA68kUAed6p4iW40zx94wtPKP9kwT6RZzRRH7RA0ZPnE5AyN/lsB/sDpXdL4YhufA0fhrXZ21aM2a2txPcr805CgFyM9cjPXj171ia9B4wTRPBtlZ6ja3GspfWja1IoRBc2qjFyyKw6ElT8oB54AyBW78QI7ybwH4jh0vzDqMunXEdqIzhzM0bBAp9dxGPegDy3V9D1HxZo+nfFHwBEdG8bRwusts4zHqcSMUaCYYGSdnyt/ugkYRk9A+GPj/TfHujPcWqPZapav5OoaZOcT2coyCrAgEjIOGwM4IwCGUbfhG3vrTwnotvq4QalDZQR3QQ5USiNQ+D6bs1wfxN8AXz6xF44+HzQ2XjSxQ742GIdVhxzBMOPmIGFbjoASMKyAHqVFcf8MfHunePtCe8s4pbPULV/I1DTp+JrOYdUYEDI4OGwM4OQCGUdhQBynxP8F2Xj7wZfaFf7UaUb7acruMEwzscfmQcYypYZ5rwC58U60fANle+KknTxR8NNatW1OKYkyXltI3lowcjBZg2M5O4Lvz84r6qrwH45aafA/jfT/iXbWYvNHuUGk+JLIRCTz7ZxtDspG0jAVfmIBZYhyCaAPfFkR2dUdWZDtYA52nAOD6cEH8adXDfCvQbrRP+Epnnura9tNa1qfWLO5t5d6vBMqbBn2C9iRjGKs/F/UBpnww8SzeZJHLLZPaQPGSGE037qLkdPnkXnt1oAzfgJf3Wr/DHT9W1IRNqN/cXU9zLHAsPmv8AaJFDFQBztVRnrgCvQqx/BmnXOj+D9C0y/lWW8srCC2nkViwd0jVWIJ5OSDya2KAPPfjldf8AFGQaLtI/4SPULfQ/OAz5AnbaZMd8AHjI5I5rW8QeGr3UNc8JG1uYI9A0qWSa7spFyZ2WPbblTj+B/mwSM8HsKyPGcV1rPxS8F6VbtDPpmnifVtTt3xlSF22knPORKHIx/dJPQV6HQBna/NHFpVxG+pRaZLcKYILqQqPLlYEIQGIDNnkDvipNDtLmw0WwtL69a/u4LeOKa7dNhndVAaQrk43EE4yetZHiPTbTW9f0Oy1PSJbq1s5G1WG734jguYiEjBA6kiV2Hb5Oh7dJQAV87/EfxbreofC/4uzRzifTbfUY9OsJwgAMbNFFNGuPvAFmGe5Zuew9W+KXie78PaAltoMP2rxPqr/Y9JtV6tMRzIeCNka5diRtwuCRnNee6X4Xn07UfBPwz0v7Zc6NoI/tfW72eEiCdt7PFCMcNmVi+w9FVTlipwAeo/Drwrb+CPBWleHbSZ7iOxjKmZxtMjsxd2xk4BZmIGTgHGT1pvj/AMSXPhjRYbjT9Jn1bULq6isra1jOxWkkbAMj4IRBzliMdB3rpaKAEXO0bgA2OQDkA15s9/M/7SMOnlj9ni8JyThc8bnvEUnH0QV6VXlFlIt7+1FqEtpulj0/wrHaXbqp2wzPdeaiMfUp8w9s+hoAsarCy/tG6DOD8snh65jI/wB2ZD/7MK2/jTCk/wAJPF6SSLGBpk7AnuQhIH1JAH41ZvdDFz8T9K1pJR/oWl3FvLH3HmSRGM/jsl/75rnvjPPLdX/gXw/aQSXE+oa/bXEsYX5DbW7CWYuTxgDacHr2zigDvPDkUsHh/S4rlCk6WsSyKeqsEAI/Or0kaSxvHKivG4KsrDIYHqCKdRQB4V8Sv2bvDPiWSS98Nv8A8I7qR5KQRhrVyP8ApnxsPTlSAOu0muX8OeO/iN8Jraey+KGhX+t+HLdwg1aBxM8SsSF+c8OpOAA5VhuAJ6LX07Wf4g0XTvEOjXek61aR3mnXSbJoZOjDqORyCCAQRgggEEEUAeUWfjWx+I2qaVqnw48Vy2+t2cLTTaDe7khuod2GSVRkI+SMSLuxnoR09Z0rUPtySLJBLbXMLFJYpAeDnqrdGU4yCOx5AOQPmPxV4K1P4MXd3PZWcvif4Xam2dU0mVQ7W/XDHIONuFYSDHKgNghWPr3wmttOv4Itf8HeLtWv/D9zuEul38wuVtmwCsSFvnhKZA27mBGPZiAemUUUUAFY/i7w/YeKPDt9o+rWsdza3MZUo/GG/hYHBwQcEHHFbFFAHPeEodT1DwJpsHjS3gl1O4slj1GB41KOzLh1ZfunIPIHy8nHFeMRXUvwB8exadKLmT4Z67JuglkO4aXck8puySUwAfmwSpyCxR930JCki+Z5km/LEr8uNo7D3+tYvjjwppXjXw1d6Hr0LS2dwOGQ7ZInH3XQ9mB+oPQggkEA24JoriCOa3kSWGRQ6SIwZWUjIII6gin18y+DfF2tfA3xKngv4jTTXfheb/kEauFJVEBxg9SFGRuTJKHGMqwJ+l4JoriCOa3kSWGRQ6SIwZWUjIII6gigB9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWJ41uNdtfC2o3HhO1tLvXIo99tBdkiOQgjKnBHJXOOQM4yQOa26KAPIPDOgLa+INW12bQ55/CmrAeJYbK7tG+2aZqcYAkAgILGWTcWBU9UKgYKlpf2ftB1CKz8R+LfEWnz6frXiXUpbk21yX823t1ZhHEwdVIwS+MDlSn0HrVFAHkvw6XUvE/xZ8T+MdV0fUNJtLW0j0TSluoHga5g8xpZJWSQBslghBwAA2CCQTXpmu6Vba3o15pl+pa1u4mhkAxnaRg9QRV6igDyz4eXGq+Oda0vxL4k0PU9FuNEsfssUd3bm2M13Mo+1MEYljEAkIQnH3nzkj5fTbu2iu4ljmBKrIkowf4kYOv6qKmooAKKKKAPC/HGna98PPi3H438LaPqOs6HraLba3punRtJIJFHyzLGowTgZBI67wWXzM17bYXK3tjb3UaTRpNGsgSeJo5FBGcMjAFT6gjIqeigArM8T6Jp3iTQL7SNatxc6fdxlJYyOo6gjuCCAQRyCARWnRQB4P+zrqfinw4brwH4y0bXGFjcSR6fqxtJWtGiXjyxIUGE+UsjE4Ibb8uFB674ri91vXfC/hKPT7uXRdRuhcardx2kjpDHCyyxoZB8ql3Tac5IHpkE+lUUAFZOs67DpN7a289lqc4uI5ZBLaWUlwkflgHa5QHaWz8oPUgjrgHWooA89+Eun6tcPrvivxNZyWmqa3c5t7efIltbBOIIXXojjLsQOfmGeeB6FRRQBwvhHWfEGrfEfxjBqFreWfh7TRbW+miWzMSXLEOZpQ7DL4ZQAVO3aRxk5rsNVt57vS7y2tLp7K5mheOK5RQzQuVIDgHgkEg4PpVqigDhfBfgi80/WJfEHi3WG13xE8Yhjl8kRwWiAYIhj52Fh94559uc91RRQAUUUUAFeWfDKC+l+LnxT1W50vUbGyu57GC2e8t2iE/kRSRO8ZPDISMgg9GBOM4r1OigDg/C2n6tD8WvHV9erL/AGXcW+nR2buhCnYku9VPfDMSf9/2rvKKKACiiigAooooAhvLWC+s57S8hjntZ42ilikUMsiMMFSD1BBIIr5T1bwX44+DfxIlvfhlpd9qmh6m67LaMNNCq5b9zMo+YFCQVlJGATknLCvrKigDl/h/4rk8W6N9qutB1nQryPas9pqdq8RDEZOxmADrnIyMHjkLkV1FFFABRRRQAUUUUAYnjLwto/jLQZtH8Q2a3VlKQ20kqyMOjKw5Uj1HYkHIJFeMaBp/jb4IXsun2enX/jHwBNMTbR2a776w3Nk/uwPmBy2QPlJAbMZYqfoKigCtpt4moWFvdxR3ESTIHEdxC0Ui57MjAFT7EVZoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18658=[""].join("\n");
var outline_f18_14_18658=null;
var title_f18_14_18659="DIP PIP ligaments";
var content_f18_14_18659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Interphalangeal finger joint anatomy and dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiographic (A, B) and schematic (C) representation of an interphalangeal joint dislocation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Johnson FC, Okada PJ. Reduction of common joint dislocations and subluxations. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18659=[""].join("\n");
var outline_f18_14_18659=null;
var title_f18_14_18660="Bacitracin, neomycin, and polymyxin B: Drug information";
var content_f18_14_18660=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bacitracin, neomycin, and polymyxin B: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/6/3173?source=see_link\">",
"    see \"Bacitracin, neomycin, and polymyxin B: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/37/33363?source=see_link\">",
"    see \"Bacitracin, neomycin, and polymyxin B: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neo-Polycin&trade;;",
"     </li>",
"     <li>",
"      Neosporin&reg; Neo To Go&reg; [OTC];",
"     </li>",
"     <li>",
"      Neosporin&reg; Topical [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F138782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Ophthalmic;",
"     </li>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F138771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic infection:",
"     </b>",
"     Ophthalmic ointment: Instill",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; into the conjunctival sac every 3-4 hours for 7-10 days for acute infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Superficial dermal infection:",
"     </b>",
"     Topical: Apply 1-3 times/day to infected area; may cover with sterile bandage if necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F138778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/37/33363?source=see_link\">",
"      see \"Bacitracin, neomycin, and polymyxin B: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F138772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: Bacitracin 400 units, neomycin 3.5 mg, and polymyxin B 10,000 units per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neo-Polycin&trade;: Bacitracin 400 units, neomycin 3.5 mg, and polymyxin B 10,000 units per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: Bacitracin 400 units, neomycin 3.5 mg, and polymyxin B 5000 units per g (0.9 g, 15 g, 30 g, 454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neosporin&reg;: Bacitracin 400 units, neomycin 3.5 mg, and polymyxin B 5000 units per g (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neosporin&reg; Neo To Go&reg;: Bacitracin 400 units, neomycin 3.5 mg, and polymyxin B 5000 units per g (0.9 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F138763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Helps prevent infection in minor cuts, scrapes, and burns; short-term treatment of superficial external ocular infections caused by susceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F138780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Reddening, allergic contact dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Itching, failure to heal, swelling, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Conjunctival edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F138766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to neomycin, polymyxin B, zinc bacitracin, or any component of the formulation; epithelial herpes simplex keratitis; mycobacterial or fungal infections; topical ointments for external use only",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F138752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic ointment: Bacterial keratitis has been reported with the use of topical ophthalmic products in multiple-dose containers. Care should be taken to not contaminate the container.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical ointment: When used for self-medication (OTC use), patients should notify healthcare provider if needed for &gt;1 week. Should not be used for self-medication on deep or puncture wounds, animal bites, or serious burns. Not for application to large areas of the body.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acarbose: Neomycin may enhance the adverse/toxic effect of Acarbose. Neomycin may enhance the therapeutic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Neomycin may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Neomycin may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7413753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F138774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7413756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if bacitracin, neomycin, or polymyxin B is excreted into breast milk. The manufacturer recommends that caution be exercised when administering to nursing women. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Neo-Polycin Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5-400-10000 (3.5 g): $52.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Neomycin-Bacitracin Zn-Polymyx Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-400-10000 (3.5 g): $55.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Neosporin Original External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5-400-5000 (1): $0.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5-400-5000 (14.2 g): $3.98",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F138767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bamyxin (IL);",
"     </li>",
"     <li>",
"      My-B (TH);",
"     </li>",
"     <li>",
"      Neo-Polybacin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Neosporin Dermico (MX);",
"     </li>",
"     <li>",
"      Neosporin Ophthalmic Ointment (AU, IN);",
"     </li>",
"     <li>",
"      Novosporina (PY);",
"     </li>",
"     <li>",
"      Polixin Ungena (MX);",
"     </li>",
"     <li>",
"      Polybamycin (MY, SG);",
"     </li>",
"     <li>",
"      Polysporin (BR);",
"     </li>",
"     <li>",
"      Spersin (NZ);",
"     </li>",
"     <li>",
"      Terramycin Plus (PH);",
"     </li>",
"     <li>",
"      Tigalin (ID);",
"     </li>",
"     <li>",
"      Topimicyn (PE);",
"     </li>",
"     <li>",
"      Tribiot (MX);",
"     </li>",
"     <li>",
"      Yentuogin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F138751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F138765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9058 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18660=[""].join("\n");
var outline_f18_14_18660=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138769\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138782\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138771\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138778\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138772\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138761\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138748\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138763\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138780\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138766\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138752\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298809\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138756\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138757\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413753\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138774\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413756\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524344\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138767\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138751\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138765\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9058\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9058|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/6/3173?source=related_link\">",
"      Bacitracin, neomycin, and polymyxin B: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/37/33363?source=related_link\">",
"      Bacitracin, neomycin, and polymyxin B: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_14_18661="RML RLL atelectasis-I";
var content_f18_14_18661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76570%7EPULM%2F56606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76570%7EPULM%2F56606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frontal chest radiograph demonstrates combined atelectasis of the right middle and lower lobes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The minor fissure (arrowhead) forms an interface with the hyperexpanded right upper lobe. The right heart border, right hemidiaphragm and the descending right pulmonary artery are obscured. Arrows denote the major fissure and the asterisk marks the upper triangle sign.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frontal chest radiograph reveals combined right middle and right lower lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The interface formed by the minor fissure with the right upper lobe mimics an elevated right hemidiaphragm (arrow). The descending right pulmonary artery, right heart border and the right hemidiaphragm are engulfed by the atelectasis and are obscured.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18661=[""].join("\n");
var outline_f18_14_18661=null;
var title_f18_14_18662="Abatacept: Drug information";
var content_f18_14_18662=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Abatacept: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/52/1861?source=see_link\">",
"    see \"Abatacept: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/6/44132?source=see_link\">",
"    see \"Abatacept: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2452297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Orencia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5663024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Orencia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2452301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antirheumatic, Disease Modifying;",
"     </li>",
"     <li>",
"      Selective T-Cell Costimulation Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2452743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Rheumatoid arthritis (RA):",
"     </b>",
"     I.V.: Dosing is according to body weight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &lt;60 kg: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     60-100 kg: 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;100 kg: 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      I.V. regimen:",
"     </i>",
"     Following the initial I.V. infusion, repeat I.V. dose (using the same weight-based dosing) at 2 weeks and 4 weeks after the initial infusion, and every 4 weeks thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      SubQ regimen:",
"     </i>",
"     Following the initial I.V. infusion (using the weight-based dosing), administer 125 mg subcutaneously within 24 hours of the infusion, followed by 125 mg subcutaneously once weekly thereafter.",
"     <b>",
"      Note:",
"     </b>",
"     Patients unable to receive I.V. infusions may omit the initial I.V. loading dose and initiate once weekly SubQ therapy directly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Transitioning from I.V. therapy to SubQ therapy:",
"     </i>",
"     Administer the first SubQ dose instead of the next scheduled I.V. dose.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6027843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/6/44132?source=see_link\">",
"      see \"Abatacept: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Juvenile idiopathic arthritis (JIA):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;6 years and &lt;75 kg: 10 mg/kg, repeat dose at 2 and 4 weeks after initial infusion, and every 4 weeks thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Children &ge;6 years and &ge;75 kg:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage is according to body weight. Repeat dose at 2 weeks and 4 weeks after initial dose and every 4 weeks thereafter:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     75-100 kg: 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;100 kg: 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2452744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Due to potential for higher rates of infections and malignancies, use caution.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15670390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15670391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F2452745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discontinue in patients who develop a serious infection.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2452751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orencia&reg;: 250 mg [contains maltose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orencia&reg;: 125 mg/mL (1 mL) [contains sucrose 170 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2452299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2452746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infuse over 30 minutes. Administer through a 0.2-1.2 micron low protein-binding filter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ: Allow prefilled syringe to warm to room temperature (for 30-60 minutes) prior to administration. Inject into the front of the thigh (preferred), abdomen (except for 2-inch area around the navel), or the outer area of the upper arms (if administered by a caregiver). Rotate injection sites (&ge;1 inch apart); do not administer into tender, bruised, red, or hard skin.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2452328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2452304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of moderately- to severely-active adult rheumatoid arthritis (RA); may be used as monotherapy or in combination with other DMARDs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of moderately- to severely-active juvenile idiopathic arthritis (JIA); may be used as monotherapy or in combination with methotrexate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Abatacept should",
"     <b>",
"      not",
"     </b>",
"     be used in combination with anakinra or TNF-blocking agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5663023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Orencia&reg; may be confused with Oracea&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2452315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentages not always reported; COPD patients experienced a higher frequency of COPD-related adverse reactions (COPD exacerbation, cough, dyspnea, pneumonia, rhonchi)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (&le;18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (12%), upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (adults 54%; children 36%), antibody formation (2% to 41%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (9%), fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dyspepsia (6%), abdominal pain, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reaction (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (7%), limb pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (8%), bronchitis, pneumonia, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infusion-related reactions (&le;9%), herpes simplex, immunogenicity (1% to 2%), influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening):  Acute lymphocytic leukemia, anaphylaxis, anaphylactoid reactions, cellulitis, COPD exacerbation, disease flare, diverticulitis, dyspnea, flushing, hypersensitivity, hypotension, joint wear, lung cancer, lymphoma; malignancies (including bile duct, bladder, breast, cervical, melanoma, myelodysplastic syndrome, prostate, renal, skin, thyroid and uterine); ovarian cyst, pruritus, pyelonephritis, rhonchi, urticaria, varicella infection, vasculitis (including cutaneous vasculitis and leukocytoclastic vasculitis), wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2452310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer's U.S. labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to abatacept or any component of the formulation; patients with, or at risk of sepsis syndrome (eg, immunocompromised, HIV positive)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2452311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Rare cases of hypersensitivity, anaphylaxis, or anaphylactoid reactions have been reported; medication for the treatment of hypersensitivity reactions should be available for immediate use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections: Serious and potentially fatal infections (including tuberculosis and sepsis) have been reported, particularly in patients receiving concomitant immunosuppressive therapy. RA patients receiving a concomitant TNF antagonist experienced an even higher rate of serious infection. Caution should be exercised when considering the use in any patient with a history of new/recurrent infections, with conditions that predispose them to infections, or with chronic, latent, or localized infections. Patients who develop a new infection while undergoing treatment should be monitored closely. If a patient develops a serious infection, therapy should be discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy: Use may affect defenses against malignancies (via T cell inhibition); impact on the development and course of malignancies is not fully defined. As compared to the general population, an increased risk of lymphoma and lung cancer has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; COPD: Use caution with chronic obstructive pulmonary disease (COPD), higher incidences of adverse effects (COPD exacerbation, cough, rhonchi, dyspnea) have been observed; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anakinra: The manufacturer does not recommend concurrent use with anakinra.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; TNF-blocking agents: Adult patients receiving therapy in combination with TNF-blocking agents had higher rates of infections (including serious infections) than patients on TNF-blocking agents alone. Concurrent use with TNF-blocking agents is not recommended. Monitor for signs and symptoms of infection when transitioning from TNF-blocking agents to abatacept.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution, higher incidences of infection and malignancy were observed in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis-positive patients: Safety has not been established in tuberculosis-positive patients; screen patients for latent tuberculosis infection prior to initiating therapy. Treat patients testing positive according to standard therapy prior to initiating abatacept.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Maltose: Powder for injection may contain maltose, which may result in falsely-elevated serum glucose readings on the day of infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis screening: Patients should be screened for viral hepatitis prior to use; antirheumatic therapy may cause reactivation of hepatitis B.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently or within 3 months of discontinuation of therapy; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2452322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: May enhance the adverse/toxic effect of Abatacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-TNF Agents: May enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Abatacept may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: May enhance the adverse/toxic effect of Abatacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the adverse/toxic effect of Abatacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Abatacept may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4795747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid echinacea (has immunostimulant properties; consider therapy modifications).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2452305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2452306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Due to the potential risk for development of autoimmune disease in the fetus, use during pregnancy only if clearly needed. A pregnancy registry has been established to monitor outcomes of women exposed to abatacept during pregnancy (1-877-311-8972).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2452308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2452309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for adverse reactions and possible effects on the developing immune system, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Orencia Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/mL (1 mL): $670.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Orencia Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (1): $736.33",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2452749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of infection, signs and symptoms of hypersensitivity reaction; hepatitis and TB screening prior to therapy initiation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Orencia (AR, AU, BE, BR, CH, CN, CO, CZ, DE, DK, EE, FR, GB, GR, HK, HN, IE, IL, IT, NL, NO, NZ, PE, PL, PT, SE, SG, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2452741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective costimulation modulator; inhibits T-cell (T-lymphocyte) activation by binding to CD80 and CD86 on antigen presenting cells (APC), thus blocking the required CD28 interaction between APCs and T cells. Activated T lymphocytes are found in the synovium of rheumatoid arthritis patients.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2452329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: SubQ: 78.6% (relative to I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 0.02-0.13 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 8-25 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Doan T and Massarotti E, &ldquo;Rheumatoid Arthritis: An Overview of New and Emerging Therapies,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2005, 45(7):751-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/14/18662/abstract-text/15951465/pubmed\" id=\"15951465\" target=\"_blank\">",
"        15951465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furst DE, Breedveld FC, Kalden JR, et al, &ldquo;Updated Consensus Statement on Biological Agents for the Treatment of Rheumatic Diseases, 2007,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2007, 66(Suppl 3):2-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/14/18662/abstract-text/17934088/pubmed\" id=\"17934088\" target=\"_blank\">",
"        17934088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Genovese MC, Becker JC, Schiff M, et al, &ldquo;Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor Alpha Inhibition,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(11):1114-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/14/18662/abstract-text/16162882/pubmed\" id=\"16162882\" target=\"_blank\">",
"        16162882",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kremer JM, Dougados M, Emery P, et al, &ldquo;Treatment of Rheumatoid Arthritis With the Selective Costimulation Modulator Abatacept: Twelve-Month Results of a Phase IIb, Double-Blind, Randomized, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2005, 52(8):2263-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/14/18662/abstract-text/16052582/pubmed\" id=\"16052582\" target=\"_blank\">",
"        16052582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kremer JM, Genant HK, Moreland LW, et al, &ldquo;Effects of Abatacept in Patients With Methotrexate-Resistant Active Rheumatoid Arthritis: A Randomized Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2006, 144(12):865-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/14/18662/abstract-text/16785475/pubmed\" id=\"16785475\" target=\"_blank\">",
"        16785475",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kremer JM, Westhovens R, Leon M, et al, &ldquo;Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation With Fusion Protein CTLA4Ig,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1907-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/14/18662/abstract-text/14614165/pubmed\" id=\"14614165\" target=\"_blank\">",
"        14614165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/14/18662/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tay L, Leon F, Vratsanos G, et al, &ldquo;Vaccination Response to Tetanus Toxoid and 23-Valent Pneumococcal Vaccines Following Administration of a Single Dose of Abatacept: A Randomized, Open-Label, Parallel Group Study in Healthy Subjects,&rdquo;",
"      <i>",
"       Arthritis Res Ther",
"      </i>",
"      , 2007, 9(2): R38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/14/18662/abstract-text/17425783/pubmed\" id=\"17425783\" target=\"_blank\">",
"        17425783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weinblatt M, Combe B, Covucci A, et al, &ldquo;Safety of the Selective Costimulation Modulator Abatacept in Rheumatoid Arthritis Patients Receiving Background Biologic and Nonbiologic Disease-Modifying Antirheumatic Drugs: A One-Year Randomized, Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2006,  54(9):2807-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/14/18662/abstract-text/16947384/pubmed\" id=\"16947384\" target=\"_blank\">",
"        16947384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8526 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18662=[""].join("\n");
var outline_f18_14_18662=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452297\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5663024\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452301\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452743\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027843\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452744\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15670390\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15670391\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452745\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452751\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452299\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452746\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452328\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452304\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5663023\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452315\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452310\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452311\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298627\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452322\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4795747\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452305\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452306\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452308\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452309\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370388\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452749\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539967\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452741\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452329\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8526\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8526|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/52/1861?source=related_link\">",
"      Abatacept: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/6/44132?source=related_link\">",
"      Abatacept: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_14_18663="Pylephlebitis liver abscess";
var content_f18_14_18663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Pyelphlebitis and liver abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 618px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diverticulitis in the sigmoid colon can result in bacterial leakage into the portal venous system. Bacteroides species, particularly B. fragilis, have unique virulence factors that contribute to thrombosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18663=[""].join("\n");
var outline_f18_14_18663=null;
var title_f18_14_18664="Disconnected Roux-en-O misconstruction";
var content_f18_14_18664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Disconnected Roux-en-O misconstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 437px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG1AkcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6lX9qnwS7BV0nxKzHgAW0GT/AORq4n4XfB34W/EnTLy80HUfGEItJhDLDdy2ySDKgq2FjYbTzjn+E8V89WssVlbp9kD/AGp1DPKRgqCM4T+RPegD7Fm/aZ8JQuUk0bxIGHUeTbnH1/f8VCv7UXgxhkaT4kx0/wBRb/8Ax6vjkAYBO5cc5B/nQyFipGGbplR1oA+xm/ai8GqxB0fxKCOv+jwf/HqD+1H4MDYOkeJM9P8AUQf/AB6vjoYKg/w45x2+tPWI55H1OMg0AfYP/DUngvGf7J8Sf9+IP/j1H/DUngv/AKBPiT0/1EH/AMer4+8sb2By3OMdefr7VHhixLBt30x/k0AfYv8Aw1L4L5/4lPiTjr/o8H/x6j/hqTwWVBGk+JCCcZFvB/8AHq+OFBOAMsGOfl7j2B5/CpIleRhtBbdyWxjPrQB9if8ADUfgzIH9keJeQT/x7wdv+21Ob9qDwcoy2j+JQPXyIP8A49Xx4YGD43Jg8+tWoBELZ1e4CnG0Jt6e49fpQB9b/wDDUfgzGf7I8SdM/wCog6f9/qB+1F4NOf8AiUeJeP8AphB/8er5Pmsmit1eByUZuMr/ABew61UCjJwp46gdVP0oA+uz+1F4NGM6R4kGf+mFv/8AHqB+1F4NJ40jxL/34g/+PV8h7N3Bj6D+Jsg/T2qZ7RCOCqNyV28k+vFAH1uf2ofBo66R4k/78W//AMeoH7UPg45/4k/iT/vxb/8Ax6vkyK0WRSig7uDkjkZ9KlFtGsZzuRV6krkj2oA+sv8AhprwjuC/2N4kyen7m3/+PUP+034RQEto3iUDOM+Rb9f+/wBXyfJGkZ4Z25xgcE/59e9DWbyxMY2BcHKZOOPX2oA+rpP2nvB8Zw+j+JQfTyLf/wCPU3/hqHwdx/xJ/EnPT9xb/wDx6vk24hkkDylPLkHG4kKMdDj3NVfId7fbEjEqchj02/5/OgD68/4ah8GhS39keJMA4/1Fv1/7/U0/tSeDAAf7I8S89P8AR4P/AI9Xx7yzDDb8jHHXj+lMOCQeueevUD+VAH2M37Ufgxc7tI8Sjp/y7wd/+21H/DUfgzn/AIlHiXj/AKd4P/j1fHYcnO45HqvGPb3NMIAb5vmYEgkc9eeBQB9jt+1H4MUkHSfEmR1xBbn/ANrUn/DUngz/AKBPiT/vxb//AB6vjgcHGACvHzHgfX/CkwvJbOCcc9T7YoA+yD+1J4LAOdJ8SD/thB/8eoP7UngwAE6R4lGe32eDP5edXx25I8uTbjK7Tx834Zpq7o03BdoY43ep74oA+wv+Gq/BH/QK8S/+A8H/AMeo/wCGq/A//QK8Sf8AgPB/8er4zuYtoDqRg8H39/pVagD7V/4ar8D/APQK8Sf+A8H/AMersPhf8a/DnxH1+40jQ7LV4LmC1a7ZryKNUKK6KQCsjHOXHb1r8+q+gP2Kf+Sp6r/2BZf/AEfBQB7r49/aA8K+CPFl94e1Ww1ua9s/L8x7aGJozvjVxgtID0YdhzXP/wDDVfgf/oFeJP8AwHg/+PV8/wD7Uf8AyXbxN/26/wDpLFXpPi/4NfDrw14jXRHHjrUL3+z31Nvsc9ltSBCQxJkCcjb0GfagDt/+Gq/A/wD0CvEn/gPB/wDHqP8AhqvwP/0CvEn/AIDwf/Hq8b+Lvww8I+HfhVofjHwje63OmqXcUSLqLx8RtHK33VRSGygHUjr14NeHUAfav/DVfgf/AKBXiT/wHg/+PUf8NV+B/wDoFeJP/AeD/wCPV8VVPbQiVsuSsY6kfyFAH2vZftOeEb1iLXRPE8gH3mFtAFX6kzYH40j/ALT3g9HZf7I8RMy9dkVs38p6+Qrm6kkiFvGvk2ydIYmygP8Ae/2j7mqqSmFgyDaVPGOQD7f560AfYZ/ak8GBgp0jxKCTjm3gH/tag/tS+CwTnSfEnH/TCD/49Xx0SSWdyXPU5Y5OOv40zBwSRuUcvx/njpQB9k/8NR+DP+gR4l6Z/wBRB/8AHqT/AIak8F/9AnxJ/wB+IP8A49Xx1t4OcYPUnjpTCpwdwwy4yD1+tAH2R/w1J4MyQdI8Sgj1t4P/AI9R/wANSeC+v9keJP8AwHg/+PV8cKckcghex7+1AB+bHXqc9KAPsj/hqPwZ/wBAnxJ/34t//j1H/DUfgzOP7H8S5/694P8A49XxueDuC/IeRn2pxGYyRkjJOc/qaAPsYftR+DCCRpHiXj/p3g/+PUf8NR+DMgf2R4lyf+mEH/x6vjnkck9Of/re1KvLZcDJOCp9PY/hQB9ij9qPwYcf8SjxJzxzbwf/AB6nD9qDwcf+YR4k/GC3H/tavj2FMyfM4Oec4yfyqwyrIiKrAgAkHHP5/wCRQB9hWP7Sfha+mWK10TxJI7HAHlWw/nPTJf2l/CkWqnTX0PxOL4SeV5It7cnd6cTYr5q8D2sS6lPc3YKR28TSyHHChRnP5dK5nTbK41i+1LWVnMMdvIZ3d+CctwAR3oA+tb39qDwdY3Uttd6N4miniO10a3gyp9D++q7o/wC0Z4b1jcdO8PeKZkX7z/Z7dUH1YzAfrXxG/mX2qnczyyTy4zI2SxJ7mvVPFV4IrT7HYSPDbWkaoyxHr22/p1oA+hLz9pTwpZyMk+j+IQy9QqWrY/Kc0i/tK+FWsHvV0PxKbVGCtIIbfAPp/rq+PZIvMJnCN85znuT6UC6uV09rcORbly+Cflz6+9AH1wf2pfBY66R4l/8AAeD/AOPUf8NSeDM4/sjxLn/r3g/+PV8c4Dvjlu5I4wKATt+vYc0AfY//AA1H4M5/4lHiTjg/uIP/AI9TR+1L4Lz/AMgjxL/4Dwf/AB6vjogHkhiuSB6E+lJtLPgKCAe+cH2oA+xn/am8FIAW0nxKAen+jwf/AB6mf8NV+B/+gV4k/wDAeD/49Xx8jKIXWREdO+cg1Rni8sgjlG6f4UAfZ/8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfpp4C8V2PjfwnY+IdKiuYbK88zy0uVVZBskZDkKSOqnv0oriv2XP+SE+Gf+3r/wBKpaKAOV/bW/5JZpX/AGGov/RE9cf8BNB1nxR+zf4n0Pw7cWlrd3+sPBJNcsyqsJht/MxtUkkrkY9zzXYftrf8ks0r/sNRf+iJ6+M7CHzrhQV3KDkj19qAPvbwJ8MtQ8D/ABCl1LStUW78P3emRWd1FdbEnEsICxMqxRqhUIAvPPJJzXwjFgxKrHooIDHrx2NTsiSMzJHGFHA+QcfX/GmBAdygYH930I9P/rUAKAeCpYdc55x+PcU8Flj3YD7eQy9eaIkLMAT8ink9SPWleVA2Il3MBglvvGgBkbNJxgDj746mlZH+YM6HIJ4OQB7eoqSJGmJBVzn7pweff3PtWvY+HLqdTJKPs8JH+slO0D3A60AYYiJO6NnIHGNuOKkUhhn7+DyrNgqO4z3xXSC00K2kQTXMty442W6bQfr6/wD1hVmG5tAw/s/SzENuFZlDE++5ulAHMQ2k0hV443kUnK7R+ua1LfQr6RfMcJGM5+d8c9uB0zxz/jXQw2uo3cga3jETL/FJ87Y/3emfpWvbaBdzRsl3dCUSAEcYKAZPAHbuKAOTXwxhkE1xtZztBAxj6+9aMXhS1cqHlbJJzngH347f45rr7bTIYGKSB8Bc5z1HY81d+yQxg7lYx5wu77y+v40AcZd+G7OPy1YSSqFy0hnIAHcAHtnvULWOjIwLGKUBclVflfYDuK6K98P6bcy72STzTztEh+bnr1wRVOXwnYyMHhWS3uVOQ6vkAepz39qAMC51PRbOQwrpr3DA4DYA/DnitDStZs3fH9jxRQk4yWDEDsPf6VBceFrgkCExSZ6bvl3/AOfwptt4d1SK5jMVrHg/wbwf078UAez3HgjR7vw7b6jY6vZ/a9qPPaXCg7M9t46Y9xiuR1XTfsEsMM0Nu6yLvjeMApKuedp747isrTNK1K1ZpJpnhkbOQkuAV6YUevT9avy2c88yzTSRM23agViEVvX0560AVpdKsL2ERyxRhgowoQDPv7Gsefw3bKWFpcHzAT8p53f0PpW+2nFsKSQ+flCHBHHOMdPrVF9OuI0HlXEgG7Khhnge/bHcUAc5d+FLre/l7ZUOMIXJwf8APboKx7nRLm2RjLDKDngRrwe/412kjapEQyJbXCAjKMp5+np71LHrMRZo5UkikPBXnb6Yz0OPWgDzK6jbaQUySNw3AA/UAdqqSwEMfMjOAf73P5d69Se00u9hf7RHbtIeWlztZRnjoO9Y2o+EY3IaxuPLDZ2Ryybs4689SM9aAOBaPJfYw2r1BP6Y7+vFIV2oGY7RnAC9WP16AVq6hp9zaugnjXZyqOV4Ye3rzVH5wxyA47Bj8oH+ewoAqDJUNgAKeN3QfT1pAzMcDOWHXp+XoKsugb5lGxVBPLYB7cD+lQSAp8rbRzyOef8AH6UAOA+Ql264OSMD2PqfpTC24hVAPOS7nt9ew+lK6hAXbOSeNwyT9B0FM+djjKqM85wB/n2oAcwQsoLtLk9NhA/AetUZ4zHIRx+Bzirg9ASc9SCAfz9KW5hiS0AygmBzjdkn8uAP1NAGdX0B+xT/AMlT1X/sCy/+j4K8Ar3/APYp/wCSp6r/ANgWX/0fBQByn7Uf/JdvE3/br/6SxV9TfEf4d6j4h+Itn4gh0vw7rFhDpL2Bs9XldAJS7MJBiGQcA+x68ivln9qP/ku3ib/t1/8ASWKvKqAPqz9ofw5e+Ev2cfCmiapqLaleWmqxrJcHODmK4YKM84UEKM9gOnQfKdFPjRpGCqMmgB9tCJZMMdqDkmr4I27Yk2DqV3Z6d6YoWOMBCDx19T6+9OcjktuXBx3yv+fQ0AG4B2bHHJKgnI56ilOTgfK2eQfUd6dcIMnc43HkEdMnn8KFfEhYIA2cHnIPHp+NAEZwBk4KnhT1/Gm7VyDhgMdu1OjXHEbBRn7jDgj60+MFVdmbaR7Z3HuaAGOSCAp4XjJHf+tCDeVA+WTG0DODU1rHBJf26Xty9rZvIommii85o0zy2zI3Y64yK+jfDX7MK3mpWF7deK7bUvDUqiYSWkRjluEIBUKcsoDZ5OTx9eAD5sjO4MCGZgdvHc+n+fSj5VOGwygcn1H9K73456Xp2mfFvxDp+iWkdrp9oLaGGKIbQgWCMN9ckEk9Sck8muJMR3dn3Ek4bHOOmaAKzAcgEuOowOfapfLAX5nUAEH3z74qwkZxyjIe7Yxz/iPWmLGiPy8u8AkDHzDPc/WgCMxEsDuDHHRRyKl8pQTkktxnaMhs1pWWnXEgUxxFlk4V8H9cdPrW3ZeFL2Q5wsJP/LMsCxHpg/nQBzdvDvUqocg8lcdfX8a07CyEzqtvGwOed67sfU/SuotvCCgg3VyqRqfm8vOPx717d4Z+Ct1N4egubfUINMuJ1V0d4PtDqp53YJADeg6DPNAHzz44vBomhQ6PBJsvbn57tR/CnYe2euPQe9cxBDqNt4dluLed/s0qmOeIEBVUngnPc9u9e4+KdK+EngM32m6ympeIvE7Ph5Em3tGWHSRvljU8nIG9h615prc+lTWMtmbicBU8iGJ9uWdThXbGPuj5R1yKAOS8I2v2nxDaISBsbzMEdcc1t6q9za3svmNz/Fvbk8+npWb4W1FtD1xbmWb/AEdgY3lRd45H5+ldve6CuqwpqFqIsSICrbsk5oA4ZJFO4EFh1Ylup7fU1Gzs4dU2tk7VXbnjp0rV1HSL+2tku3sJYrTzmtEnx8jSqqsy59cMD+eOhr6b/Z7+Co0j7P4o8X2+7UziSzspV/49u4kcf3/Rf4ep+b7oB8kOkiSFZlcOjYcHg5z6dqYeQMAMxzgjOT+H9a95/auTwlD4zj/sM/8AFQuCdTWAAxKSPlZvSQ9wOo5OD18FY5JH+sJwM4yPoKAHgkN3T5duAAT+H8qa+7CkAgDPU9PyoyoU4LHOBnOPwx7Ug5O7np16/jQA5chVzgIScAnJY/hSZUhhKxdmP3F5P09hQjbQdg+bGcr1I6dewoUjAznoAAB39B7UAUZojGf9k9P8KirRCBo1U52ngnHGPrVGRCjlT+FADKKKKAPv/wDZc/5IT4Z/7ev/AEqloo/Zc/5IT4Z/7ev/AEqlooA5X9tb/klmlf8AYai/9ET18g2Ya2tN4Uh34yGxx6/0/GvsL9sxQ/wz0gEMR/bURwvX/UT18gSFTEpUKpHBwCefUigBrFlbO7BXnLZ/n/8ArFDGRuqIy9cdz9D3pqMQBsnCntg8D2INGCWwqq3IOAccnjpQBZRWmztDeVyo3qCfp6mp9P0x7xlSGMMQeWJIUfX0rT0GwW9dZbwyfY4Bh/lPzMOx7giuu0e2bWZvs1sJrexixukTGWbr1xkCgDPtbaLTrfNjb/a7oAZmZD972HT2qK+0rxFcQwXN9BKkFznyjICu8A8lQewPpXpc0tlptkqmEFVAUxsCAOORj+I56Ac1SP2/Vp0uL24uIjjbFCzFiBntnlRx068UAcfp3h+OBkkdGuLnaFCwAk89Dk8CujsdGVpAZJRFIAdyEc/ifQ+netnAjBjWBoWcYBC/KRnncD19fWpX+0eWzAlSVCg5wDzzg/l1+nNAFOApAqIpWIAcq0eBj6jmnuZNpjIRvlOSuCSCeue4qd+NxkUMoJUhRxk9/X1qNA0TKikDB4DAAj/az3549MUAM35SOOQu8eeGYZK+30qMqR/q/mGBhVHHXj3zxUo2kMmY95G7AyNv0BqLLqACY/KPcKSVbvj1+lAETqJeA7RsOWA+ZQ3+GOvtWbPewRxLlV2M2E2v8xI7e/t7VpXcMt3bvG0oAkQneeBj19z/ACrldK0l5b5Unkybf5Xjzjcf6HpQB1FurGIGUNEmN+c5DDHAI9vWrceX/wBW7EnkeUduD649DUccHlFQ7oueQW6ZxjBPWpWeORUVVdY9uGIPzgenHY0AOY4wApLSEMDw5Qj0J7expTE3lszL8gOdzDOPrgck/lSRLCwZRGSHAIORj3B9Ka2xCYmRXZeWCsSq46f/AFhQA9cg7YWIiDDBZivPuOoAPp1pUDZZ5JFy5OScduv40vlHDNMpZMDG37z+mT6U1XRSWZN2Tkkjn6L7nvQA2RUYYLvkcNvI3A+pPcc1Vmsop4sRoiRZ6kk7vZQe3cjrVldq8DzPkBHlhdqNn1Hp7cdKYJCWkMrIY+gcggD8O5x2H40AZsulJ5m6BzGeOTjHTqO9QxQyJE6pLGkbsNzzAfOPU9wPYdcVuY2jzHidUPUyAAYHfHWq0yrKfmRmcqGUuuS/PAAxxxQBkXa28saxTFZgwIDlSqsB05I6ew/GuW1bwqZkMlmQ5PSLhVJH93FddM32WQeapERztmlUs3P+zngVRNtd2zs9lIsyONzxyMNo56s/9KAPM7qwmhlcOhD9AzAYA9B1xk/Umq5DR7hFn/aP3ifb2+ma9H1K2tdSXy73EVxghN44U+x4z6Y4FcTrWi3On3DfaQTEThJsrt47ZH9KAMtwCpjwiTYPDvuI9RjHH+eartHlgrvGiHsrcH8amkygCK26HorY2r79qRZ/MZlEZnBHIAxk98kdqAIgQhJjADDvjoM+h6fjSoQW3xqxPUnd/NvX6UFSCv8Aqzuz1OR+A7/jSbN6ttDSOvVmPCigCncx7JOgGecDPH5171+xT/yVPVf+wLL/AOj4K8Ouo08rIfcwGeBgD1wP617j+xV/yVPVf+wLL/6PgoA5T9qP/ku3ib/t1/8ASWKvKq9V/aj/AOS7eJv+3X/0liryqgArUgCxWqqkJM+7c7c5x2AHSqdsgJ3tnC+gzzVwq2ABnPVSO/09RQAm4kFiuc8lh3HuKfGQMkAkjoD/ABZ7EdCKZGymTn5XP3SDwf8AA0rr8oYHDknjoM9uRQA64ZZApOF3cfN0HtSYBO3cB2Gev+f0pF3Pv2puIHTaMg/4U5Yjz5mxUB/i6nn2oAaVwoDMASCASMY/+tUkaZZQ7sp43DHBHr/SnxxIGKuwJ6n5fuj3B6/hWtZ6HeTlTt8uMA/O64Xb9CM0AZMSl2UjcWHUjjcK97/Zi+Kv/CO6hD4P1+bGj3ch+wTu3FtKTzGc/wADHP0b6kjz2y8M2cbqspa4dcFlVDt+n5dKuapb2iWMlvIbCzhlj8vLJu3enupB5ByeQKAD4m6fdat8VfGF0ssaxrqksI3eqYX+WKzbHwjDIr77jlACVgIb8M/zq1pmix+a1xcS3epTSyPK8kuQrs3UkEkk+5PJq5LaauysLOKysYT8vynnHXrQAxvCtj5ZVPNiZGG2VjvGO/HSr5tLWGJY3gs4ti5D4UYb+8RnnoK5XU1v4C7Xt2gwpJVCSMdmBFZ1rq0dtCyLCxEnBZ2/MZoA7GbX9Nsm4Yyy9NsS9T6Z6e9UZPGW8FIVKtz0wc+vPrXMH7M/7wWJ543bjz+Hb60z7Q5gAW3WLryRyPz6fyoA62x8UrJKu61lklUcyKxGO+CD/Sum/wCE3cWkSC+uVjUfu4POY7B1OMHGD+teVQiW4c5mRUBwxyfzHrmmanqMVkTBCRIpGQq8cf7RoA9Ev/FkEmQ1k7EHO1lBH1rNOp6ZKfLn0u1+9nYY02KT1JPf2rzmDWZYj88EEqf3XB/mDVlfFN+i7Yo7ONR0C268fmKAOzi0jwzLemcxXCCMiTYuSmR7dx24rtotQhlhQwGEW0YJwmMKvcnvjvXjtv4rlEiteWVtMQc74x5T/mOP0rYZk1Sxe40ybeOVkhc7XjLdjjqrDI3DjnnFAH2j8E9Ihb4W6LLqNrBLJeSNqm10DhWeQyRsue6qUwevArH/AGiPiDq/g7RrWw8PWkq6hqYdE1Bl/dW4A5x6yY6D0ye1eQWv7QPiODTrHSdG0rSNIsrW3S3V7lnndFRQowQVXsOo/CqGu+JPEXi/Tfs3iHxFc30MrLIttDBHbohU5BG0ZODg5JzQB43KrmWSR3eSaRi0kjne8rE5OSf51C0RJIEe07sYVh19q9NuNPhuCY7m3gmIHEsa7SFz+prFvvCoEcv2SVSq8iOUFdhP8Qb9ATQBxBjLcfNnlcnnPpUTKVIzEVPbgjj0/wDr96177Tp4d4ulkQJgEscgVVkVAo3nCnAy4+YDHr/SgCgcq3zLjByF29TSEFeW8z5vu5OMj0HrVpbdGbdblEGMhZT7fqT+X1qIQupAkQmQ5BBzuPoPagCPb5jAEknuC44x2x0H402eMSxn5QCOBz0+pNTFhEmH27yeFUhiv/1/1pEjkZCRHtX1bkj/AAoAyjSVbvYsHzVO5ScE4xk+oqpQB9//ALLn/JCfDP8A29f+lUtFH7Ln/JCfDP8A29f+lUtFAHM/tmf8kz0jp/yGouv/AFwnr5EQ5h2OOclkbGCPbPcV9e/tk5/4VrpGCB/xOouoyP8Aj3nr48O4kg+WNo5CnIP4d/rQA2R2bBZB0654YVq+H9M+2zk+WREgyxXnAzjHHQmsu3iErDFuHHONmQSfp9a7uxgWxjW2ijAkEXmTuCQw6E5HqBx25oAu2NrcaxJ/ZujM+Ik3EKuSVHJb3xXoWm21v4c8PPOXjYRx+ZLJg4Y9Rkd896zPhlANKX+2BFA09yQBA6nIi5JHsWrd+IVxpN/cafaaSojhth5t0uSVL4z5QxwQvc0AcfpVs1xcNqWoqVllYvDbu+3bnvgj72OntW7H02IxkyMgNnePYev1FVkIZss5U8kfKPr3GR6VMqFxKJJJJiRzgk5Hpg9Bx9aALC7nTBe4lB52bMncOvy9umcjioL0S28Re1jkZOSylyQ/HJIHQ+1LsbDAvIHQA7HycHPTrnGO/QUGCTaVjjZixBZlfcD2A4549aAK0V6jbHijVxjACt1XHU+nTr09qnhliY7Vif5gCB1Ax6f4fjWNJBJBLsb5RnCOBtPOf1+mKu2klyEUBcqDj39sn1oAtuF4VXfaCQ2V3Agj9P6UH5WVJNm0YIVicDjoSOPp9aRLlsFVc+ZnBxwV9cDvkfhUTXJVAC4ljH8JyOO2B1oAlaP5gyycnghcsAfTI/KokhWMzTrKGDcOo4KsO1MV4xJuEbZbGAyjD88YI60SFEwblQGL8TK3P5DqaALatCu3K5Y8KwwVB9gee3SmAwCQokfmTbsnEmVDevvn0pNyFdsoZkfJDMPlOPT0NGzzAgjUJESeWfHA9B/SgB7tCHUyhQWz8pBwxHdsdhU6khD5IkVRguFPz8c5/wB329KbZW73Mnkm7+eQEo8iABcc49/5Vow+G9Sjk+1S2yzhV8z/AEZ854zhsHj1xQBRjUyRgvD5ULHIKMCM+uP89aS5jvnTNlskOMmMEHjtjsPr1rrIdO1ImOYae0eFUkvDlmU9CMf59akkt4J40SQAqTkojA7SOmT2z+lAHCo0kgMd1unbGSqghOfXvn05xTZJ3T51Z5pgfkjAwEGOT07V3bWsCGONohsbgIqEswHJA9Bn+ZpzadDcqM27Qx55QtgL65Pc+1AHn9xctbRLcSbpFPzM7Ll+nqemay5ddtXR2efzUDZZ14y3u3fHpXdazpGn2kLFlQuSMBl3Fv8AdX24/pXPafokN3OXjgjeR24eVQqg+pHb2oA4PVtaNw7OkIkRTy2DtU/y/Pr6VUsNdktlzcJN5IICG4IwPUgdB7cfSvVG8JQ3ax5jacDOE6Lx29Pck1l6h8PIbi33Lbwq/OHSQsgPoD1P+B4oA5qGax1BQVidpjzukG1cnpgd/p1wTWfrKS2UareCKa3kBZbVlJBxxwBxx2GTjvVfU9LvfDl+i3BmeHaQFAOB7YHC/jium0q1/wCEk082clzHB8u5Uhwzq3+8cLjuaAPPb/TVWD7XbQPPZOdoaQECI/3XPOT9KxpISSQCcDkoiFQOO/t9a6+G0uNC1i4sb+NpYHJhmLSHy2U9GXkcewrG13TV0+7lhAVo0+5kYQ8enfrQBj74ypG4lfukY259/X2qNj/ATx0VFGAPwqTO0YhYqp4BAJOfU/0FDwsrDPy5HWdgCR9Ac0AR+WiJhvKVz1JYM/4AcCvb/wBi1dvxW1YemjS/+j4K8PAiGQVMpweQCq/kBmvdP2M/+SramdoUnRZflAx/y3goA479qP8A5Lt4m/7df/SWKvK1BZgAMk9K9U/aj/5Lt4m/7df/AElirzSwGJd/Bx0HrQBbSNUhT5kyOjqCPzoMnXYrYOCyZxz6j+YPFJ+6Kk8jHYg8fXHB/SkVQ7qsZ5PRQO349aAFM3mA5JUkcsh6n1I/rSjzNuWPAHU4wwz+f41aismb/XsCoGBIoPAH94f1rb0rQprsRyruS0Vjibyw2G9Nvv696AMBI3d0VIph3Ukc+31rp9M8LSShHvJBbqQOI4/nP+zj39a6fT9Pt9OfZDGsbPyY92c477udv+RVPW9aS1ciyj8+4dtrOvbHXcp6HsMcYoAVbPSNFQSSSwQDrukO6QerKO2emDVS68aQwCRrG2M+PlLzP1A9uuDXJXSvO/mymXzHyzM5LZOffoB+VRqJIMF4s4+YtkNx6/WgDal17WdSZI5boQ2pPzCEFdo6kDuc9h/Ku08PaZpiWy3MbCa4bkzXJySPp0U/SvK3lbILMSi/d57etWYbyeOMhJpSd2Rg7T+Hb8O9AHrt3qcNhEhlZbSDGQSw/L/Paua1TxlZE+XbgsmBtkK5z9fX/Irg55JZlUlnfn5QWztPsKakInnURoS7nGIxjn2/nQBbvL43NxuL7WY52joT+Pb2qu7yEHyoxHEgwztxz+NWtN0yW4LSxoUVSQZNuQ+Ow960dQOl2iBdWvJZnxnyYjvk47E9B/OgDEHmStnztgRR8277mT2+tEwkVvnlafPU5z+n0plzrlqpI07S4I+ciS4Jmf8AXgflVJtb1AtuFyy+yqFH5AUAay7IXTaNhGOOnP8AhWXrloYJIZw6slypcbegIOCP0/WpbG+W9kW21IlgxxHKDtKE9j6r/Kuy8BaHZancT6ZrZGYiSsbZHPTII6e9AHmlFfRbfDfwpEAJtGuCAvLrduBnPX6ehqvc+BPAUe1Wtb2MnHP2luP0PNAHz7Wv4TuJINftBECwmcQumeGVuCD/AJ7V7D/wgHgpm/dJfYJ48y4xkd8fL0rSt/DPhvQFkl0ixJ1ArhZXn8woOhK54HBx6+4oA8qvxt1CQwLzGxzuU8kcY9Oldn4emsPIhWZ/9KhXknI4PpjrjNY0+lXY1Qh422zMCCvzbhn9B2rYhsZoZ/PtnRMIfkZSD+XYe3WgDa/dxy7Y7iPoCpK7fbK9h6fn1xUe5DJhV2ZUqvzcAZ6k+g6/lXnerX0/2p1up55ckjeOx7DA4/KssXlyjbN8v+yA2Wx+B4FAHq9/b2/2fzLwDauAAAGJz6j3rmL/AMMW1zG02kSnd02P9zd3C+lYOneJ9S0+TyvNaU9xKu449S3YV0ekeItKlZYxE+mMSc+axKHPVvYk/XNAHEX1lcWsxSaF4m67iBg+hB/rUU5P2dkjeGQAht6EjBI6Fj19gK9V1CztdUtWSRVuI1XKy5B3cfeI/hUcdeK8/wBd0GazYvgzQsSFYngY68dPoTxQBkaZbLPcKnzFesjA8IPU/wCealkto43Y3M6Hn5ck4X0+XqfwqqxWJQDIHYkkqM7R/QmnN+8jMoXzXT753ZCD054/GgCKfbIXHmFg3AZxz7cDp9KzHUo5VgQR2IrRYliMSKCT0jy34elVryMjEmcgnHXP5nuaAPvX9lz/AJIT4Z/7ev8A0qloo/Zc/wCSE+Gf+3r/ANKpaKAOa/bM/wCSZ6R0/wCQ1F1Gf+WE/avjxY3zgE4xklFIOPoa+wv2zQp+GWkh22g6zHzjP/LvPXx9DA0pVEeJi52j5SP5UAbnhu3LXAuSh2QnAypI3e+O9dnp+ml3eK733BkKvcODht2cqvOAe2areGrBE0ePCPcbM7vJOVZj+uelbDq1pp22P/WyOqIGUr87ex4OBk49BQBbgjubqeR5FDxRthcOBlh6jHatISvhUaFJl788j8R/n1qCztvJgghhj3qoA4YEtyctwfXNWFLq2XiZgSQAmFbA6Zz1HH40AJGCz5SNvLLAGOVgQR659utPW28uQSNGuTxtKgbh25B5zTZZVdXMtzbjII8vcEKn1xz+tNRmTcYzC0bDIGwkPnpkjofpigCwLaN3V4Jtjg8cEEf7J7/0qKaEW6uJFiwORJbykqx9ecZ+namecwOyTKMFzhCXIx2PGc+9Xm+zPAwSFgwQCRyfm56MRjj8KAMq5iR4y0TRMwzjIx/kZqja7BIWkYxuGCyHcR83qB29M1qAjftdOvBAHJHsOM4qnqNvJLbu1kjfakGfu8SD+6w4GKAIrZmTzUkiRVUjy9hyME9PU+vH41oCVhCsjSK2T8sgAXr1ya5eC/kMUcrxs0oYqMHG31GOgqzb6lfC/WzFo7uw3KbZt2R/t+9AHRIzMAqKWK5Uqo5Hc9eM+wqvLeJZuFhMcaM4U7gd2SOnHb6ViS+ILUSPFIJhLE20RkfOG91zyDWbf6nFq8DxXFzJZKjZiUHdI57FsfdGfSgDs2kCrtLy5+7h0+U+4H9KTz9zHKyyuOGVGx5fpk49Oa57w/4hW+gMd7Iy3MZ2yRRp8xH97PatZr0uVAMgVjlQr43e+Op//XQBrWil3jLskTOcB2GEb2Pt0x71uWdu9my3CzlHHzrIsmMZ7hR7nB/SuKGow2mSxtw7D51XLbh7buuPWnL4jeScJAoubgEHIbATIxkn09gMUAelP4ivYIpBLJvWQbcleB/sZPOPp0qrozyTCdI0tYpXOWiLNuHPBJ6AVg6TpV9f/wCkXchtlPSPccAdz64PPNdTZWMVnAYoAApALzXHIY98YGBxj+lAE/Ee8JG+TyQsmwgdvn689fypl6JESSW4SS3jA+bymCqcegJy3Xr9anjTMe6JQsaHmQjJjPfDHqKx9bhEen+Y0sQRhyZHPznPAHqcdc0AcxPNDqFzsVJWgkbnywQW5+8z8dfQdhXU6damOxEcnlLb8klnwM/3iP4R71z+lWs+oXyPtLmP5pHkJYBfVVwBk+/FdRpYS/SKafc0DNzN5ZZQowCSSOSPYHpQA1p7VYZbi9lthY20ZmZ5GMMSjIBLcfNksvPvTkjDww3EDJdQzxLLbvZnCMhJw2/jHIbkDtXm/wAX/EXizS9J1u21vwxYRaJqztbWGpWsmQIvMDohKMUY7U7qrcE1o/CHXfGHiTSvD1rYeGNOPhbSwllfanctz5QbL7S7BQwD54UnpzQBs+LtKS/0l4JIwvUhEJ3A9ck9PxOfzryDwzf3eheIY4vJjWVJRGQykuwJ9TyfXgAcda96mby4pFhgj+VSu63tzsj5+8GOSxPqefQV4F4tt3TxLcRENAsrYy5wWPfqeRjPNAHdfEXS21fSzerbNJd24H+kucRxjPIY9z7cYrir+2XUNLj812uL1BtzGQM49MdjxyOvrXrEmmNfaAVWcXW+DdGzAvnA42gAID+Bry60nNrKIphIoKkFXxGrH0PGSSe31oA4i5i8hctASWbHlhtgB75C85/Gq0ypgG1kj38cIuCMetdBr1tHaXZCQxiCYD5NuDu64I6++T1rIKXgMkAMixD5tuxVAPbI6UAZ4jLFVeZcHkgZ5+vr+de8/scKq/FTUgikL/Ys3LHJP7+DmvCZF2YEsqKcconLMfwr3b9jgAfFXUiABnRZgQTlv9fb9c80AcV+1H/yXbxN/wBuv/pLFXncSbIlRgy55POQa9J/aajMnx98RouMk2vXp/x6xV503UgIEOclA3f6GgBY4XebEZBcAfcO1gPUg1pCzaMiOFNqn7+5ck/4DPp0qpYxP5oaQGOPBwWQlG9sjOPrXX6BaRKUncRzz52RhiVMZHZs8Z/nQAzRNIiWYS3IImC5SBAZBnjrj9RXRGcysvk5V+URUYEt7AcHj1IqaeRbW2lkuU3jgSPEFYk9QgHHX1H41p6bat5TTzMryMBknJ2eig8kehzQBDbaTEtsRcK6B1+cwqwwc5JyM59z/Ski0m2iOPlcKuSpX72Tnk/TvWlIFVsqxeMYXaGK5YDuucAD261Md8uSMN5YHcZY+m3jBoAxLnRYZxKY1XasYCtwQp9CR/OuM8R6RcaZubY7RNzvR8hQff8AzxXpBjEjsFjboXZD8pAHOOOo46VDc2S3atGUM2/cSqrypP8AeHHPbjjmgDyK2khRXSVFERX5xyDu9R2qlcfZefJ3he6TH5gPw/nWvqtl/Zt3Pbuhli2syuVKYPfHbAFcvPdrvGwF1AxlhggegPWgDX02K2ub3y5o5pYdhISM5O4elPszJb3MdxI4jCOQjkcr2/wrEF4Qu2MMnqdxz+dXkuJ5LZoGjlfHzqCMg8d/XPrQBe17W7m3ZrO0Zokxl27knr/+sVy5OSSeSa2JbO71iZHsrOZ5dgV1HPI9P0q7F4D8UyhCmhX2H+7mPGfzoA5miunk8A+KY/8AWaHeL9VFRDwV4jbGNHuj/wABoA52vTNDurSfTNO1i1vWOtI5truz8onCADbNu756FcdqwV+HHi5lJGhXQwduCVBz9CafH8OfGCSLjR7iPcD8/mIFwDg/Nux+FAHVa98TdQ0+M2UCWs1yGyXI3RqCOgHr9elcDeeLNcu3dpdSnG/ghDtAHoAOlb8fwr8TurNJBaxYzw9wuSfTjNKvwo8UOhZYLUgDcP8ASV+b6UAc5a+KNatQoi1G42qcgM24frnitO18eaqkiG7WC6QHLBk2lvxFaA+E/ikoWFvaFR3+1J/jUkPwi8VzDKW9mV45+1oB/OgC/pHi/SLu8WbUXmt2ZCjxHJUt2YMOmPcV0C3EN9FILaeKT5dkixuHZu2WI7e/euVi+DfjCV9i2tmD/tXcYH1zmnR/CTxfbqXjW1j3HYNl2vz+wx1H6UAMvdOu4JwG3BCP3bov3vcegA7VQks1O4SnZ1LZ+XePUnuT6DoK2dQ0Px1pt0En1JCzD5mE4KocdDkYBxUcuk6/eZmutTtCWYKImiHIzjIXHA4z05oAx7pI2ihexVBCPkdFzhWHXJ6kfXFZDbWG1S0mcnBYcD8Pp0r03VvCN/GItkDRwOoVpUi/c7/UjJJP4VwmuaDfaXO6XQd4ifklKlYnPfA65oAfp+sXuluiQM1zFnHlkAp6nA6fn+VdbDqtr4gt5IjcxxX7AZRgGJI7jPy49z+AFebMsoYea5Kjgq3yAnvj1p0Z2SCSJl353BgP5dhQBv6zo00G528vBfGYyXRT3DydT+FYbxSQzKxQmQHG7soHoo6DHrXc+H9ZOrWnkzJCbmMbD52ZjIvrt6A59MVka/oz2LeZHJutn5EWGOxs8jAHPP4UAc4xhdHaOMNtxuz19yo9O1V7j5lKyMQWGRu4/SrJBiuG3byRxtRguPqRxUXmGORljWINnqE3e/U8n60Afdf7Ln/JCfDP/b1/6VS0U/8AZjJPwQ8Ok5yWu85GP+XqaigDl/2yv+SaaRltv/E5i5/7d5/WvkTSEWS+RWKODxtUEtj6Dqa+uv2zDj4Z6QcA/wDE5i4Iz/ywnr5U8LQo2pWwkSU85z5eR+eaAO8igt5JoLVd67UDAfOu8DsR7H1rZWDdq8JPkmKCEun3jvkbjr6gDrmtT4JeH28S6j4mvR5n2TT4QkbSSf8ALRlYngZz92qkESr5zYwx25XDKdoHYZGDQBYZGSEsqxhWYbyFK5x/e/Ucdabtck7rdiG4IkkAOzPUfj60SxhXcyTY4B2uCvXHXn0+opAquxCtFI54CxN936Z/lQAsKYZBCLBJY8fMs+CvPU57e9Olj2OFldY3znKptBPfmhsDaju4jXs8Qb5fb1/l3pQ9ttTEbg54MRwp9CRn6/WgBu9owBFNvXHQEde3APFMDMMPNBnjKMg3FR67s/p1p58nPyt8ucEKiKA38i1O3NvIQAAZL5UAn2Hr9BQA1yNmHIW3YcCVMgY985x9KjdlVFZZZJIx1Cvwg/nipY3EbSeVBEQW6khe3QucZ59ualmmWZOIS7phSAqkZ/u/Xnsc0AcaITd6pf3LGC0093G0uDhyODjGMZ9DU1rPKb6ZtMJEyEBEAKgrjkr6j6105SM4jaW32qciPbuY+uPp1q7b253B4IYlkzuWRf67uOe1AHF6eXttfmvm0iWNjhFaOMjOBzuz6+oqLU9Ja61P7RJawWqyg7/JYYYHoPQGuy1jDDyrm5eWYdDC4IQ9l6Yz9OKy0geAho4Udzyryg8H1H+1j2oAS0sbW0iVTFDAnB53N1H51n6jYxqp8p3kDKS6qVZmX+Y9RWnJGfmdkVcr873EhKNz3A5PPbvXOa9qq2sZi+0xKuckRDH4g9fw7UAYOl3MureILfTrKOCCCe4SDdKTmJWYAu2ecDOT6V7Dovguw0bXL+zjnhvYbR9i3EfyrKSAfcnGcYGRXhmiyqJslo4JXkKQyY6jPzYx0J96+ltKtxBpdvDuSOHZjgEFBjI7ZBoAkWJm2hxNKAdxG7kY4wxPp2HfipBiEw+VsjQE7dw8wk+vsamk8uQrG32qWPAwgKqFGO/t7nk1EMpkeWZUI2sLfG4j0JzxQASLbzNuYTBlx88rFcj0C9D65ptxbyu5aJTLK2CG6Ej0Gc4pRNDDEksyycnKxk/KrH0+vfPFOXzpCQqiPnJjThfck9SPx45oAxNTuo9I0c2FmJXluJCbvdLsUE9FHGSfXPWptL865tFQpNcuuCUQMAo9xwBTtZsgtuscjWyK5OEWHfK2TwM9wTz2xWLEZNPmkt5oZsDkQmQpzn+Pkk9uDx6UAXfEHhbTfEPiPRNQ1a+WTQNJiLNopQqbi5ODnfyrKxADE8hUCgHOaf4U8JQeFrvxBLp11HLoOrBZINHmz/oU3UszkjG35lUKCXUjdjGa0IdTYwvNIsDoF3N+5wgB9yOn0p9tOkkQYmRNxzygUgDuvr7H0oAS+K/Z5Ha6YoRwq5QBR6Dt7V8/eOnaDWBKRNM0hOBPIu7g/pXtWt67YpbTNFukXBLgkDee+TyevuK8E8Tzz3WrzTtagwIBwWDqFPONw5IoA+o/B2vaLr/hHRdSsdMMksAW3vreCfyoonUDDM5HQ4zx7jmvA/HyqnxA10wW8VuiXbSxMnzKFIzwSOnpgCsjwBrcmmaxJZzNNHa3ucqJDtQ9QcZ9q6jXYYb+M6gIBJKHBd3KnIzgnC9D7k9KAMTUXjm8PTPAxj8zbIQsO1pW9c8sfrXF3wmcJLKrx8bTnk46Yx1616BZIPss1o0kyiQhXWCQxKc9AXxkjH+ea4q9iFrezwKY0j5PyRF2x67m7e5oAzInyu1FY8EAbQo/DH59a90/Y9TZ8U9Q+RUB0WbAB5/19v19K8SeCBCplZiT8yrJu+YH0C/417T+xyoX4q6nhME6NNk88/v7ftQByn7SqBvjv4pJRnIFqAAAf+XWKvNQgKh0cBemFfJX8Ov4Yr079pYovxw8UF1DZNsDkZx/osPNecWyJK25miJH3Q4Y8/7yjOKANrQbA3coWKaeKCNcswYDoc4GfU13tqu3kiOOQA/cUKyrjJZh15+tY+gabbWvkoLcLcbMvKr53buxUjn0xT/F0yvHa6ZayWzzXjqisGIZF7jB6UATaLGNY1T7c0Y/su2JFurq27I6v7811sKFyXjuIQ5OAJFPUdeevf8AxxVbSNMFhaRQ2n2fy4yNq/aAdxHoc8E88GrbW8oBaSJBgnesrKfLPYZU4Hfn0oAP3itsxE4xtXDbSM+h7fXnmmSwIzEfKjAhTvcAD3P90/ofamOiMpMiJGrZx+8VtgHQE5/I9qbJGDHHgsynkeUd23npgknHrQBK0j9XhWWPOQgkUFR7An265qF5SFAVcuMBZCcOO+OM8U9LeNmYglmJBw0OMfTP6jt2qOREdjiMNIc7WilEbDtnH6YoA4Px5Z6hqNxJ/Z9lPPNIVSUxjcdvYccAE9a49/CPiFZAh0a+JJABWEkH6EcV7t4RjC6vPHLHOUaLEYnTHI4yGHGfeuo+1sl69rDYapexxRpLcfYbYziNGYqGlVTu52tyoP3aAPmRfBviNlVho17tPQmMgV0Og+D/ABApki1LTLq2WFS8UzjaUYc7Pof54969yk0V9P8AB3gzXvM8QXt1qc7pd2itLMCNkhULCASpyqgccVNZgXK3cN3p9/bSQuIZYL5hHKjFVcZ+ZuqupwT3oA8Lt9UstLv5JLD7QkqsCwlGG3DocdueCPWvV/C3iux1yzha4YrN0b5gFz6HmuS8V+GbW8mlM1ssU6EhGI3A98Eg/rXGW+jat4fYX2lyRXMfIkVf/iTQB9AqqKGMYZxjgK244/ukfSpWuIViVsSRseFLRAEt05Pf2zXnfhD4jWt0IYdWYwyY243fKP8AgWM/1FehwXkdwnm2Ba43H7xXzCQOgO7igCvNcSsVGPdViU5P+8eTinL58u0GKUn6fLkenp+FWR58qZAnj3YO2MAAjPX5T07daicBVIla6kC9V+TaGGP4getABFGY8nASMngl9gBHU4OTk1I0yzRIsoZULZXJxjt25/Klwi/vPIiJPcnhT68cD6VYE04csxCY+9IWLEfgo6fWgCiJQivIqRRLEpbcWJC45J6VWs9QttRmEMEoZipmcyKU3pkZZRgZBJHPTmr+i2s/i7+3dLs/FeladeF2tYNNu7dGedDEoMo5WQZZmAxuHyg45rtvH3gmaceHb648RaZotppWnvZXNzdJuB3BOV3Mqj7h5Y9+hoA4jYHUAYnwT8jDAZvZV9PenhZOd0MYYHlhyRz0JY4UfyrP0G7+3QXENnOdU8m5mgS6hURi4jRztdSuOCpXOBjOR2rRG6M5wgRRzGuP3Y6fMx4Ge+OaAJPJguJjJ9htZZiuwSkjcU9Ax7fQD61FJaxyuklxDas4x+8KKzcdixwAenAoa483Jlmt4IlxlE+YfiTgk/XrU0WZGWSJFb+JSYzkD2BwB9aAIgkdwNiQmdlAO4yEgY6YPCgeoGc1Q1XSE1KxkM0YZNuC0ONkZ653t/8Ar54raYu0e4vA6R8sUJIU56bj8owf7oxUXmAo2LhIBHztiiIVRnu7AbiexGOtAHz94w8Niwkn8mCGJoVJYzlmyvquf8muMdAqnzSscmeXcZYj/c7D8K+gPiho1tqWkvdW8cclzCclFDFhzgFiBzn65rwd4JnklDeTGC5DAHb/AN9H0+tADdPvHtb2GazFy8y4ICkAsP7p216UscV9aCW5iMdvPGRJEZt7e4OOF/H8q85iTzY5EF3HCu0sBlkjPPc4y38q3PCEiSW9xBG6M8LfaFjJYLgDDfIpGRj1NAFXXdPNhcGJIlMXBVYmJ3jHQk/d/Ksz5rhCr4h/uqh2j8WJ5r0O6tEurNo/Ll3IvmRFVSJTxnGFBYnt1rgr22YTCVdqKRnbAh/Unofqc0AfbX7MIx8DvDgHZrroc/8AL1NRR+zCQfgf4cI6Fro/+TU1FAHM/tkF1+GujmIkP/bMeCDj/l3uK+Y/DSiO1urybKOPlUtIxJ+gOM8+lfTf7ZQDfDTSA2cf2zH0IB/495/Wvku13xNFHBebUZgTGxKFj17Zx9aAPq79mayitvhn4qvGKyLPdzBsc5CQr1/M15npqxC0VAFkHXayc4x1BH8q9S+BOqvcfD7xTYzzxtdRJJOERvmCvF1OOeorzWzMi2cSRswQAfK8YwffJ/z1oARikalngiTABV5CyAD2AJNOd45txEkbqfQnbj69jn17U4I0Ubbdu/HAJRcHt0PI/nSBmfK+UJQADtEg2gds45z7UABUoSsZhQ4yqGQEgHqCMk/T2pqtDKzI87lFyNiAso9M7sYP44pRCYNqlGRuMhuCc/rj2+tKzgHbOzybTgLGcgew6Af/AKqAE2DfiP7VI23nZHkAdSN33fwHSmgJtBa3Lg4+83Qe2COPpzT8NlhJGYwTuVRIRtwerDgE+n40GGSIbmmJcHCozgFcHkHPUexoAux2dxlHTyhG/O0OJPlA757e1UZJnDKGeRwoIAEQAQHtj+v0qw8zYdQ6xkkAIi7y+eSAfUdc9KhDTeacbY8nBZgodj7kH5envQANJEOAjSqw4Uoqso9TjJOKYY55pjtimvNp/jYAgdMkjhse3SgDBJKlkZsufuFvQE98en0pVinMcRjRViHKtuYsBzyAMAenP1oATYYAqpbuTjAELk7vX2A/pQuRuZY5YQ3URna0g9z2/CpI44EZwtu002AwJl4HqQBwanFuhJUkkBshY/uggcZOew7CgDOvIYo4W80RWu7JCbNivn16sSce1ebavb/bboQ7n/dvlhEm1VBPc/8A6zXY+Mlm0Wa3uDtjgkf3aUdz9MjvWe0Meqx3k0NrOBNGNh3bM49cfqaAOU1R3i1PdataXMgdJVeI5UMAAQF6ZwBX0PoeoLdabYXd9cyQ+fGNrIxy+ByoY9MelfM19bSaeyGRghchlEQ5UnPG49/evWfgp4qMmnT+H9WeNAz+ZZzzsGKSdNoU5z7cYoA9TG1nVQEtpevzjdvz0JHQ49TTvNS1DtcMu3BJlWQIWz1JX09ackUiIyShIV3cs+VVj64/h9aztbsvt2g39pZ3hWWeNohui2xtuG1iMDPTuMkE5AoAsWUt/rWs6ZZaPLpssuprOy3vmF4isaqSPlzydwGDUFtqAe2gGqz2lvcyzTwJEJ/L8xopXj3KT8xGU6Cu2+GV3oeralqmsXXhLTdA1HRX+xSalbyJ5ErFRvUOApJUbQQ4+UnGcg1zfxBtLC21nVvDmg+E9M0y5cw6lLrNwR5s370SF4lUF3AdSGBZQM4IwwyAN3EO6lFI6uIzuye5Ynge4zzWLqWmX11eQ29nHJIkhAijRQilj/CCcbvxPFbxMkiqzeZOMD5WQIpHYA9296VlS3kimCqk0ZEkcjvukQr0woPX60AcHrlneaXZ7prxLiBJcB4Ji8Ucg4KHjgj0GOlW3nXSvC8+pajeRQvcgrZxiMZbjJfB4A9Oc1uT39lFqF6t/FatY3gDFoyR9nkH/LRQeDnJ6ivJfGWlzrLLdTXiXlqn+rZWDqR7A/c46jHWgDntW8UXF8dgnuXgGdrcc49QMAHpzXNySz3AZpJSWlbJbcWyT2Y8AVLesI/k8l0DY+XdyfYnj8sVo6XoF1qsMJh8tV6sG67fZelAGfpSS6ZfQyGJFmU/LuVSGOOPmfrx6CvS7BGutEhaRYycMMpIXViD22gL6Vy+o+HH0+yVpI53mSTcVmXcAOCBgfMR3x2rrLdfsejk/YslVaYruKqCc/dGRkY9aAMoW8SM264ikl++VyG3HtknJP0GK5jxNDs1PzZpmErRg58raMjtgnmuwtpoTAjCe5UYyVVREo4yTkc/hXBX8wku55IY5HbfwckFh9SAeKAKklyYnUxOowdxOSCw9v8A9dex/sdMH+K+qECMf8SabhFx/wAt4OteHSGViR5cZOcFmG9gPx/xr3H9jksfipqW5lYjRphwMY/fwcUAcx+0ruPxw8T4dV+a2+9n/n1h9643w5CkmsQCaS1VUPmbjKBkjp16HPvXb/tGlF+OfiZm8wEPbcqqkf8AHrD1JrivDttcXWppFbPcR7idxSJGwpHPTpQB6DZ4lcmd2gWRRt3IZMjPTOOM/rWXoQj1jxhf35eNoYD5Mf7sAN9M5/8ArVqCa4s9Ikky+xI2BebADADglQePrUHgCOa28OfaJG06UXLM0riU+aBnvwc0AdHstm2YtTK2MlTHk46ZyuO/RRSiyRUVYkJA+6dhXbjn+Lp360LskJFtcKM+i7gB7Y4PX606SEuWcws6qcmSLKDj+8Cc5x3BoAIrdZhsgVCvAwYlPPoNo6nqTnHGaSaBYmw1uVIchXjYMR788kdjxTwVgTzJAFbkDdKGKYPrnDD8MmmtJJO25YnkZnABVg7LjrnA4zQAiGSQiPYpUDBWRWAx/eHb8KaGDK4fehx8joAGHHsOc0HAdonE0ZyMRSNv2g+w7E+/ApwdmyqNKUAyDLGY8D1JyckH0oAlsZmsb22kuJXEecMCzDr+n5V1dnLqemeIbGPwTq7x61rUyQeW6JJbvHECXeRWG4KikkbWViWA5ya4+S3cQPiKKMY2kv0+rAn8a0dAvdP8QWX2K7mgS5tXyGichww+7KhXBDZ6MPegD3PWfGB1tfE3h7wPqNqPF2lxAr58e6JnGNyrzgkcKeu1mGfSvHtDnOrxf25LdXl5eaiqvczXjKr70yhUIiqqhWDLjHbr0pJtGsGsLa0aCeKK23AO0rRs4fIkDSL8xD5O4HIbvVqWS0tbJjA8WyNdqrboTGAOnQAAD24FAHJaxaym6uD9kkkiDEMUYhh6gf571T+x2/kP5KnzCMnkg498cVXe9jmvX2K8jM+4z42KG9MZ5I9a1IiEfJu4UfPAihJz9eeKAPPtR8CahcJJc6fGJ25ZoVbBPuPWq3h/xR4g0NzFuuPJQcxsp3Dt1zXqM32pI3QJuCgsvnMo298hV5GD2681w0WlXepahqVxcoL+8iycwSN94jONo7fWgC+3xIjMANxaTbm6mWXao+g9K1fDfj3Tbl2QLK8xPyxyjIB7BccV5bqMDC4EckUSEcHzGyPXtn/61QQT/Zi6w7o8D5n3kAewU9frQB9DJrNrMwzK9u5IBjRQG56kDpz0FbcdtMWUpFLcY+be4cL/AMC56/pXznpGo3MRkFzMWd1xBdTSE+U46YI7HpXtvgzWrLWNKijuJG+1Qj54923ZjqGyfm/rQBoS3ul6f4n0fVPFMJvNE0sNcILZVuZYroZ8suPvCMc425G8ruwACX+I/GFx4o8LajpXjjSfNv7xxfaCthCJ2tZQfkhl3AKGQEMzMdrK7jqCKvST2sCo9ugVywG/oqcdAOO3f1oV2l3PbzkrgAyuhbpzkZwM9aAIYTezadHFeLFbr5SedBajaC4HITOPlByBk49qkMEzKjxC4BJxuQI5H1PTP5VKiiVzICku35gLiMHt/dJ/rSbIGw0q56ZV4GweuFBXgD8DQAQfaSiKPJUbgfMdPM2gdSCcDccY4prrPKxOwzf3mKZwe3AJGfwOKRFt5TvkuZLmPPKI3yuey8enrUFzdWlpHvnlit4iR88jDa3PTaOST6mgC0fKLBprs3MqYG942l2DsNoJwufpinl2ZlkN0qRbsDfiFcnoMclz9MVnf23bTKojnM6ocMVwEB9vc5x0p8mr2cLLI6lrgHDSKMsM9VBbgfWgCv4xaU+GroXMwa3VGHksxVM+yLjJ+v418xFvNd32rGM4xHznnHAx/OvcPitr6W/h54LBJA902C6w5dh7yHp9AK8MWObG2V5W+bDRiQHn3A6ex5oAsW+N4lw5ywBd35+mcY+tanhu6K6oI5bhYIHJjI3qFORwSx6/lWVFEsZZvJQhRhjKGO3joM1NDPHafZ5ka2VxJz+63Y59x8v0oA9BiKmG1eJcnmNiuDuTrkn0z2rmNVtP+Jvcxi0ifDAxGQMw57Bc4I7811clwjWsgea0kUYdVXaAM/h/jiue16zaQxTLBC7yfKzecxJx3OcZHbjigD64/ZpG34K6ADjIkuxwMD/j7moo/ZpBHwW0ENtyJLwHb0/4+5ulFAHJftmnHwy0gkZ/4nUX/oievkEBGmUzRq4AydoJJ/xJr6+/bNbb8MdIbJGNai5H/XCevkewXznwSXjAJKITkj1P5+tAHq3wv8UvpF1qNnBFNDFe2ZglCjYM4/iPQnBret51FsvmeaYvu5zkA46A4H5YrzXwfIPtLiEyQbZflGfbgjceDXpETAxgmY+qiZQWY+hbpigBskgAwiLFtHzBVCgntyfxx9KXe1w/MksZCkYZR84x/DjAH1qSFAWH2dIlbsFlExP5jC/gae7zlCt1e7FzjZtWTIx2JPHrnigCAJtRNrsiuoyR8xAHc55H60KyOpUSsBjlPMJ38cZ3D+RFK/krGjyRpuBx5rESEr26HHvk0oLsUDAuvXM+EUj/AGcc/higBpSfdtEwRW5L/e3duvf6dqEgEYG2HzHA/wBZn5175BPygfhTvLc4CTuwOfkKeWCOp68gfjTY4J5MFo43XoTGen9MfnQAROmCfKaVs8tIfMYe5ZePoPzpNrbMH7Mo+YHICsvoTz79Mmp5S8bFJ0VSQMQ71ct9cc/iR7UjHGRHG2WOUClXf2AHb60ARuUVgJZkuiBjLnA9OPf0PtTJ2RUZ2KyAHkef859we35U+SJwfnZinqVVgG7gD7oP51SeLcxjMseAD+6RAigepbv+NAE+j3Ml958sSqI4pNoVVKoR/tHrWs8ckIAO6PeCyoGG5h6Lkc1jRRtEVmR3t0AClmG1TzznP4GpYNTh2TLa37TOG3OFwQWH9/1+g4oAp+KTBb6X+/t3DvIgCxjgtnOMnOfel8MaVfyLch7eOTzpOoVmZy3TB6Y9M09ka6vrdrtoyUI2Rhc5J/n+FdFEkkMaES+WDyHVsYP07fXmgDzPxLpcemTNZXqm3leQne6HJJ4AOeaoeHdPn07xDKqPE6wsCWtmyV/2s9cnpXoni9W16KJdTle7jiURhJPl2qCT1HfPr/KuV0t45VmvbBJRFbqYpoVyFwuepA3ZoA9X0HUlubYCA7pVGJG2li3qCM8/j3rXE7h4GtikA3Hy8Y3g+pP3Rj2/GvNPDN/FcQrd2r4kC7Txtz7EH+tehWEqz25lIabIAdZCMIfXjt2NAGcNMc6LD4duLlJPCEMrSpprqQXkJzsaRSC8YZmcA/MGKlmbFWYk1C7utObWNSbUX0dHgsPNAhby24JlkGWeQgKCThflBxnmtIAFzscxbf4RJhunPHdfYdeKGUkEEOUY4WXyQA/oSDzntk9fwoAUSO+6WIRsRlXLyM8afXI4H50xoZI1fMOnpnPO4fN3zu68475xSzQlGP2q5jjY5Cu0rKo784+X8PwrNvtVttPRUVo3Ix/q49u09uMYP60AZvi68sbfTy7TeZMSflDCYHHU56ADpxXh19rUpvDcCOIW7HPlE53AHrk9Ca6X4h63LdypA8cgjbJJkgMaYHU8flXOvZ26aPCunR3F7fzy7YxG3mrs/iDDHHXigCxo1lL4rvmaT9xZwkB5AAeeoTcxAz+dd/Z2NrZgrbpDKUBUmEhuPRl747dqpeFbCPTtEispYQ1wG/eDnk9cBT6Gt1lnMwVVD8D93K6lsHsABnGKAIvPIieJpzFlNqxqhPTsVHJ9vernjvw42nfC2x12SJjJfS+U+wsW2NkLxgkcDOBVMiZ98Qimjdx5eLc79xJABy3A64wK9J/aKtksvh74Z0SKK3QG9ijSIblGI4WJ27eaAPB9Mlke2Xyre4uGZBjnAHbA46cHjiuU1qORo7iR1kLNNkqz8ADvk/lgVsaZeNYyS2d1OIGx8qjcoYejE5z+YrmbqFPtjNuSQt/zx+bk+5Hb1FAGZNGUc71jdB2Ysfx+n5V7j+x0qr8U9RC+Wf8AiSzcpn/nvb+v9K8Tn8veY2RNw+cGVmRvpnv9a9s/Y6Ro/ilqAaNUB0WYqVOdw8+370Ac7+0WH/4Xr4laIKXDW3pkf6LDzXIeGUW21KRWhjWRh3DAnPTof0Fdd+0csT/HHxR5hwVa25MgVcG1h9etcpod9Ba3yEXKRjHGJN4LfTA2/hQB2GjwxatDrdhGhaZYmuU8pA2SFyykOQRxVrwDA58M2mIWaVSwyJArA7uPu57duavfBQiT4t2c0PnCDYWlNwqorg53ZbndgHgd6t3vhS58J6/qek38qrbrcNcWLIu8yQOSVbkgDAGD6UAWp3bcVliaNCxyzMGDMOmeRgAc5FRPCFlyzRYbkSeaCSfpioAIhvKyTsQABJvwSPU7Rx16H8TUoiUSMixASPhS3lFmJ6becAnmgBBMsO0Mi54/eAH5QOxFSJPFIAWeO4YL8yQghh6nB5I96Z5kiQsVusRo+BGsW4/jxjFJI6DAuRNJtUBDK4VVHsyckd+lAEjujqRlTGoIJkYAr3A68+nI57VGXicyCNXnfOQsQPGDxgZ9+lOY27E7pJV3AEJtRSo9FYjJwKbc3a28Rb7YjQE4/fSOXB7EAgY6daAIbmSO3jDmGMZG3/SsKn0Bz+mK8+1a9ns9YF9bXEdpMjYEig7fXkY5+mMYqx4g8RPLcSiJ4jk4zCufx3Z6+wrlLl3LjfJOsw4+TGPyPOPagD0G0+KN9b27C8sRNOvAkhKpGPrn5sciqVz45m1m5iW9ISMuQ6bQAmfTGOa4c20zY2sr+iEAsfYDuarkFSS9tJvxg7jjP596APSdHv8ATppmKOUuUOAGfOef4R1xjvXdRwXNxA+1p7yFyHIUeXzjkMTjIFeU+EJHE24JcI8ZwvlIM4PUH0H869a0+9WOyiS8mkVI2B3OpY9eo/hH6/jQBOmkyxwBLBYrZnfchwH2cdc9cg9hyaxbPw/rNlLdo5jlFw29yCyjd0+pz/Outn1CxhRZJbpIIj8wfO0sM9j3OfpWamsfaZ99movFwwZi7bgv+0R1+maAOUg+H8IBEkxE4JIgj78989OetYOv+Erq1cvbQKpAOEYjG0dSMda9RXXNNaPy1mRZBgLFK2zA/oM9Tj0rlvFuqxEJ5Dh7nIIO7EYPYj1FAHkptZd7FpPM29XAzGv0XufrVzStSuNIvbeWK7l3KcgqgyBn0PBB9O1WtWv7e6udmqRotzH/AHRv3+4I/wAiqKOLiErKRGFyYo42BXPsTQB7V/a661pkF9bxvNKFxK6YbacdTngeneqs2rXIEWYraMDs7dPQYz+teb+Hdck0ZWjT99EW3srEvjsTjoa73S7jTtSVXglhs1b7ykgux7lvagDctdTkfl7tpdg6sFCk+obrx6Y/KppdXSI7XEVxldwRmYEnuc9PzzVe10eS4KYmhdh/qwQcMO/B5H1qyfDE8y7JpIhajhkVhn6AAk0AY15rG+RVjuFRV5WOzj+YfRvT8KzJpnMplaO18wnG6Ri5X3x0z+ddcPCW9WLTyxA/KBHKFOeuAwGc+1QXXhjT4j5t/qM0UaY5mlRSAe3y889u9AHHySl5Csk+/IxsdMMPckevt61dtbprdwyzQxbU3A3GenU46kfWt7xHL4a0PS43sr+aa8C/MjQ5XJJ6cbsdsnmvIvEPiie/gkgtpjFbEgGOMFfM+pxyPagCPxzrn9u6rEHnnubYfJHGk26LfnqATk/pWLqNtHZSx2saAzmPL5YEjPbaB1+pzWl4fiGkg6lKYI5dhWHgqTnvz37VmSXM1w8t5LFE/wA3ylmwTx3HH54NAEt7YfZrC3UtbhiSzBEJcf7OW9Pp1qDyk8+3jQPGdwJaQ9T64GO1W0vGn8oSIsG1gpVAzk/X1+nStTwvp0l/qst+0NuII3IV2BHP944zge9AHWOGW0WJbiQRBUUA264JPAx/jmsHxQqJZRLLeyykyEbHjOGNdDf3BSQAx7jjrGokGPUAjgZ/lmsXxRcObdWR3DCTgKArMe/IHX2oA+qv2awF+DGghRgCS8AGMf8AL3NRSfs1/wDJF9BwMDzLzjOcf6XNRQByf7Ze4fDPSNhw39sx4Ocf8u89fJ9jJMkEhWW7kkYbNkR3Lz2J7fnX1h+2WCfhnpAXr/bMWOM/8u89fLtgLiNLdFZmcr5m1yeRnHfhSe2ccCgDP0a5ktNYt5JCUdX2szPubB69iB9a9jsZohGqSu6ScFUfLAgjg5b8+1eP6xYiCZnEtuF3E5Epd/rkDHXsMCu48F6jDf2CQzrcCeLC4U7hKvqqjvn1oA7IR+YyxRyNK56oGYtnn7oHT60qW0iSYaIM6jDJ9/B9SzfKP1qFTayQY2hS/WNQGY/gMDgDvUzQo0bK0dzsK7tgIeVsc9OAo+o/OgBjF0Z2MsbEfKPJ3MVI9wACf50qrJGquIGPmfMC+Ax9zwSaY5hC7oyycjLXDdD/ALJGBn8KkSMpKrRt5bS85ih3ySkd2zk8d8UAL5jHaGjERf8AjeTBbPfOORxTQklwUMT+XG/GUyXOOuOnHviniGVMsN6k8HDKQG9z0H0GaQusSGTaqKTkOGzuI6/Oev0FAD2tWs4xvlit4scGPhiPUtg4PsKhVHdMR+U/GDJhTsJ9eckkdz+VN821eYvFHEJm4Z5ZNxyO+AcjHvxk0yWcEq+5TGwON67WJ9wM8e5oAY5jOFWFgQCEMwMpCjrgcDHvWZGwN8kbXKvnLYUeZsA6E4AGO1JdTvNK4edWwPm3bQoUenOCfeqzXtto2nT38lw4llG1I0XzS2eACeAB34oAh8VJJqWuWujtcvIsg3SF35AxknZ6CtmWS08PaesWkJISg+RFwoJ7kt1P1/CsH4cade31xeXcdrLLfX7/AGW0gQjLydTnPQevYAe1fRPhP4cafoMca6jpseu6zIBJdyyHMUJJ+7Gp6gcj3oA+fUa6ufEOmXkNvPJLBIWdiWIKnjGe+PyrvbiIB2k89pjn5ujbT7j+eK97hSOBPIs4bFraNci3S2CJtJ43fTp9etcd4s+G3hvxRGsukzjQNYKkIIzhGbHRl9vUfrQB5DqN7bRv9m3IkgBlZOFTb3Oe5xXIeC3+0TaioUXEUjswjLlVXt9Onep5fD2reEvEeo2viKEW+pPbSKjSMJBMuD+8T1H8uRXHeF7/AOyXaTyQqykcsTkMPQg9PyoA3tHEun6xdwvMvmpITFCyfKy55HPT616Boet2RucJchJ4TtZItuFyPuhTz75PFctrljp+r20VxECSVyCqsNnHbP5Y5rCj0+C1tJV+1uZuBCYDuPsCOoNAHuNrq6SBZZxbSKOA7uqbuOpPp9BVKfxXpNuWWa7HmbMtGjZRwPRz/KvIrbRNSu18z7UyyEfKjjdjj9Kmi8FXCoDeXtvIjdYiSxB9GU/0oA6m/wDiAj3MdjptyYrdiFkycCMZ5x6dulS21hbLqJvZr6a6idMhZbkmMf3jnHTnofXNYel+D7KF/PvY/NdW3bAAhTHf069q6XyLXzC0ZYPtwymYRk8YGFIIAHrmgDk9d0238Q61BBZGVbUjdNOBu3442oeg44zXQ6Pp2n+H4Git7V2EgyZUdixPo5OMetW4khNu0SYeBePs6tu+uMY/SnKY18xI40ZX5IwfmHcbcYPuOtADhJ5m9d9qZX/d4O1SMdAeuQfXOaWdGVGRrpvdIJSm1c8gcE9fU1E7xSIVLDY5IaOT5EkGfukdye+emOKYieWy+T5SMOd3C49jkkgenagDW8LW0Fz4n0W1dpWtGu43lWYhNqqd2SenYenvV39oHxPb6r46j0pZglvpFvuLFiQ0z9fkxzgADr3Nc5HewaZcR3QNjJPCDJHhQQW6KpOCOvrXmuoXWoXOsTxS3BFzg7hMm4YJ5xnp7dqAMLWpxdahLNLJO+WwR5ZQEeox0FWF2tC58wQhRt2M5UKO3GMEU5tNewuw0rI0bjliMcnt14/KojKIAYInc7juMZj4X6Yy2PegCrqJjYBWk86MDKEfL+WOnNey/sdoifFfUwsbRk6NMSrZz/r7f1NeIXMskrb1RY1JPJOQT65x/Svbv2OXz8VdSQBVVdFlwFfcOZ4KAMH9oZ44/jv4nLlAS1svOc4+yw+1cBNKXWbFxM6cg7PLbv64yPyzXf8A7RDFfjn4oy8iRhrYkqwA/wCPWHjn1rzyKWIE7Ji+0YxEvX0+bHr70Adp8KLyfTtVtbq1hkN5ZzedlioG3uCCQOfpXt3xU1H+3bXw/rIht/NVpbSc7N4dWAePGeOqnPXBrw/SdNEdwmpWkUTB4djrPKHywx3PB+lbd/q1xJoDQJJbxrBOs2FjBYsDnaOcDqTwKAOg8u5RQ8q+ZGF+8in5gD0LgjAHU8e1R7h2mBCkE5mbCjrnAGcc9ifenQxx3Mazxwi83qo35kBx/wABOPzHT606Ry1vue7UbCC/7sHbzgYz2J6gAUAK6STFQxkf5uzkAAdwM4/E1H8ysPKiaEPkbbhdykf7JAwOOc01ngZmSV45J25IY+VgDsBx+J7VX1C4NlZPLcXLRQnnEa5Qn0BHB+p60AGq6lHYwGS58tww5AOVf6EcjFclJ/aPiO4/0KWSK3H7ohm2IQOeSfmx27U3TbafxLqfnzzRQWYbA3yg5z06DkV6hpdg0FuiwCFAg2LJs2AADsG5P5UAcfZeBYVH+nx3DIWy0akEIT1XPXr0Oap+JvB9hp+l3F1poeOaI5JChsr6c/8A1zXpksBiiRTcST4626OIxnvkKCevrWLfP9oMlukEeTkyfZ1B2j+6SenPr35oA8dsLDUImBFu+4YyuShGehZsH9K6aC/u3geC/s7YKwwSyBWA7jc3H8q72yspI0XyUW1UEgB2DMD7n7v86W50a1u7OZLt4laRT8823HTqhHU89O/NAGTp0eneSssZt8IoVh8xHsCwGGPuPpWqvkDaBC2w8AEMgx16t1IPtXn+hatdailoJbiS3No7QEW/y7gOhAXp04961Ge4udV+ypc3UwKjEfmAkY6+vXHrQBN4j1i3jVba2SNWlO1tqsxx7D2z+FdfDp6xQx28RkEgUARgMh5HcH/61c1beEJdQmNxbxSmBwq5iVl5B7sPvHtXUnRtYsoCt9pty9mmMmeQtJjHpjJPcE9qAON8d3Fpp1xZ3lxFHLPKDEyqAGIA6lh/9euX0eMSmbzppIknb5Y0DEsc8DOOOO/oK3/Fem3N7eia/CtaxgrEpXaMH0x/F65rLtIZZporbUIpZINwVJxJtynYKO+PftQBuP4M0t4fvR2u8cCHdI59c+g+uK5S/wBHFrfpa20SoszhDLImRnqD6c1bj8R3OnXE1rPepcx7iq/NvYL/AArkY6f3fzrY0vULO6NzeXN4iSW6EhHG0g/7WM5/pQB57ftJHcSpLMBsOBsj27wOwI49sdadbzO2yNW+z55Cxtl2PryM49uldBZ6GniG7a4sgbTcxZpGyB/vc9B/PNd7omhafo0EfIlumBJnljV2z/vdh7d6AODhtvEbRjyb2Sdc/wCrZcY+pJ7VLbXniuzbCNcMwPIQBVXHcHp9O9erLAZVMkcjxxBdpcSeWo9dvTI9sYpXsUCusk6ypjIYP5e36nue+fwoA8sl8VaztWO4S5Z05y5OEGc845P1rJ1LxPqzTE+dFFliSEXay544OMgceteu3tpa3iGNjBOCdqhVLgA9+OorzDxfpDaZK32eVDbOThAwj49SD6+1AHKvMZhuuLiRJcYLPliffceB9KgmkZZmELuYtgy4BUv7Z5p/2swnbDMVQH7rEnae3PofQVCBJI65labg8RfJz9O/PegB73SS/I7SDHbzAQRj36Unmq7oCDuU4yJiTz1OcYx24pRHPs8qNZxkZHnHCsPQZ/H608QPDEHlMiqRsGHG3r7fd57UAWrNmazeOOe4MsuIoUSLKrk/MSzdcDvnvXoEVtaaNp1vbJBChGEVw+5mPcnpgd6yPCmkzWkA1q48wWseRbsF4du5yQMgeg/GptKvLq+1G5u7i7SF2/1QON5XOSRnpQBbvRFa25aOGFiv3g0bKGA/izkA+45xmuZu9TN3bxoZkA6lUBOc9OSMflW7rhMdviJuXBIKtu2qPpyD+Fc3JaNPDIyr5gBAbzFY7mx97P17UAfY/wCzVn/hS+g5OT5l5k5zn/S5qKP2agw+C+gh8BhJeZx0z9rmooA5P9szP/Cs9IxjP9sxdf8Ar3nr5V0q9tH/AHd+xPAjO+Undk9fl9K+qv2zNv8AwrPR94BB1qIcgkf6if0r45ZvL+VnhjIGCIRliO/sKAOmOmS2/mPDcxC1HzGMLg+X/eXccEfrVawubrQdbDQyxtG/DSKjESxnvhefoMiqOl6pNpzq6tCUIzskiEgkX0OeR+GK1xL/AGnDK8MCNZJ83lnAeM55KKMAfl+dAHpdvcboDdRqGjIJzIME+gVckD3JyatJNaiMO6QNuwQzMzFj07ZHfsM8V5d4Z8SNoV8mxIZ7dWzym+QDuAD0P4V9C/8ACHjWdBtvFfwykbUbW6B+02VxMI5oyPvKpIIDAj7vHt2oA5RLiVMCOF4D/C0kQVmGPuopBJ+pphmk2BTtklzl42Ys3+8wHzY9j19KYs+TMJJU+0qxWVHLFkYfwnPIwep/Cnu02EEWFUnI8txGpz13McH8smgBp3eYqyO4kTKgcMef0A9cDilSIuBM5Abbw4QA4+rdvcUnmKrFCs0rED92uBjvgdvqSe1MZomYFpRLIT8qpl0B/wBo55x6AUALI5ZDlllTPyncuPqWAwR36d6q6hcbY3ae5O/GSzuGJ+vv/kVblfywHyeMsqrtBz7r0HHuTXDeKNUih/cqoJYZPkMuR6jjnPvQBFeastvcSmdI3LYbaYywx6YPOPeuZ1bUry8mIeUqM4SFU3EfTsKivJ5ZdzAXCqxChT8+4/XIzWz4M0dJ7tr65kEFhbnftAJLMO/uB1oA98/Zv0NLDXLiadfNu7DTg4eQlQHlf5zjtwuP8K9YgvWvbiUqFeVpfl8gHzFyejA8Ads9u9eRfs2a9Cda8YzajNb21s8ELRSzjadoLL8xJ7kivoSw0wI8Vz9oWbcN5KjCsT3HsBjAoAgsoUmhTynjfa2ZDKpDY78D8fWud1jdYzSLbEx3SjKT+XuXaeeQeSSMc9q7SKy8mbfEygscsWXJPsD2HT8qzNf0VtWaB5oYGZBg8nP0B9PagDxD9pN4b3wr4f1MXUctzBDdRswXAYMi7uTzwVFfKsTuI1KpEYgNrbmPzD/PpX17+0iNuhabotsg8xrWeRYt2M7QvXjtXyVFcsIHRIkAkUEblyFI5yDwM9vSgDdsPEFzaKqTQl4SMs+Tz78n2xxW1ZTaVql1C0cUgmyXaJFwQe+T14HauOBMiIHlV5E42hSdo7fhzU2m3j22oW+LdWlZwEXJBB9wOSKAPXrVYIlEYSQISCY5FbcD2J7H14rQiZlOFcRMRyyLyTn8x+VUNKvZ7i2WSOC3gLDa3mtgc9seh7fnVw/MNuzCIpAZc9P7p7H60AKyMFfbDKGU5YyZzj9P8/WhiwVF2vG5GVEqErnHGD94cfUUojZGLBmLoCd0ikc+oyePxprSNG5xdiKHA4SNWZwerAH1PoeO9AD2lvHKl0t5OABuYNtHrkDgH1NNLSpLsDRxyk7to6EjqwI7gdOlNXDsGeKeZD0aHABHYY649aVlKRiMRs6uBzL/ABDr36enHpQArNK675Y2mizlikZBY+pJwAR+NMkYf62aa4SFf45E3YAGfvDOf161ASu5FaHHIJYtuAOcnAwMVVu5LWVWEkTxWkeWbGSjkHOA6j5cdcke1AGR4j1ZbG2eeeXz8jckfClewGCMEiuCtrhS9xqOoCeSM/6pckEH2I7fpVnVp01/WpJVDy2kLYTAOWHcgHjJ/WtG8eOGa1lvLaSO1jXy3iSMIFJ6Zx/F7UAUZpJZrWK7vTdrbsQg3xKrBj0wf4l9utYt1LHgKzkOAQXJIzz2OeD7GtbWNQ+0ySJaMbqB1CNuJGfUqOx9QfwrPjdYERvKkhTGBIo3D6EYx+dAGUoUk5hBY85Vj2617Z+xi/m/FnV3PfRpf/R8FeKajJGkT+Wc5Py5ZlYZ/wBnpj6V7R+xV/yVPVf+wNL/AOj4KAKH7QkhHxx8Tokm1i9txzx/osPPyjJ/OuDuIy0RIlllz/AwKqD/ACH1zXZftFzmP47eK0G85+yHCsR0tovSuB81JDh8LkDcuX6Htkkn36UAa2mXtzp95BIEW3hxsZfNySO5wflH1rrVZLyQ3VldRlZITHJsfzCAeNxKqBnr37151JKqozCKJpMAFRGG49PXNa3h/UJ4bjytrRRScmOOJQXPOASSMDHb2oA7Dw1fRKqabcXksV3aMI2FyygMv8L7e/BHHNdZIpR1M8tzcgDco3KA3pwozj8a4XU7SadILqwmdbmJeAkSN5idAG29D6fnUlj4oeyTyL6yWKVDzi3KfmFO4ntkmgDrbi6eCDzJX8iPnhYg3zdeCw5NeeavL/b2sC3M2/5wNgRmOPXnAHP0q9ruuXt9YslsiQpx8yqFOD/tZOPwHSqfgKzafWd8zmURnLFWBH081uPyFAHpmgadFp1rFDApt2xgvICisO+DgjP04rVMS4WR97uM5ZwCoP8AskDkY4wKjjkhVSou97suCsTs6n/edh8x/wB0YFTbXIDyyIpGA8ctx5aD1GQo577Rx60AF1JDLER+/kjUbfliKx5GO46muL1vVvsakwy23mSy+Si7grL/ALQGeCOeua6PXb6eKDymkklLdFSXblcdeRz2xmuX0LTvtN0l1JAqtG7eWJ4t0jDpnb2HuTQB12h6rZ3VjHL5NzcqygebKWO8dMFsALz0xVXxTfx2mjXd2sEsYSNvKkKhgrHjABwQfrgVtJPJHEg2wxOoyqx7kKjvgdAfr+lcH8Ur1otDe3lW5WaZxmPeGDD+846fmTQB5TpsDySf8S9ZNxyXkQlmX2b+EA19K/AXwC1zpR1O9t5XiVtsaOAvmPnOMgfdHc9D0ry3wRHLB4cE8EkKeYTv3jcuMcKB3/AcV9h/DiySDwLoSxuzKbKNst13sNzN+JY0AZl3PBZqttBBIZBHy8B2Rkg9s8YHTJxSaVq6Wz7rmESK78P5u7HoATxn6Vs3WiGaVlaO3miDZK3EfyleoAx+POKrS6VK0jZtYJSWKkKGUqOo+bp6ZI+lAEtvBY3thdo1rBEl+GikHlZkJIwCeMN1JB6CvkX4qWN34L8SR2OoNczx28u9XLKgeM/xIF6gj16YxX2FpNrNBfgiBI027Czklm9cH09OnFeTftQaDFqlroNx5GZi8kDMMAlcZAOe2cmgD5Yi3a34hxp1lbvJcyHyl8sqIx/eJ6+9en6N4QsbO3BmD3BxhiJgCx74Y461yngWBdN8aahbXsjSTInyBsnrznjrj1FeqRPCSjieR8cBY4+Bjqcng0AU7WxgUCKG0i2KfkQvl4x6lRwf8avBnilkNssNuE5IEuVz6vnnJ65rM8SaiukJD52mfu52AijjjO9j1AJ7+uMiuIn8R3816skMT/ZzLy0yYIGeVGOfpQB6ohubpPMuo5LgEhWPmYyewyOT9OKbItwxx9k2pnPzttcqP9/INcwmsaVBYW9zcyTRwudiNdSDfj3H1roLIWN5Zma2kaVWb5nB4z2xu5H06UAPYvyge1V87gACWPPbbx+ArgfiUuLUFDED3jHUZ9eK7/7OEChbe6jXrsWH5iR6MOB+FcN8S40uNOMJODuA2TKzMp/D14oA8nLEv8m0NnGNuCcDrkDJpPKmbhwoDLhWMZ59B69K6XTdKEX+thjYgcbpDE34gdfxq3fW0sW9XSMNjlC4UEdeT0P0FAHLPHDamI4uGk2gkBcDP4nJHtWt4E0ZvFXjrRdJtoxEl7dBZCFwyRL80pzk9EDVi6qS1wWLKpHbzAoJHYV6n8GrOTR9N1PXZDMb67iNnaGAq7RRHBkcZ4ycBaAPQ/2kNV0uaz0bQNCjHloqTOIyyRRxYOwYA5yMnr0rxmDWI2iK28sTKmNzww4wAe2SCTnHU4roPGGsTBJN7TNLOQZBIqNtHAPy5444/pXEahLLFdzRm4kVM5CxD5dpH3fmGOnNAFpnlvrjzZIDHG4LNn5t+DxkDPHtVe5ngWGQR3M2xmyqodoJHXIzkVWN80cOYZZty53lSqgk9yuBnis+OW4kYhbgTHb8wdghX25P8qAPt/8AZoIPwV0Ar90yXeP/AALmopP2Zf8AkiXh7Ix893xnP/L1NRQByH7a3/JLNK/7DUX/AKInr4+gaSaFdpjRM4IVQBn1PrX2D+2t/wAks0r/ALDUX/oievjC2YCTDZwfQ45oAujeWZhtLf3sbix9h3/lT0mmtZklE08Eyjlk+U/Qc0hSLC4jkU46mXPP4Dr7UmBGMqYwVODsGD044xn86AN5dUh1FFh1Hyoi3R5CW3+gYDoffj3rt/hl4u1b4Y6ybzR5E1HQ7kj7XZAktJx1UZOGH98DHrmvKCCvO6PcT/fBY/WtDT9Ql06QSbiIyACAQGYe3t7dPWgD7Lvbbwh8YtJXUvD9xb2XiYIDG08QEqkfwyJ/Go55GcdfavINX0/UvDupTWeuW80U8aksySb3YZ+8p7KTnB6kdq4Lw9qYa4kk0JzZTN1hluRGxHXIkyPrxzXVa14o12706C11J01JbUF4PtJJnj7ERyD5nXpw31BoA1Y5vNiAtZZhBnG7ARM+ndj9AO9LLeRwpiS7SFmXBSPqR7nHHpxXCWHirT0leG8sWguD2bdiPHfPXP1rcttX0y4hVCyKrAj7vH/fIPJHQEkZoAqeItfjt4QqGFmcfKiNuIH1PQ1wbyXV9KXSByHOcnOPwFd/Jp+ktcnbYRF2Od0n3U/4COP516n4D+Euo67BHey6pFpVoedtqFeXB7YPC0AeEaZ4Unk2XOrRtFEV3GMYMjr7Dt9cVe1m7iZbe0X/AEbSoHXzYwcu/PTA7YFfWk/w78BeGdLa81qJWjX/AFtzezsWlbtnBGT6ACvmzxzJZm41S58M20cNmhLwhl/5Yjrngn3+lAFbT9fS0vVOnNawWO4oIVJEjDuHGDnPpXXJ48197Z9I0+71C0t7b9y0Ui4KkjJHYhQK5r4KXuiaP8RdIm1+OMWs+UjkkQRwxTHoxz/WvrLxx4J0vxRp10zW0S6k0JEF0pKMG6rlh1GevXigD5gj1XW7S4WeLUr/AM9CHVhOwZB2IGcc12d78aPEg0Uae/2O21QRE/aG+/LnIG0dAw7/AJ1meH/h74s1vU7jTZtFk0pYH2T3V4S0IwP+WbdZQe2OOe3Suy+IPws8NaF4P1q9e5mTUIommtJpZQSQqjKbTwRnqevPtQB5F4rvvE+q2+na/f6nFePaYBi3fdTo4B7+4rz7xRYJZXhuLMzvp92DLDIuNoPdMdsHtWnYavcyzRuC4hCKVgZGIdecNwP/ANddpqPgfWYdBVrqwml0S+AuIZ0JeO2YjO8FckZPBU+lAHjsJjJ8tw0aY+Vwm4q3vjse9TTC6t3dSrKw4zuO1lxyc9wetSarp9zo94LS5APcMpwrD2OP/wBXemM5uAiFk3qMAOSAR6L2/wA5oA7f4f3k7brdl5VAVw28/jXeCOXyl8yEtFtADI/ygD0/HOe9eL+HLkafq8M8sUagvnjggfyz/jXscDpKiSxoMkHaQCAM9h7/AE9aAJJFMbbHAi5AJcnOfZs8/wBKRJI1AjjKiPdjadwZGPTaO2emO/PNA4UrEDCy4UYKt9eo9+1TgTMCgPmMQSRv5xj25wfT8qAGeXIAxa3eaRW2kruiK49c8EY79Kh8kRACCAxoSww87MPTnA446k4qzY2Nzq919k0uxu7q52hRCJmbHPBLDG0fXpjnNO8caTceB7SCbxFdQ2s90paO1hmMjA56FgOR9RjNAGJqWpW1vbSyzXBgghBywO5ZCMHGRzivP9Ru5vFE0cWmu1lbxLhw/wC7VsnjkZB9MUavealrj4u7iGysAQzqx688FgOSfbpWdJqVnp7CK0mN44+ZCwCKh6Z9/p3oA0G04WkBWO4jht2whaSQDB7kd8e1ZOsX818UjRn+y267Y1WTdn1Zh15/HFZt9fS3k/nTKoZcDjlV7dM9KgCSNJgqiyLkjI2n8CTzQBMFEihi7suMHJC0s0qNOR56uM4LOuD/AN9DGfrSxvtBYSCTPBBXBU/X/CoLq4aDcyu5Yj5TngH2I4NAFPU5vNnCgkiMbc7ywJ7kV7p+xT/yVPVf+wLL/wCj4K8ANe//ALFP/JU9V/7Asv8A6PgoA5z9pWQR/tAeImbG3NqDnpj7LFXDpNGv8IbnO0EIuc9+5/Ouw/aj/wCS7eJv+3X/ANJYq4O3ld4VcSuD1yMHGPbr+fFAFqaXEbNE7BSfmKAgD1G7ofoKgM0a5C3Hy4BP7rIJ/E5NSmcy5X7RLNKeeD5jAemT8oH0ph84OQJQDksUG1mB/AcfiaAOgtNRnvrPZOsUfl/OsyiNFHHViT+nJ9KuaZr1tJeJ9oit523BgiR/M3tzkYPrgY4rJ0DWbazcC+Zmk/gk2KBGe+Tg5/AVPqOhvNDJd6VO93C/JEMLKx/76bJ/KgD1fxT8J21vwna+Jvh5Jd39rON0+nzupmhb+JGAIBKng4+vvXmXg+/+x6rb+Y6fvWMXkpPgoQew+6Bn1Fa3wv8AifrXw71qSW2jWfT5yv2vTpJcB8DAfcc+W2OM9+Mg16D8SdK8P/ESwk8X+AB5Wrqqy6lpITY10qgkyxgY3svfH3gOx6gF6KSXaBHNIu4Z2i53k8dM/wAOfQc+9W7VZ/3ZjtXnbICuJCAv4Zz+Z5rj/BHiBdU0tklYtNbLgq8aRbRnqMjPXPTJrfNxaEsHhlZmAAHnM7E+4HXP4CgC7cw2d28jT29/dNyCxlGDjng9u9MiS7tiPslhcWSkDJEv7zjoe5x7mnRMWUiS5kt1IBMECEFT2yx4BH51i+INe0/RY1M0URnfJCyO0jufUk84/KgC7eC7tbWeaPfOiqfMeWXkd8s+cD6cnFeLeJbm68Q6xi4uIAittjTzWdfbAHT8am8Ra7eavc75Z5Yos/JDG52KMdwOv0zUXhWytzqiPOxWJeSkali349Af1FAHodlay2mn2++W1SKNNgeQESsO4we35V7n+zz41Gp6R/wjN6hS601CLabORPADgD2dcgEemCO+PnK9111upBbQNE4QKGkA+UeoJyORXq3wOjL+IYfsTTRyyWT7d+4DzQvG44/WgD6Rv7+z06IS393b2sZ4DzSBAfxNUtM13TNQl8u11KynkJOxIpwzEfSvlfxrL4gvtdefxCkn9qrlWjuFwiIDwUUj5VPqBz+NY1sphlS4VpYpY3DLJG2zYw6bT1/EdKAPtevnf4z+LrHxLqyaVpUyXVtp7sJpFkQxGTocHqSvT05PpXQHxtqusfBDW9Q1CCa1u0V7OO6jOBcDoZEx04zyOMg4rwmC2g0Zba3EkS2l58yBJOVcDOBxx64PWgDGmmXT/iNpsnnbIpUChZEYqByMLxnA969WtbhEwYr2QsWwFCJtPru6Yx6H615B8QvPgnsb23ZUA4Lls4b17ke2a6nwv4ts7rTkTVR/pWPLeSaM7ZAO+Qf6UAdh4nsV1GC3jurqXdE5cFyQvTnjqe3TiuO1vRfsGhiKK/QqsgkztDcem7OeM11oWNyrW6SNFgKrwylFX3BqRLO3Z0lfypnIyPMjLBl7cAZPegDzGy0V9VmVrRZ5EIzuSEBOT0bd/LFejeG4L7SbUadFlFUl8CTC59QDnA9q2kuxb2qpFF9liB+RWxhj6KP859aq3JM7iRmmBbJzGmBu6nI6g+5oAbMJZnIkaZn+7nzXLr65xgHn2rzPxpdeZelNzFojjZJIRtJ9V6e9d7qV2tnYzGedkQryTKxYexxwa8g1K+t7i5YpJHJGGwsnlbVz9T/npQBt6fdmG3C/aPKGAGZcFR79CSfxrJ1y5tliO1YZygycSYIJ9vT2NV5tZeAFbYRrMOh3DcDjnnv+Iqtp+j3OrTpJeTH7OTkuRtcn0yRzQBW8OaTLq9+zzSiC2j+aSRlznn7oz0P16V3C6hDHA7z3TQW8B2xQfMoIHcYGPf8ArUQ+y29o1tpkBEUbfNuYlT6k4+9n0rndWlVjITLNkMV2qFwD3HPpxQBavvEYcPHZIZEPTBVdvrgEHOeaxL6dbh9yrcoQMbWG8Y+oOPSqUzb3IHnkkZxsDZ9c1C4BALpKrDJKMmQPU9v50AWBaXErlEMsg6qPNAA/PP5U6RJI1eMoGIG0MzoWA9Rzg1WZVRQpeE9g2xgMfWnRXqwQSb0tplA+75Xf3oA+4/2Y+Pgh4d/3rvtj/l6m9KKZ+y5/yQrwz/29f+lUtFAHKftrf8ks0r/sNRf+iJ6+Kq+1f21v+SWaV/2Gov8A0RPXxVQBft8yxlskFcbscce56n6CpDI42hWcdsKo5P0/xrPikaNwynBHcVo7laNdkj7ccnnJPp70AOyjKSo/edCXYMT9PSkAMb5Rot4wchC5z+I5qMfMFBfPH3VOf16CpvMDxnczSZ4AQlRn69TQAzBYknacHdgpyT6nFdPonid4gtrqTie14HmGL5lHt6/jXOSx7TgAY6FUJYD2yTyahyGJ+dic8bR0HtQB6JJb2uqWyyQs1w6523RYI8Z9Ccc/Q/nWvp9zHFbw2srlZANpMUYQMR1y2ML/AJ5rym3uHtJ/MtnkhmXuG6D3rpLPxdO4EWqJHLCCDviU+YT7cgH8aAOnutFne5S6t5pDIp43SkMe5BPXHv0+taSLdyK502/fS2SXEz28zRlhjoecn69azrDWLa9K7NS80nBKS/u5QOnUnGOwFbdo5WEyS2r26xsQrYHzKe4bPU9KAL9zq13PCkeZrsKgH72Z5Hz6qW/IY9arG4AgciKSWOTgKkmAfYAdT7U1hG8Rd5sAjhVYbie/ToPofeqwmjilMdsN0bAEncCxA5wMcA9aAKU1mlwI4Li1edceYEdieR0+b2HHPeuw+GHi7WfDPiKwhsmu7nTLq5WOe0luN42uwUsNx4YEgggjIGMVxuq661pbyTwPGtzGNmxGDMSegwav/DnxFY/8JR4fn1y8XSbP7QDcPIgIZgcoOOxbAJ6KOaAPqv4meMD4R0eGS1gW41G7kMVvGxwoIGWZvYcce4r538f+Kda8ZWkNrrV2sdtb5kxZxBW3Hjrk9vwxXfftJarpscOgXwvoLlEaRDbRTZLhgCrDHTlcZPqOteUh4Z7pnMDRLIMkRk8ZHBJ9SKAMDQ9MiubsTxLKqRxCNllfaGf1U46Af/Wr6H+FPxD0+z0SDQ9e226W6mOK5ABiKckK+PukDuRg/WvGVmtkwscjrjPMn7zLe/YYH51F56tJiOEHkMzQqWLN7LkcDpnPrQB0nxl0Pw1LdfbfCdzFqlvP/rtMgl2xw9y8bAcZ7qP5dPIZvCsU2WtJZ7cZ+5M+RntzjnH610uvaE2oTW81nIbKePJ3p8289iQD057dKzLHStXJ3Xmpw4XJwqly/PQ+lAGM/hHV0wIXUqSHf96DkjuPeu60y9uIbZItRXZPGNhZCSp9DnpnHeqV7p9slqxN21ttXc08r53Y9e39a5MLq99PILS6MNscqZMkBlzwT/Ec+oFAHpFvdS39zDZ2Imub2XhYYwzSSH2AH456e9eu+G/hlbpAL/xpew2kMX3raO5C44/5ay8Y+in8a8Gsrq50DTkSTUktYgcmcSESOMdMj5sf7OQD3xWDq3jJJFkigSa83HJ89PkDf3gD1Pue1AH0l4q+Meg+G9P/ALO+H1jBfSj5POVTHbRe5bH7z8Dj3r5l8SeKpNS1O41PUr+81DVpGLNIJcKh7KB2UdgOnaue1LWbzUlIu5D5RwPLRSqADsQPzrPG0naWcNjlxyMH2oAt3+pXV8VNxKFVeiBcKD68dfx5qmRxsZwp/unP5cjFPkQDdvJcbeq8r9fWo2kYBk3EDOcYxkev1FACqIwPlCyuemDyP8aRixXKnCN0HAH0FIRuGG2Z9V4xz1PtSBHAPyITyG6nI9f/AK9ADtxYlm2u2PvNj8j/AI1nzOHb5QAo6AVNcyBflQjkc47D0qrQAV9AfsU/8lT1X/sCy/8Ao+Cvn+voD9in/kqeq/8AYFl/9HwUAcp+1H/yXbxN/wBuv/pLFXm+nFHcxyBcfeG4gDPuea9I/aj/AOS7eJv+3X/0liryxGKuGGCQc8jNAGtK+08yLjOVVVLLj2PFSQwxxxvLcKgXsrsRu9sL/WmLKuxJMD5+QWyxH0BPP5UrRosUSpEfObLlsfOfTAzwP1oATckOCrxhiDlRnI+pHA+gqWxvXsxIsF19micBmWJthf2PU49qgG+Ifu0CEkAc5JPXOKeJHKrhnUHO6QKAuepx3NAGra3VnqFt5F2Ft5l+eN4Y+PoVzgnIzljV/wAOX32DVxbNPcQXW7MNwHBkjkHIYYIA/En6VzLF3iRZGdU6gNxx7D0961LPVZVtVsr6XzLJhhUdASAe6jGce9AGrql7d23iBrptyajnel5HDuDjuccDOeuOPrW5Z+NdbkHlW1zp0srZLK6eWzc+o6nPuKyZL5bjT/sutedf6cQGS8jQ4tyOB0/LmtPwvo1tHa3LzxQv8+Elky2VP3cAd/bNAFe/17xGAVuf9HTbjci7E+oPJY/hXPzx3dyq+abzBBPnS4QN74PzH6k16BZhLR1TJv5gSqTSKQ8Y/wBrIx9APxqK9fT/ACmnvxbxwhvmZ1M2D65HBP06UAZOkaZotvbvNcsbqRU3OFbJ49QOa6jQL7R7rT5bgXsNqkJCR25BUSjqeR0A9PX1rm/DVlJ/a9/f2MMpt5CViDAIr+vGea0LnR7e+nS4vljbywdiZGyMnooA4Jz3OaAOhg1vRZJfNtdMjkkzhdwD7vQE5wPpXX/Drxt5XxJ06wt7c20UwWOcOqxKFZTxnq2CAa8YvtMOi6aNRt7uc7iPMgdQmQT1wPuj69RU1tpElxexXFrfT280kZdZwMMCRkhSTjGOp/CgD7Z8XeHNO8XaPJazsglXPkXSAM0D+o9e2V6GuT8C/Cq10iY3viSWHV9QVj5RZD5aD1wc5P6DoPWvBPgHq9/p/wATrBLeeeK1uZTaXtrglWYoSrEfUAg9vxrufjh8UdSOr6l4f8PzTWcGnt5dxLEdstzJtBKKRyqjIBPGTnnFAHq3xT1DT7TRLPR7mNWbU51t4oQdo2jljx2A4x715p4g+G96IfP8M2xurSIArZXA2yxDsUPQqf7p+YcV5NqV9rOpT2C67dTXstov7ma4YloFIzyc9umeT61ctvFniyW5+0Wl7doyP+7mVyi46BR/eHpke9AEfiLw08rmO+tru2u0BO17YoEHQ5z296891Xw3Npknmxv5p+8oRdvHuT1r3Dw58aPFMOo3uneJLCLVUe3aFWWNUMTkcZIGHDZ5XAxjOa8ruNUv725Gkx2g+1ciYSrtAQfxKfTpg/hQBY8J+M/s6R2upWzgD5RIMKyj+7kcn0rtYPFWjXTsyTM0wB4llCAZ69OorzRvCmoTzHKbIFB3ShVOR6gD8j2qvJ4d2lY2uAx6LthADEc9fpQB60deslX5grkL98TAjHoAQcf41VufE+lQNzLMpbjaPvZPUEj9BXkFvEDO1ustwJB1hZ8AnoSf/wBder+AfCvgfTLAa74/1u3e3iOY9KhdpCzf7RAzj2B+pxxQBRisvEXxOuFsfB+lXC2IbFzfTAJDgcY3Hr/ugk+1Q+M/AOlfD5ls9Q1SPU9ekQFraBdyQIRndIG6E9l9s12fi79ohV07+yvAWnJpVsF8uK4aNSyD/YjHyqfc5+leJS6bfawz3WoTuBKxkea7djLIWOSWOOTnvQBPdaoltY2z6fAolYnzGwCV56beoOPer1hc6hcWZur2aVbYg4VX2oQP7w7/AM6zYn0bSX6PLMgJDfNn3Hsfzqpq/iKW8ysLfZ7c8Y2AhvbNAFjWNall3QQoIj1Kq4TH0FYTOf8AloIjknaGXDH3zyDVYtuBGfpnLKPbmnB2XzCIoypB3FTx9fUUAPaUqxA8ohfm2kjn/P8AWmbmyASqgdcSbcf/AFqeAcowRFGc5JBGfyzT1jRwQ8YUkEfu3GM+tAEaqzRn5I2xwv7wE++QTg1S1EhSsYQqfvEF92M/yrei0xGtZp54WSGPLOBLtJx1+Ujr05rlpW3yM2MZPSgD78/Zc/5IT4Z/7ev/AEqloo/Zc/5IT4Z/7ev/AEqlooA5X9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACpraVY3+dA6+h6D/PpUNFAGkTkgv8yjuxCge4FOkIYkkb2PJLjk8/XpVfTzG86Q3E3kRMf9Zt3bT2JHpW3d+H7+CDzY4xdwsNwktXEiY/vHbk/gaAMseUHxlfQqgz/wDqFO8xGHKnnr6DH86b86/K/wB4HlH42/Uf40hKDG7PqAP88CgBwjcIHCYXoOck/hSB3LMA+D0LcZHt6CkU5y7SKjAnLAZP4U8SFwA3K/7Q5H5dqAFXAwAXKE8kHGT3P0q7Z6tqVouILp1jHZ2OPpg9fSqKrCwBdpO+WIBGB3A9KcgjPCsjZ6DJA/En+nWgDYGv3ZyZW38fO6RiNmU9ge35VDJq1zG2ILqQRIcpuO0t+AqgsW9xHGys5O3uefU/4UrqTJuwpA6FiMEegHegCZr+4Yk4IlY5zGNpJ9c+tQBzJKC+55P4ixxgew7UGNkwJMrx8u1gOPUU+KVYtwiVRIRlic/qaALOn3klvGYYUheNuXVhgSAevuO1dfY+ME8tI53k8teNmNpH0YDGfY1xHmsxJkC7gRuIQZP4f5xQGPIjkLMefm4/WgD1Gy12yuV6IkhHzK7AA46cDv8ASrn9pxzOkFuP3YBKnGAT06jk/wCNeQoq79xUlgQQATgf/W96mF3cxqf30qdygY8/57UAetyRK8eHW4wecoo3OD2yOffFVZ7iKLcZTDE65GJpNp6YAC/Tqa8ulvL+Usr3E77uDuc5xnj6H2qs4dtpl8xgSRndzkUAdzqGuaaSxu7xbgjA8qGLABH+16+1ZV34tnCY0yBrYBcF2bc31z6da5rDK4wQdo4wcbfpTSiLneVB7YPJ/wAB60AOllkuZCzO0jsSSWPJ9aau5mUKm7Axt+9tz159KGMYC4Uk7f4uR+GP60hbcCOQGGGwccf40ASBfK4kLIWyGjXIIH8qjYkkRo4GOQDxn60gAEakFvmPswIHbNCmTIxnd02gAn8B3zQA0hQoEcgRgSSpJAx7UpyCVLfMfX5gT/Q+9alr4e1W5haX7MY7fG7zZzsQD1yatS6XpGmxZ1S9NzJ97yLYjaD6Fz94e65oAw4beWWXZFbSSSf3EySPpjtU2qWkmmQoboGK5kG6KINh1X1Yfy71cufFJgQR6JbpYIB96IkNn13df1rmppXmleSVy8jHLMxySaAGk5JJOTSUUUAFfQH7FP8AyVPVf+wLL/6Pgr5/r6A/Yp/5Knqv/YFl/wDR8FAHKftR/wDJdvE3/br/AOksVeVV6r+1H/yXbxN/26/+ksVeVUAXdNlCuUKMztwgU4OfStWfIcJiNUGE2NmR2/AYH4dK54Eg5BwRWvFcLNGHEUbSY/ePKw4PqBx2/rQA+TKM+TGGz85RQ23jpkHaPoOnrTDmRg3mysygYzyf8MVIcMHLupweSuOB688AewFQ/KVP32Rjg8k7sD9f5CgCRjGdxZxI5GDJuJ/AE8n+QppCJzv4OMKuT19f/wBdNO5vvgIMexP5Dr+NSQKFJGQmDnccKfxJ6D2FAFrTNUurGQiGUeUDlomBaMfUdM+/5V0mkapGriTRZWllYHzbS4B2rnr5bMePT1+lcgDE3y/vGA5GSAq/j60pXdHhYiQoG5t+do9FzwDQB6dpeqJfwrHHL5bxndJZ53MT3DHqw/z0qfU7NbuA2spMMaEfvAqxop7bgMDGOorzeLUrqMozMIdh+WQ8OuPfqx+tdDp3ia2aMDUYFZsYF1jb9QVzz9RQB29nFL9mQXEW1h8uNuFIHAYk9v5ClvJ5VgZIyssn3OFGEUnk8+3pWUstrd2/m2d6khUb4pixZlwOu0cnGMY6Ck0XxCNTgEX7iC7xmRZnA3j2OPzoA0Hgi1Cxa1uY4pVc4A3Dj/aZun51Rs7OTSoBbLcefCGOwxpvBXORznJI9fSrgjkitTvlIkHOzbkNjsoP8Pr9apXM1uj29xeTPFJbzCXYgKtIMY4H8IPv2+tAHTeBLRx8TdBvoxyt6k8sijA8oIQzEjr1xUF+I/7e1y8aWWS4u7yYh5WRDguzDPXsePYVU8EfEhPDertejSorico6KySklVYcEk8fkMGq7apDqemP5FmkfnzBfMRQyqR8x3rnPtQBVkW51G7ERufLtYhuaQ8lmH8OfTH4VpI4hjiEDkJGMovzLhcdCDwPapIZX8lUYsURBnaNqqTyDgHO08H600JI8ZjkkdCQCwLcL7g9/wBTQA62tYFj2+XPIWcyEhwrAn1PbHT9KxdXt5YfEOnXVsonmctGIc53AjLMW7Y6YPFdHNv8os8m9D1Vuh4+gz/jWYdxMNzcIIpQSqo2PMAOePTnHQ0ARyXJW6EdxCY0OcSRv1bsA3ueopsdmr30tzKyS3LkBMJ9wYxtAPf2P8qnco8TiQeZ67jlcDqAfpzzWTc6vFCphtyryDgyou5wO2McNxxk0AV/FWmpPgW7tFKCBKyphfqR/e9qwJV88CCKYxWcORksF+pIPXnqO3SrWpazGiBHC7sf6kFizH3bp+Fc7fX8t2QzhQM4A25/DP09aANC5msbIk2z+dIPuuxxgegH+fasy71O6uGxLMxjJyEWTA/z9arA7U3HzBnpjDD689val/eNkByykZIHGcd8HqKAIm+6WBDoDgDzOR9R2/lVi7C7YYniZQi5BBHPqcUxHCOqoyONwyzHg/nS3JV7qU7gDvJ27s/iBQBBuG3CbkU87SRjP0NIFdTgqDn0Ocj8P5UoCqCPMO/PBAH5Yqexsp7mYRwDLgcuvYfSgBttbtIQqpJnOMopbB79OnbrXVaRoSqqzXRWRgP9WydfUZ/xrS0XSE0yISszNcEE+apCPz3DfX1pPEOtHT7CSSWRZ5GJVEkwSx/2lPUD1oA5jxrqK/u9Oh2gR4MhAx9FP0rkqfLI8sjSSMWdjkk9SaZQB9//ALLn/JCfDP8A29f+lUtFH7Ln/JCfDP8A29f+lUtFAGL+13omq698NtNtdD0y+1K5TVopGis7d5nVBDMCxVQTjJAz7ivkX/hXHjj/AKE3xJ/4K5//AImvur41/EX/AIVl4VtdZ/sv+0/PvUs/J+0eTt3JI+7dtbP3MYx3614p/wANc/8AUk/+Vb/7TQB4B/wrjxx/0JviT/wVz/8AxNH/AArjxx/0JviT/wAFc/8A8TXv/wDw1z/1JP8A5Vv/ALTR/wANc/8AUk/+Vb/7TQB4B/wrjxx/0JviT/wVz/8AxNT2fgT4gWcoktPCniqCQfxR6dcKf0WveP8Ahrn/AKkn/wAq3/2mj/hrn/qSf/Kt/wDaaAPKk8P+MbuONNf+H+vX4XP76PSp4Zzx3YJhue5Gfenp8Nb+6iLjw/4xspdoJjl0Od0/3V2qfzOK9S/4a5/6kn/yrf8A2mj/AIa5/wCpJ/8AKt/9poA8Vu/ht4vilbyPDmvTrjhho90P0MdVz8P/ABmvyjwf4lZM840qfJH4pXuX/DXP/Uk/+Vb/AO00f8Nc/wDUk/8AlW/+00AeHN4C8anIHg/xKF99LuPwH3KP+EB8anr4P8S4HQNpc+P/AEDtXvlh+1Re6jIUsPh9PcMOoi1Itj64g4rbT9oHXAxF14AjtAvLG41tUx9R5OaAPmqPwH41iYNH4Q8S5yTk6VOOfwT9KYPAHjPofBviTA4AOlz9P++K+k7n9pL7Ovz6FpLPjOxNZkY/pbY/Ws2X9qfZIyp4UtpNp+8mrPg+4zbigDwI+APGIXA8H+JiOTzpU+Sf++KU+A/GZYk+EPEnT/oFXA5/74r3Y/tWt/0Jsf8A4Njz7/6igftWyYLf8IUu3BIP9rcH/wAgUAeFnwH4xVMDwj4lYAbcf2TPyM5/uetIfAPjFhz4R8Scdv7Jn5P/AHxXua/tXSN08Ej2/wCJt1Pp/qKQftYOWwPBIycgf8TbqfT/AFHWgDw1PAXjNTn/AIRTxOcc/wDIJnH5fJxTh4G8ahsjwl4m/wDBXcYH0Gz8q9zb9qyRSN3gpRnv/a3T/wAgUSftWyxyMreCV4JAP9rcNjrj9xQB4W3gPxm2N3hPxKfUjSrjJHbPyVG/gHxmXb/ij/ErDt/xK7gfj9yvd/8Ahq6Xgf8ACEjceg/tbk/+QaVP2rnYgHwYgycc6sf/AIxQB4P/AMK/8YnKt4Q8SlQOM6VcdfX7lMHw+8Zf9Cd4lBPGf7LuMD3+5X0HaftS/aP+ZWtYu37zVnH6/Z6s/wDDSt80YeHwXbSqRkbNcXOM9cGEGgD5zHgLxrkg+DfEpHvpU/P/AI50q5YfDfxXcTp9r8O+IbSPux0e6cj8o/Wvo/Vf2g7/AE3SjfzeE7F4xjMcesOXGfb7NXLj9rjJx/whX/lW/wDtNAHmA+H9/ppEo8JeL9VueuE0ieGPPvlM/pULaL44h/5Bnw+1ewBHDR6PPJIPxdcZ98V67cftVzQRiQ+CFeE9JI9XDL+kPH41W/4a5/6kn/yrf/aaAPDbvwX8QbuYyz+FPFUshOd0unXDEfTK8VUf4d+OXYs/g/xMzHudMnP/ALLXvv8Aw1z/ANST/wCVb/7TR/w1z/1JP/lW/wDtNAHgH/CuPHH/AEJviT/wVz//ABNH/CuPHH/Qm+JP/BXP/wDE17//AMNc/wDUk/8AlW/+00f8Nc/9ST/5Vv8A7TQB4B/wrjxx/wBCb4k/8Fc//wATR/wrjxx/0JviT/wVz/8AxNe//wDDXP8A1JP/AJVv/tNH/DXP/Uk/+Vb/AO00AeAf8K48cf8AQm+JP/BXP/8AE17f+yJ4T8R6D8SdSutc0DV9Ntn0mWNZryzkhRnM0JCgsoGcAnHsa0P+Guf+pJ/8q3/2mvQPgp8c/wDhZviq60b/AIR3+zPIsnvPO+3edu2vGm3b5a4/1mc57dKAPCv2j/BXirV/jP4hvtK8Na3fWUv2fy7i2sJZY3xbRA4ZVIOCCPqDXmv/AArjxx/0JviT/wAFc/8A8TX6U0UAfmt/wrjxx/0JviT/AMFc/wD8TUkHw88bxShj4M8SsB1H9mTjP/jtfpLRQB+c/wDwgPjPk/8ACHeIRxwP7IuOP/HakPgPxkWI/wCER8THjBkbS7jJHoFCYAr9FKKAPzmPgDxmAQPCPiUjPA/su4X8ThKa/gDxmWA/4Q/xGRggn+yp8D2+5X6N0UAfnN/wgHjMAg+EvEZzyduk3HX8Upw8B+M9oB8H+JOOgGlXCge/3Oa/ReigD85x4B8YZ3t4M8StIepOmXGAfXGzn6U4eAPGBO7/AIRHxMoH97SrhnP0+TAJr9FqKAPzpXwF40Qkp4U8TBiOWXTLkZ9vudKsHwd42fBk8HeI5Mf89NImPPbolfodRQB8CW+h+P4goXwv4jH+02kXBPt/B0HpUFx4Q8aXnF14Z8SsM5YnS7rLex+Tmv0CooA+BbXwR4gghYt4T8RsW+by/wCyLr8s7KrWvhTxtp1xI2n+FfEYV8bt+k3IVx/tAJziv0DooA+KLC28TtCFu/BPieJkB2hNLuCpP/fGcfWpFsvFEsyK3hTX4Y15WU6LdMwPsAnH/wCqvtOigD4yXStbi3MnhvxQzMcsBolyA3H+5xzWZc2XipGZbXwP4nk775tKnIJ7cbPwr7gooA+Br3Q/HF8W87wl4lRCCRGmjzhAewI28/WsyTwl48kj2f8ACLeJ41P9zS7gHPqTs5r9DKKAPzqXwF4x3Et4S8S88n/iVXGD7fcpr+AfGG5dnhDxNt6D/iVXHA9/k5r9F6KAPzq/4QTxkAS3hHxM7YIx/ZM4A9/uU0+AvGcgG/wj4j6cD+ybgbfQDC9q/ReigD8508A+My4LeEfEg5zk6TOQPX+ClPw+8XsxB8IeJAuSP+QTcHA9fu1+i9FAH52R+APGJcB/C3iPYOMtpNzuA9iE/nXSaZ4N120g2p4W8SI2DjOkXR2n2Pl9D9K+76KAPh8+H/EaJ+78MeIyCMFf7GuTkfjHiuG1vwX471W+ad/BniREHyxxjS58Kvp92v0ZooA/Nb/hXHjj/oTfEn/grn/+Jo/4Vx44/wChN8Sf+Cuf/wCJr9KaKAPNf2cNNvtI+DHh6x1WzubG9i+0eZb3MTRSJm5lIyrAEZBB+hFFelUUAeAftrf8ks0r/sNRf+iJ68r+DfhTwJL8EvEfjHxtojalNpl9JEm26mhLL5cOyP5HA5eTqRnn2r1T9tb/AJJZpX/Yai/9ET1xH7Pc/hDU/gX4k8L+L/EGmaWNQ1KQ7Li9ihlA8qArIocjOGTjjGVIoA73wv8ABPwfqTxvrHw6trC0nt1nhmg1+6uCpOP3citsKtg5+XcODz0z8SV+gvhXxho+meVHrXxS8J6lbQQCCJIZILdnIx88rGZ9zYGPl2Dkkg8Y/PqgAoorS0rRb7Uwz20OIE+/PKwSNfqx4/DrQBm1bsNOvNQk2WNrLO2cHYpIH1PQfjXTQW2g6Ox3q2s3adScpbofQrwzY/Ae1M1LX7+4tlhWQW1keWgtV2RL6cD+dAEcXha3tCra9qsFr3aC3Hny479DtHp1qeO80TT9p0vRxdupJ+0ag+4e2UHFYrIQP3nDfe46H06UqnDbjnd659Pf/GgDZuPFusyw7Uuvslv2jt0ES/kKx3meQ+ZLPIwPdySG59aktZ1tryOaSGOQIciOQfLjsD6U29nkuLmSaVkjeQ8qg2qPQAdMUAMZSBtU7c85Ht6/401jjkDBxx2Gfb39qmP7xzlcHjJA5IHY/wCNR8YJYDAz8v8An+fegBFiBO6Q7eCcDqfw7HNfSP7Nfwy8I+OPBGp6j4m0f7Xdx6m9ujLdzRgRiGFgMI4B5ZjnrzXze5ONzFt2cZ7g9h/9btX2B+xj/wAky1jr/wAhuYc9f9RBQB88fHDQNM8L/E3X9H0W3+y6bbtAsMRleQrut4nb5mJJ5Y9T3riYsIC7Z8wEAsR930AH9a9H/aTBb47eKR2X7KcZx/y6xd684QN5oIDbdu3GPmI9Pb2oAUv87EYOfXof8/pUTAKm4gk853cYHp7UsAbkRAsCTgL94jPf1pXQKNxBPQDrtPPI+lACxx+Y+122AnDHuv8An9an1SC3trlora5FzbIPllVdu/2x9fSopZ+WCqEVTgIvJ/PvUQ/dtzgsBwSckd8+3rmgBTnOFyMjAA6D1xTAxKfeIyc7u5ApWz5jAbj7fxZP9KdjoCMk8EntzxnNAE1veXNtiSC5khyCFIcncOmPpVr+1jcKEv8AT7O7OMZePZJ/30mDWa65IHBdjk9gParVnHbS5NxclCq5X5DyfagC7FF4fuVxvvdIlxzIp8+In3Xhv17d6bqHhi8nQz2T2d+PvFrVwrlfUxnBz9KzJNu8kNuIOFCjBPPJA7ev0oDunzxP5b/eLqen0P8AnrQBRawullaJoJFmX70bKQ4/4CearEEEgjBFdhY+JtQiMa3IS+hjwQLhcsmD/C/UH6GtXWW0XxgiTiQaXrGMEug8mY+5X7v15oA85orU1nQ7/SGU3cP7hyfLuIzuilHqrDgjisugAooooAK+gP2Kf+Sp6r/2BZf/AEfBXz/X0B+xT/yVPVf+wLL/AOj4KAPtSiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDwD9tb/AJJZpX/Yai/9ET18VV9q/trf8ks0r/sNRf8AoieviqgAqS3hluZkhgjaSVzhVUZJNR1qaWptw8uXSYjClcfKp4JI68j9KANaDTLDR2EmomPUbxSM2scmIoz6O38R9hx702+1O4u5UEshWCPOy0b5IQv91R0/rVBwCcjPl5K7l/zx+NKV/dgPgc4wQQPbI6DNADprlp3YvGpBIA8sbSBTBhQzRuQ5O3pgsPT0prcttIAK9Mnt7HvQD0AYhei84Kj0NACsGC7sBcZyRyu7+lIrgqzFdpUdQOP/ANdKQ4YHJBHAYcfQH2p8b/aCpRcMOSAcbz3PtQBHHhQMfNzjPHzH3/xpB96QxscZJIHY+uDUzIo6nsSxHIwOox1xSFTtH7vao6MpyD/hmgBq7lHyqQo4yeMe2e1SogXL7wSpym0ZGff0qW1ilu38qGNjxgKi5P0P+NMnglt5thwkoJwo4I7YOO9AEDAbmLbvMI+UggZPevsD9jIY+GesgdBrc3b/AKYwV8qaNpz6hqdtDfM9lZySqs959n8wQJ3kK7l4A+YjPQV9z/BX4ef8K08LXekHVf7U+0Xr3nnfZ/IxuSNdu3c39zOc9+lAHyb+0kWHx18VhQMn7IMnoP8ARYq87ywADRkKoI6c7ewPtX0n+0j8Ko/7Z1Xxs3iDZNqM1vBBpn2LdvdY1Qjf5gyAsbOfl6AjmvFU8KW6bftl/hmPBC7cL65J/wAaAORHIVl4BGV5x09T247U+MsXbyuc8svqPb09faugMfh+zlfymlvULbVK+oH8R9PTFOXW7FYy0GjWsci5wzHkdhx396AMEWrXLJtwATs244z1x/8AWqOSARzFJz855BXv9f8AGugTxFcQjL2tmmF52rgkE9D7fTmmzarZXc2660mM7xxhsYHt7fWgDnimHYAmNF+6zcHnt+NNQIy8vsXPG7g//XzXSmDSL7elpNNBOedk6gHn0Y9Px9Kjfw1cyXAiDpCwXKM5wxU8/wAvTpQBgbUAO4Nk/wAP9P6+tR/MrKvBbqoXoR2yfSp7i2e3kMc8LIeu3GBn1yev8ulNbgbG2LnOTnAB9+/rxQBFsKnALO59OD9fp2pXPzjBG89lHAb0HpUi4IyCVU9WbgHn9DUbxGNcBQx7gdB/9b2oAT5eCzE4+9joB6Mf6e9W7mGFIVe3nEiuPutwyHuMd+KqKHfG5hszgAcAn6U5xvG3lyBhj7/ywKANLTddvLEeXFIJrRxh7aZd6SDpjaegx349quTaTo2vRs+mP/Zeqnn7JI2beQ56K5+4fZsj6VhDc4BwFHVsEDLUNjA2AbcnBbj8h/WgDKuIZbad4Z42jlQlWRhgqR2NR1q6sjzkzyNulUYctwSOxI/TnmsqgAr6A/Yp/wCSp6r/ANgWX/0fBXz/AF9AfsU/8lT1X/sCy/8Ao+CgD7UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oievisUAT2cXmS5YZReSPX2rUDhmByRjn1C/Q9abDA0ECKhV1bk/MME+oI6UjAF/nQg99/HH1FABJw21xtcjqVxn6+tKd2cL83bO7aSPQ/zxQMjajrKqZyQfmHtj/8AVUmzC8BZADwEOSw57D/6xFAESuJFC4xjgBhkH6+n4UvlPjdswTwGHI/Lt7VJDGkjHY4VVGTgdMe/UflV6zsLi5R5LS0eSJeBMozGfXc3QfjQBmtGCQEbIHy4XJJ+vqD+dP8AneMAoFh6bsfnx/hW8dHa1jD3kkSjqJRwp9gf6dTUZu7PTpgbJVnk6G5659lB688UAU7PSZ7nHk28koHzErnav1z/AJ+ta9h4Ya4wXu0BGAXVTIAf7uR09M1nSa9dyRFWWNogclFJGD9P6UHW7pYAsVy+0/eRBsz/ALOcc/j+dAHZW/hPTrUJ57SyuTtKGQAN+I7e1LNNpOmzRIi2UeMl1xkxrj3zg+h7156bi43Hc83mEfdYkkj2PcCoVXoGDleuS3Of8fagD0KbxhpsS+V5M9wnRScYAx69SPbpX07+zb42Txb4DW0mkZ9Q0dhaSeYcu0WD5Ln3KjB9ShPeviEsrRFfn8vIBGBk+nJ712Pw08ean8PdauL7SkE7XNpJbtAwIBJGY3K9Mq+Ce5XI4zmgDu/2nfHkuteP/wCydLuSlnom63BQ/euDjzG4/u4C89CreteLXEss7B55muDnJYHOO+fr1zXW+FfA2ueLL7DeVDLclmWe9lK+c/U+/JPc9as2Pw/d3Uz3ioCxw6jj/dI+tAHCoruyeWCo7bTyfx9fapUQKoAGCG4Udz9fXrW34gsbTTrryrfczIPnmHRz64/QHFYYZlZXVtiD5kYjlfbPb+tADpIEaV9rMQOY9oyWPH5mmL5glAiGHzkrH9/6mrH2gb0eJF+8WJC8KT3A9fbpUkkgmmYtGzLgkRoCcenHf1oArzTiYM85DMThWzwCO+epPbmtbSNfvNMaAeWLi3Ykqs6kscdQDn5fQislkYfPKrMwGFHoM9f896SWJlVyCyKQN+7jPpgnrmgDuRrWka4ghnhSO6YnzPP/AFww6f8A1qqX/giOWPzdLuQu4E+W+MbfVW9T6GuQMbsgLbo5N3C4+fAHpWjo3iG+0kgQGO4tycvA4yjepPpjt6GgCtfaVeWMuLmB4MH5ZG5Unuc9P/11RHyFs8HJJJ6Ed8fTrXpumazpviCMRyu0ZzzDOAd3+7njp1xzWfqvhewu5dumBrSY7nKSDcCB7nnrQBwWBvy4DE8Lg9fr7etDBtgZ9zxYwM8Ko6cj+ner2r6Xd6VN5WoxMjkfKQMgjtnsPXFUNp4Z3JHIJJyCff2/WgBpbIOBtjJxu29T7DuakhcRzYO1CchgBucn09B+J4phJkf9yjSyY6gk49MH/wDVRyo2u6rGRjEPc+maAHl0AygIYDLMeWBPYdh/Osu8gMEuMbQ3IBOSPY+9ai/cBii24J9yPx7H8qZdR74fLZlDHlUX5mJ9ePyoAxq+gP2Kf+Sp6r/2BZf/AEfBXgBBBweor3/9in/kqeq/9gWX/wBHwUAfalFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgH7a3/JLNK/7DUX/oievjfTI8zh920r93kDJ9s8V9kftrf8ks0r/sNRf+iJ6+RbMvbW+wmQKRuZWj3Ix9CP60ASsWWQM9tHKCecqY2/Ef19qYi7wBAzg5yAzbl49CKVVYjMQXZnBXBGPYZyOfrU6IrkLGEEaj5nwVxn+f0oASGAx/MG2sOQGBK7j3BHSrWn6dPeShIoyx4yZE+YD/AHu/atvRdBkZVuL+FUt2zsKxhnlPf5QfwwcGuug+z21vLJ9pa3t41Aw5L7B69mGBxgA9aAMTS/DFuzL5nlzMo+YgAgkH+IcMOeo6cUaxqljpW5YFSS4UbdtudsZ+o6H9T9KyvEPiSe93Q2Cn7CRgOpw8mPQ9RXOw2rTMqxxb1cjCnqT6DAoAk1HUru9k3XEo5/1fGB7jjj26VViR2YbeSxwrEZGe/Hp2zxWi2h30almieMt1WVNuVHckfpwfrVMOlu48yOWMtzsAKg/j3+h9KAHC3VJHGFZwcYXjJ9F54960bLw/qV4ilLN9zfNucYT646niuj8C6dpF/AZ5E826DFCGQgjHpg8cfhXTa3q8GjWga7/e5/1axggE47Htx36UAef23g/U5gxkMMMX3s7yWbnHT09q6LTvAFkdNuLrVfEHlXyKBHb29mXVic8MxIA7e9Yy+Nb0ENFbRZBJCuc4Xvge3GT3qK48YX7k7IoLcMMkBSM/ieDQBJH4ZRJWjlLPcJxggrg+34V0mh6DYQ7HkUFkXcyMu4/Xd65rnNCuJtT1pH1C48uNgSsQbYGJ7V6PYax4b8KWc7alo9vqAyCiTTldrYIG4d15yRQBo6TY3dxc24ihuUtNq3Lu/wB3ykP3w5A44Ix296818T+NJLy/uF0iJLSF5WIZOWVM8Y9eMVd8afFjxD4m0htLTyNO0YxeUlpaEqqoOwPUjoOe1edW8byhRDvIGN2CCo+nvQBLLcTTyu0u+U5JLEkOQP4j+Na+iae+qSAt+8Xbxnk47/UVi3RC3A2v+7IHzsvJPp9P8mvVvhT5FzCxI8tsgMzKDJweq0AXdN+HaXS7mkSL5QpYDG7/AA/zitgfDnRkjJvmEaE8yqSM47HHOfp1HWu8jgRiNsqbFc/PIoJP0HanGREQMiPuyRvMe4jB6Y6e/HWgDzvVPhhbPbTDSUaO9i+7HcXG1AenUdu+PeuNi+GHixWR5m0iSM9QJTuUd9vHPrXvO/KsjhVUdFQcA+qnvn06DnFRmGCRWETFARnd0Poc46D0NAHzP4l8LXuj3BjuVjkQ8sizB9v65I96wWiQlg6gqRn5ei/7w9K+kofAPhexeQ2+lJK80hZp3kZ2z1Oxz198DGawPGfw30y+t2u9Nl+yXYPSNC659ePvfX+VAHhTK6uARh+wCnJ919ffNa9n4n1G0g2Ty+dCePMlfkkejY7egqLVtLn04IJmDeYxVJDzG5XunHzfSs0NKMR24LSjnc3zMnvz90UAehaZ4nsbyH7NdwxsCBtW7X7w9h7+pOax9T8MwzMZNKct67m3D8Ow61x2Gdl3gSSAknj5SfXJ4/KrtpqF7Zttt5rlAOfK+6p7nHtQBDe201rcSW9yDHtb5lcFmB9do69O9QplG+RCyjhZJcZAHb0FdIdXh1lUt9TS2tpV4WSKPcSP9onn8azr7Rrq1kYi2cIMHeI8kehLNwv0oAz4YPNBEZaQfe2g4G368Zx+ApylI90aQqTnJJBI/Jev8qSWMpLtmYydwPMOH9enNORFdtn/AC0UD92Fwue3AyWJ9+aAMrUlXzy6AAP1HHB+g4H0zXun7FP/ACVPVf8AsCy/+j4K8ZvIWlhddnzKM54B47BR0FezfsVf8lT1X/sCy/8Ao+CgD7UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8G/bJj874a6OnJB1qInAyeIJzXyLK2DmVCCMr8hBI79MAivrz9sXJ+HGjAMVJ1qPkf8AXvcV8n2Uci3Ef2d5JJQMZj+dgfTbwfp1oArxoxWMIY2duSEBjYD/AD9a7TQ9CdUW4ubWOcMoZCH7E9cDgHIzyB0qfRtJEOGuYkW5LYZpYjtH+znu2etbwihtRNc3Fq4hhHM5Abt1DJgj2zn3oAYfI0+3Nzch4kUZdiclR1C5B5J7d64LxLrR1m7XJi+zRn92jKQSe7DHO4/pUnibWf7UugYHKWMRxGszAnHqTgY/n6VjXAmRzE5VkJDctvVvzH9aAIjGfNIVZFGdyorBnY9jnsR1rV8Laotjq8U1wkcqv8mcGM5PcY7/AIfWsp438vGX2E5Zhxk+hU9Pzq3o09pFq1tNcxZKMCqbzGin13HkH86APR/E2rw29ky/ZvMupARDErb9oH8bAdB6frXl0tzLLKzTlSXOcxtjJ9ef613Gr+LLKRJEawSaVsktIp3BvXeOT9SK4Nw0jMXlJDnJ+bcPpyOcUAbvhS623EqB8Iw3HcdvA/lUXiFib7ETmNgOQ4Jb64PDfhWWjyxSK8IBxyJIvnB+uatG+1F+CxwoyXIAI/MZoAokRndmKNm4wYQwUfh/KnqkDNtxJKv3UVcjn8Tk1JN5zIGldpCO7YUkf1GahWORisYKu5XJWROTz0x/UUATJBBEPMUzAgEbgvJ+g7Ux/NusS3FyG2YUGTHy+mVpJFuoHJmLwEnB8wZGf9n2+tLEk0sZlTycR8gnGT9Afc0AMaPJHkmNi3IcHAx6Y60tnKtvcF3idoiCrhflBH9cUjRRMpk3ruztZT8pUj2PbtzTV2xMfMduT82OHz7HoPpQAhAErSWxcxDLooBwB347Cu9+E+tpbaqlq0q5kb5Y9gIz7Oa5i3vENvCoCRKVwQ5w7AHr35781WdGmnd7SXbnJ2KPmwOACe1AH1bFJ5kYJle3CgDKJuGD2/2v0qUTuORI7M2MSE7hj145A7EV5b8OvHttLbR6VrkiQ3KLtSWTcwYds46+4r00S3NxGJFlgaJwBGyrsyMYBBxnH60ABVURd0RvMgncykZXrkfTrgU5JFncfvMzZyNpG38e2cdqkCyoQoi2gEfu2yCx65LZ5x7UkrLLIqSzNK6nog2Kcdcgc59jxQApjjXINxskUBZQqZbnoAe49uKazBMyujtORtDrJhCvsnX+lMSJlCJAioeqh2BwSeSoXjGO5JxmhzEku9Z4gUOC7SblHsD3PfaBjtQBR1nRrPVNMlS+tI7uLGGknjCkZ5GNvXnsD6ZrwD4i+EJfD10Hilnl02XlSq85/wBoD+tfR25Q6/Z1kZVGQUXcGx6lsAfQ9M1l+I7W31rSLi1crbuRuUN+8MuM9DjGfoDQB8uwy22VN3bt9nC4Kq+D/vKT057YNJd2M9vFHIyxR2kx/dPnG/HPuc/Xn0qa8jjtbmeFYreCeFiJCpZ934nv9KdYzxESRSRpHDMNpdwWaIn+NfQ0AUfKdBuZ/LAw2/Z8316/Ln3rtfD+tQ3tullqlyI3iU+TLlWd17qScL+WT71x8dhvF5LbW8t1b2hQzzqpMUas4RXducbiwHT2pIXeF1ezcpKrjBijCgEdDuPzH8APwoA6rWfC6rG8+k27+UBmRdu1cdchmwWH0zXLGOPYMSoyKfuxZOPwGAPxJNegeG9SfWrdYLsxG6jBP+kP8v1xkk/icVU8VaRHOv2xJQxX5XWCDj/gJOBj6Dn1oA4tmSPDWtrbwk8Zc7mz64/+tXsP7GkTQ/FvWEYEH+xpTggjrPB614+6LbS7BE3mEdZW25H55Fe2fsiKD8WNRmARd+izAhCSARPB6896APsOiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDw39rsKfh9ooYhR/bKcnPH+jXHpXzZ4U0u2u5Ve4QMwY7I0AlDH2H3ge+egr6S/a9Bb4e6KFTzGOtR4XZvz/AKPcdq8Z0e0MVnDEYZXZY9z7nLZ4zyjjKgegP0oAltQbFlggluLRtuAvmyCJR/ukEcngmuN8V600t0IbZB9mjGQ8QEZIPUlo8f8Ajy1vanqMdlFKRH5kt0+ChdsmMccD7yj8MVwVxCxaWW1SdF3dVZMD0G0nJoAUmNx8hhDkhtsibmAHuPvf0qtJtG5fLjUZwfnMYPuRn9femFcsftMEJbpgSeST+AyD+H41ds9LmuYw9uL6O36hpog6c9MHv+AoAovGxbJaQMRgYAkGO2Md89zTNspbZHNlyDucqPmHf6/Sukh8LXDWxkkni74aFlkUnHUrkGqreHNQez82WxiRCMnAOWx0yMnmgDFd5g43RlSw4bAXI/E9/wBaam2aMboZCvcozfKfXbjGaFeOPIjMiBflZdnf0PJ/TFLIwmXGy8G05DMeF/DrQBb06ON5ctcAr0AfKH3yTz+NdFp42SYsgsqxDbGzoJUA/vYHOffms3w7aHULxbRJJOeSpAzJ+GM17bofhuKztlefTQjKAwbhucdQBz+NAHjV5o94zm4ljGCd37wbFXn1HH4Go1nv9OnWRwbd1ORthy65+v8AUV9BTWMOzzLi1UHAUMznaPcnv16Vwni3wlBNG80MKxY+YB4iNzdOST39uKAPONbv473zPs7vdSuF3S3aBGjI42jjFZZK/YYPLiIuw5JkfBDj1Hp+FN1G3kSR4Lh2gVOuSCv5DPNVZIiXDfaopgRjIBwMdOO31oAsQtbpE8clqJrkNzJ5hLZx6dx36060uYbZWF1EtwAc7WfHPtnmtHQdBiu40eWOXaOqqmEI7EsxFa9n4Z1dpku4dLtobYuViWQK7EdPm9vSgDEmuH1BwbHTUhQA48sHoOvHeiGzaUDzZhbqp58xOmOnT+tekaP8P9Z/4/Zbg+W42fuJBHHEnoTjp7D60zU/BWux6vBBBJpsujsnlvKiGR/VlyeSfccUAeaQXdjaXiH7aWxgGWE7MN3OMdOn1r0HwL43a0nkt729luNP4HmsQ209sd/wAqZfhTocsKtcyXtpMWIO1wYz9CQST9K6Lwv8OfC1ghP2S91N/MBJdQFwO244+X2xz3NAHc2N1aXkatYyi7QgljE+WB4xknG30qyPtSxlWjeKFjtwqfePux6+wxkVxj+FBpTNd+G5ZbFgctC7blYdMBATz6Y5FXNJ1k3E/wBivSyXQBQmKQxBx7KfmbPrQB0slnFHGs02zY4+VZDtLLnoGOTx9OakijvgpEWYLRAQvlKcY92bGD781VsxbRlyqRQTsM/6gzPn1Hv+ORU77hGZmF1cRFuWmfA+u08AfrmgCWOFmIWFTLuHCG4DgkfxZxj/AL5p2RmQLPLJnO6C1jD4JHf0Hrz1qAJPcxM8yCGIHBeX5tx+p/QCq13Nbw2RG+WeJcgiIvFn1+UDLfoKAPnjx6gs/FM6JayRsG3IsxBJBGf4e31rrfgj8I5fiTJJqd9qEFnotvL5cqW7q1zIeu0Lz5Y92GfQEHNcL42uGm8R3bvZvbRA58piEH14yAfrUHh3X9W8M6rHqugXTabdx8+aj8OO4ZTw6ng4YdqAPujUPhh4auPh9ceDbK2k0vSJ/LLtZELMWR1cMXYNubKAEtk4/CvPD+y54OYYbWvFBGc83cP/AMZrlLr9o261T4aanHbn+yfGEXkLbXcMIlt5yZkD7Q4YKdm/hsj0OeBwEfxs+JDD5fFjy45Yx2FqRj/v160Aeb6bftBcW127SPIAvymbYGGOm1QTj3r1C0ki1CziuYfPiR1+7Ekgbb3UO4zj6Yryso1sqRKYYBjBXzi7N9QnTiuv8CX0Zml08yl93zpvXcM98Dkge56UAZ2vaZaRSt5JvZFkBI2oH3Ef3uSc+5Ir1L9kWJIfirfqqFGGjTAhmUn/AF9v2HSub1q2lu7GaO4iWRV+dPOn2KhA/ugAflnNdd+ymuz4p3Si3EIGiT42oyq37+35G7nH4UAfW1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHj/wC0zFHN4Y8OJNF5yHWlOzzBHki1uSPmPA5rw95IRauqpcqsm3AI8xTk4J3qMHofT8Ote2ftQZ/4RLw8BGJCdaVdpbaObW5Gc+3WvFU/dtEBaySt0U2rzQvjHpuwx9gORQBwuuaja3PiQLIUlt4F8tSt86EYGMDzAwH06elYywTXs3kW6RsqkqjXEkRwM9A2P1yaha98m/nmJZZt5O24Z2PXoSVP/wCviuzttTsLaxiAS0tLeRd4jV5UbpknlCCfTHAoAr6FocdjL9o1NT5Y4jL25nj9+UAIPoecV1EE1um0m5ZIIxtLxu6KvoobHH4jPX2rGg1SIYkgubmCQDATyvMAHXAdcZPufXrUd94tnij3QybWU8MV35HqfmyD6igDpXltZWKh5LmPBX920Dn6ZOM+4Iz+NVb6x08wySJbXkF1g+TNHCYz0/hKuQ344NZFl42juYSl+8JIwB9mjXaPyBYn/wDXT49ZSSZm02ylErn5Xlutqg/3Qm3LfjQB51dqLaXyLxiJQxLLLAyOpHoT69frULzI4ZYZp2A+7mUnA9Mf4V6U3h68vRJcSpbzPISSkdw2N/qS2c/hiuH1y2ks5fLuoiHBwACoA9gT8xoA9D+EmhR+V9qkkDu4z80W3GfV+n+Fep2Avr7WUs9AtZtTlht/tM5tLhYzEu8KAnmYDMx3fxKPkauG+Eo0/wDsZXUShkOT5cvmKD3JVhj8Paup8RRMuo6dNpmo3Gi6pezxWkWpLemARISWzMoAVkHzbVbGWYDuaANRPBmqReAfD+rf8I3eTeKn1qeS/hH+taBpbjghmCBdpjwScfdqtcvqFrc3+n65pUVjexCOQLNKk6LHIPlZm6dVdeM/cPNeiXfjzTtV1fVfBVpq11p98ltJb2+uts2PdRLmVRwFLoCjNjA5YDbivJvDctuuntf+fq93qdypjuL65lW584ozD93M3WPO4qRgYOeuaAPMfiJok0t0Jbe2gAbkrCoUdecDg596m8D+BZLnM1/EY40O9sMARn13Hg/TNbHi3VLGW6aO5MhAOS7srIOOcleTW34J1HQJYlezit2YHiaR8Fce3Qn2oA3bPw9ZxIfK0+N2AG5DCJG+u7oK04bZLRyYrCWwKH5/MIO4eu09DmhHkkGEN6+BuETHCtnsCOFNPE2oLMVjPzocCOaNWC57lj0/WgASO5fbNPDHsbgHf5yA5/hUHHT+9ijTWv8AUtSuLbQ9M1LU4bOFJLkRXMcO1XZgoVG2hs+Wx27xx65o33zsjyvLAVBLfZZ1bA9BwCD9c96yri2uh4m0aOy1ubRdS1S5SFr6K/YbI1G4iUHKOxHyohByx9FNAGzJ4O1Wz8I+Db/TdA1CTxA88g1GNceZtZJAN4kcIoyU5JGOMVEkmrPeXtjrQFjeWUqxvb5WYhTGrqwkAA6Nj0yCO1dvrPji18UQeI/D2kapc6DcRwyCw12TCQXDw484xuRjCHCsR2JK9M1534W0/T59Bg1eZr5Li/USXE9/MbiVyuQeWJ3DIO1uAQQRjNAF5prZ/kNzl0AGWQsTzwAo4/8A1Vi+MtPktdl+89uhThi8ROR26HGO3WurWZ4osQXwtoiMFncbXz9AST9K5fxvJbWGhyl5GlnbjBKofcbcfr+lAFzTdShlhEd5cwzTZG2NU4Y9QRxkYrYjKTfvrcSrnnfHKsgXnk72AVa8Gs/Fd1pUvlw3Hls+SYIpyTjPTcM9u1bsHxACgfbo43XoTMD37hVXnnucZoA9fnikaQm51K2uJg3ESbZ5CuOMkfLx654rmfG2r2Vhpswme4KY25nHlk/Qx8D8zXFzfEJRDsQWdvDnoqMce6xDB/GuJ8TapcauzI88LQLyBIAAB64zwfagDOub/RLiQ77ZYCOjWi+YT7kNxk/nVcQ6S8m/TpADnAS4AZvqCSFH5VVntZlZlS+tpYs8iB8AexJGAT+NIkJUNJuiD/eYpEJT065Y4/IUAXzGXEbzRnaTxJLC8m0eozhKrXWwrhI5pChwftTIq59lXqPbNMM115Plzlpi/A+1ytt9RgZwPxp5hm+zhp5oI4iNiiRVAP06Db7igCg20gqzwAqPuRDqM5xgYP4kmtfwxczQavaNbBYkY4YNwwHTOPuj9azkaNUKNc3R2tkSW0YdScdcnHP41b0NEk1e2bdK0gfd++baM+xJ5NAHpt3JLJaSmOS2u3UlX2RybkPQ84AB/P2xXTfss289t8V7xJ4JIh/Y1xtZhIQ/7+35DOBnt06Vz0ksEUD5vvmLEBLKN96n3kY5z24H0rsf2dLiK6+MN1LCLz/kCTrm4EnzYnt+QXJJ754FAH1FRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5B+0xGsvhnw2skohX+2lO8yFAMWtyfvDpXjMTMyKIL6WdN3+rGovjPYlQMe/HT617N+0vL5HhvwzJuiTGuJ80quyj/RrnqEIb8q8XaZ5ZGjW+g3k5AhtWDjPp5rbi3XFAHlWqWsun6xcWzm72iRlYJMpye2MjPfjPNV432QkeVcqy5DDy5VfnuSpx+Yrp/HulXC7bue8nHAEjPExwv8P3Y+O/8AFXGRzRoSRerMoHAiLjd7EE5IoAdvRQUe1Uptz80JU4z2K9/wp0V9FGGEKJ8/3fLeQEexIIz+NWNNtZL3ULK1sZ1ja5kEQkncwRKx+6DIwwAfTj617Fb/ALO3xBvADc3vh62HHEk0kj49DhMGgDxFL0yMgjvVHAAC5DKfXcQD+APFegeF2dIlBbzncdZbtQp/3sEn8zUvxX+GR8AWFsNX8T2d3rl5gW+m2ljy6Z+Z3csCi8YBCkk8AcEjmfDuqw2U22JrVmPDRuxiXg/xHOcd+1AHp7SQxwOHitTIoGRDMSB/u4PH0rzjxoUvLiRRCZpU6FyyNj0PHzY/CuguNZs5YGJsYd+CzeQpUfXcMkj3xXC6pJa3M++NJ9p4LAgIPZd2Sc+uc0Abvw51y60O98mZENrIwPLAsG/DnHvXuS3FveWUqX99F5FwAkkZZnDj0cD7w/3sCvmSSzhLAiCRABuURIQxP/Aif61v6brEum6fbLpqfZ9kjLIZmyzg8/MAuPpigD3e4stFh0eKyksLNtMhAaKK6gHlIynORls8knnvk5yCa4vxn41tAj2llBA0kg2NDZyJFH6c81znjbVWNrp08EWnpcXK/M+3y249QxIH0qfwJpUF3c3E89nJJJGMRzOEZRnrt/vHsKAK+iaDNqJjkvLeK2jyHVmVjtJ984P4V3ps7WHTNnmWT7F4Zo2AGPQnjPfpUkdmsU2N95BnChGtSrqD/sqSD9a7nTPAGq3awzA3jExiRftZXywT6L2OKAPJNHtdSvXm+z63GkCuEZFfan0Yd/rWldeJL3wyYk1ONLuzddyyWqjAbPUggE16m/ww8QBZRby6WgJACmPAYDucd64bxL8KPGWoTS/a9Jt9RYkrFtvBHGi44AHXPv2oAt6N4r0fWBGtjqdo0m0s1tFFlvTBz0P41fvGsp7eSxlgmCSqVZHiQ71JGfMXBGDgY5HSvCtS8O33g3W7ez8R6dqVrEQXWGJCAw6ZEnQir+leKdb0yUwNcC6tieLeaQx5z0y+cEgfWgD1e8sdKlsbWyu4IPsUDK0ENvFj5lBCkb+AQCei9zWkIvNYzs98SQMfaUQ7vbsT1/GuD0/4n2UEzrdi9hmKbTGo81Se/wA3Sp9Q+Iuk2yKU0+T7Qw/dhmxJz0xuzx70AdvvjtoVnukkWPkh0hEUZA6jb2+mOa8W8eeKZtf1D7JZQGK2ifYisrbWJ6tkf1ql4n8Z6h4h863jtRaQkgyOl0djY/vu3X8Ki8HXGnCXy7m5twwB2qZGx164Xr9SaAN7QfBMzWyNeCFY5ONjzoob1xxvP9a2bvwrZx2rx2qpHj7vkqYwPoD1/Gt+wFpIgNtNYHJwMD94R3+ZiT+FXJbVokBTS4Zdx+XdekheP7ob+eOtAHiviLS7nSists6mI5/eHyy59i45PftXPGS+n4ijLsfmUYZt3uG6D6V3/jWeBo5G2W/nKPma2Rphx0zj7prz4m6uVcSG9IA4+Ykjn+4MCgC5JLJFEksnlgMdqs1v5rhu/J9+1VHuTOU+02gaQMSksj+Tz+A/QY+tNhtUM6+bdsAEyFaByR9OR+lIIxLzDb/bCGJJ4XjuOSaALui/JdqCttGSeRFESSvszHA+vevRYtFsLmNZY7dyGXIuFgaRW/4GwAB7HHFebWk15blZre0tYHQ8NFHudR+vNdFaeMNUl3NfatfCdcEyGJpXJ9slccduaAM3xJYLYXTGG5wmQQssbSbc/mPzHFO8JRW8+oxNPewKI/mzLbMpyOwIz/KmahcS6zfBWgv5ZT0aQA7e3KhMY/X3rvvDmmS6bEUg0m5JPE8sFykSkgZ5RQGHpnmgCa8vrcCNYb2dAThG+zrH9AGk56+ldp+zw94/xhu/ts8soGi3ATzZzKy/v7bPXoPwA/KuI1KaUWj3D6feojZVUFwGVvcOQST6jB4rq/2Y4RF8VJ2+wi1d9FuNxyzGT9/bcktyfyFAH1XRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4h+1rM9v4E0KaKTy5E1qMq3GAfs9x1zxivCNFumvCpTVtMkEgLC1LGNyx+9t2ZJ+p/Cvc/2vc/8ACvdF2pvP9sp8uAc/6NcevFfLNrd3On/Og+yJI3zyYAZiO21cce4oA9FNuXguLZ4x5nzDyWuZiOemA+0A/UH0rgPEGi3GnytM1nK8IP33mYLH7ccnjvXQaF4nsbgJbagYZJFABMM6QBgDnBLBv/1810cqWd0XKafDMknyjdIk6yd8HaASPoufpQB5Gzgptl877KHx5QkcqPbY3J9c19N/Dr4txeEfgFa32tXEl/qcdzPYaZbSv+9nCEbQxPIRAwBbsMDqQD8/6/psUV4zwRBIed8FvHIDGx7FpQdw9CBWVaiW0zNGNQiXaUGZY+Bu3YGRkDPOAOTQBY1/XdS8Qa9d6rq+pW8+oXrh5pAgfbjgIuASqgDAA9KqK88pC3slu8QP3pIGfHpwo6/XNE6zDJJuZmY5VJbQsT7Fjt6fSovMkaNQyRIoPJSMLtI985/ACgCdJo43P2kEYGQEDIMe4PT6CmrNGhWTfDbhskNltx/4EM/l1psKTTwj7OnmAHIcssYf6BuW+vNMKzW5LRySw3BOG2ujD8waALVta3F/cKLVrKdS38LMxzn3Ib3xXa6P4Ye0minvtWt1IbcIVjcjPcZPf8aueGNOEGk2+oS36I8i/LNcpHJ5Z9F6AV0W8FGLatrMkbfIskUSxBxnogwcDOeRgUAPe1ke2QxRhLdiczSLuA+gbkfTFV7i1iW0uA1wZ1VT89sxDrjpjcoA9cU4Q6c82TaXMsoySwuJJLhsjq4wSB9MYrM1oxx6NdxXcdzDblHXykWQE8cFic/pg0Add8B9EuPEWpO+pz6mYrcmXZiPayBvusc7vmI7CvoGeS4nffJFf2Z2japk4UHgjCggexNeT/AWxRvh7fPBFcQXUkcFvI8qFPmBJyB94kAjk9eK9Dj8Oxrb+ZLZT3T9ZHiuJIucdQh4J70ATW1vErSC7kdkzvO6diqY5yc89hk0tlq8unBi0WITllzfIVCjoQrcqP1qKzktbKWWOK1ljtIyscs07KqsT/GobDHnj6VFr9rJZh5LqzS4VTlQkBIB/hGQDQBj/H7R7bxN8Nru5e0Lzaapu43DAlNuNwwOSGXPA64FfNNtomlX2mRTQpNZl03AFGkReORtJ/lX1LqEs0vw81oT6a9jwAyzOsg2nkudo9Ox5FfMnhAmDQ4YZYEmMVzIoSfaX+9wACc9PSgCvZaTE0kJs7n7QikAJL+5AAz+PHXGauzXK2urpeapAt5GAxE7KSp5+VQGOMjp6c10C6iUjCtaiNlBG24DNhfbYuB+JzVHUbaxu7F4JjogR/8An4BBX/dAySe/SgDzrXri2vLt5La2EADH5QokVV9lJx/Sk0vULmC6QWd0rOWBYfZomCAeuf6E1T1myisr2S2SJJiuGXypGA+u3GB+Yqm8jtCI5ZHjXPKxH8hyOD7g0Aes6frDNbxteXkcUJA/eW9vGu715GcH2OParrajpKQvNaapC2MZ3OqJ9G3ADrXkNvtgdZZBdAcnzGCpg+59PepLjVFnVI5HsiwOC25pD9M89aAOg8Z+Jru/m+zJeWnlgY2pKZseo6AD9a5GNbq4KZnJwpA23KQ5x9QO9PCbHb/TLSEHgfOZSfyzyPTili2b0V/PvYw4J2QiNMd/mIJzigCr5e2fcTE8h5JlbcT/AMC5/SrCJApkDxWEr5yPkk5+jdKs3kUdvdyRQWsrRkZjLBJio/AZ/lioIYJJpvKto5RKBwikRDA6jJPFAE9rP5yGOzgeH18iRlUcddoIBP412Pw2+H178R5fE0cVwz3WmacslqxQx4umcFEYHsyrIMnpkHtWDpuitczDzGjkZuCkm24IJP3chDj8M19Hfs0jR/CXw/1rxDrF3aabaahqjRRXFxKER4o/kQbj1O7zaAPGfB+gMNMgu7C31AySRnk3KxIjAkOGGQcggjk54/CtO4EUBXzG3SHAyllJLL6j5t/5EHmus+Lvh3SNK8XvrVvH9u8PeJt1zFNa3aJDHdoCZfmIKnzFG8cgllcCvLPEmrafKjWtlOBsbK7rh5x684QAH6njFAEWrXEEcrW8UeoSu8jNIhPkhu5G08Z74Nenfsri3HxTuhbw+V/xJrjcCULZ8+26lf8APJxXkCz24Xzby/t5pDyqzWKyD65dxge+K9f/AGWbgzfFS5X7ZDdBdEnIMSooXM9vxheg470AfWVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHhn7XqeZ8PdFTEhzrKf6tN7f8e1x0HevlOOzDSqxtJQq5XL2wQkfTzAc+pJr6u/a6UP4A0NWVWzrUYGV3c/Z7jBxkfzr5Qaxia3aUzF5d2DClg3zenPYe4z+NACTXsW544YlijD7lMVqAijpnczNz2zz7Utlrslg7FLjKZz+7AYj6ycEfh0pPIjWLYRfGV+CjCQA+hAwqj2yTVZ1lWVkhilhZDsO1w+32YnCjPpmgDsxrkWrW0Ud1MkYZSAn2gKDjuGfgjnpmsa98MXsIN1Atg9s3IlS6SRmHqdr7uPbFZ0GGG2/eErEMf6mSdlHooDbM/kKggY6fdNNbMQdx2h4AhPf7x4GPagCN45ftDJOs6EfxtC5LfQFunuaQ26BYXLTgOBtYxkZI9Av6ZrXur7S9Qt1fU0UXGMLKsm+VfYIThge278q6zwJKJ7eSGDTfOeMA+fdTJDhfTYFoA4aSyC/M6tGjLgyXarIMeoDEFT+VVFhAic2skaRsMF2jVVJ9sNzXrskkUErS/ZrO4nQ4ci5DRrj0HA/HHtzUE0AuGJl8I2eZCP311NLvPuigA5PXjA9MUAcH4Y19/D8my5ttNu7N25aaxMhQ/wB5WIGPzNeh6ZqzasC1glnc7wD5cdxiNT6sg5P0PSud1jQIXQvb6LHYOPm82TU2THuULnFc6+nMU2G/TzMn/VSxlTnrnjOPxNAHqTWOpzxkS6dblers1wR8p/ugED8Sf0rkNUs5zqtrZG9v7lZGAht7S4dyrkjaqqufy/HNc5ZQ2hnjivtRuPKX5htJYL/sqMkbj2r2f4YeLPAGgaharbxail+7CP7YxC7SeDmRyNoxnIUY96APefhB4Yu/Cngu3tNVYNqcztPc4fftY8Bd3fChQT65rS8Y+MNG8LRwDVbzy55zmKCNDJJIAfmwo7Y7niughdJIkeJxJGyhldTkMD0IPeuA+L/gL/hL9LS5sQv9r2anykdiEnXqY3x+h7H2JoA5KP4geEZTb3Ei3l3c/anmlkuIw0iR8lBgnoMqAB0xzXrHhfxDpniTTFvNHvFuogdj9mRscqw7GvkG1ttYuNTbS7e0vZL8OYjp4sPNZCOu4HAUD+8TivqL4XeEJPCmiML14X1O72vcmCIRxpgYVFA9MnnvQBnfGiO5034dajNolqHfz4pLiNW2l03jcc8+3PoK+UIPtGo393JbzWVhcxyb5Jpw5DA9V3nkk+3FfdWpwLdafcwPD56SxsjRFtu8EYIz2zXzzB8MbC0uLv8AsC7i02Tfua11Z1volPT5XU8enPSgDhY9VsjlpLqOaQgEC33Fd355Ye2amDWzB3RnXnOfIEQB9CzDPX0PNafi7SvEfhfTpNS1rSbe70qNwJL3TbiJEUngbo8EgZx7dK8q1jxvp88Zj0/S1inYHNxcXUoIJHUKPloAuePr62RBa+Z594WzItuqsYh74XqemDXGeRIy4WwcJ13XDtGP++c46+lOTTb+7+aCJ98gyXSZzvPUkk8H6Zq/D4P1mQK8lpksCd0g3g498fzoAyUaGN8zR2wcHJZMA/gS2DUtxdKyf8el25/vM/yZ9scVuDwtfREqbqxjcfeUKqsMf7GefqBWZqdrPp92losXnXEi52whkOM8cd80AUWuLgr+6it1UDk7I0IB9x2pnmSSlUKvO57I7N/46CBmuk0/wrrN2yPdeH0WEnG643xnkd3X+orVgs7bStwvLPQDInI3zsQPqf8AH8KAOdstHeRgkmVZhuIcuCq+uAcn3FdfpmiTC2j+ymVgfulYLgjj3Mfb1yBUd34zaIeXFc6fGg6LAsezj8A2fcGse88UXlzKphurllcdRczsMf7rc/TmgDsYtQvUxHBqt8c/KqQX/lAH0/eAfkefeuckWzsrO0std1C4uWskK2qkMVtgzZIRAQASSSW5JPOa5m91G5dTFPdXcu7loWiIGOxBYnnvyKpxwohYyiBFbBxcM0isPU7RxQBtXs1swI01720UOszxxypBEXT7j7BkEjJIOMjJqJZxPASGSSY9WF5kfhkdf6VlXItgybLe0Yg9YGcMfoT1/KnmSKU7miSYk9JHT5vwCcH6GgDYtZTEcrfafa7Bu2m9z168FCc/y7V7H+yzd3Fx8UbhJ5/OVNFuGQgNtAM9t0LKMjivDY/KQkNYQnowDec6n2J4xXsX7Jdws/xj1ZYozFHHokqiPeXCnz4CcEnpQB9gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeBftouY/hhpDjBK63CRnp/qJ6+XbCe2bL2SLNIF+Yx2e0oCP4cHj0LMQB719Qftrf8AJLNK/wCw1F/6Inr5N0GR7nTntvtdwTE+5LSJGPmA9TnIAwfXPWgDQubeaKKWS4W8aPGTth3LGf8Aadhtxz/Dmsw3ax7UlkkWEZwI1QKD6hSP1PNXZBfEhZLg7FIwJJfNI/8AHiAfbiluUSERFJ7GRx3ZVOfQhBkn6mgCktxFNsTLzycjYiAKffOOtTiO5O1VtUUtgFo8F/puc8H6Uy4+1NbFikCRE4YiPCnHvjJ7dKcI7d1VZrIuygYWOSOAN6luC5FAA0M9smVK22R94mNSAe5Yc/gOagWDzGEgmlkkXkeS7SZ/E8D8zV+305zGGs7SK2yCHk+0iQkfiML/ADps2nu8mLhb24/u7pQqAdOM4J+vFAGzpPiy/jeJFuBEU+USIz+YpHZpCfr06Vr6bfjUGVjf+dcylmaK2uZ5p2Pc4HAHuTmuEih2zKLa3t5PLYcNHkfQkE816J4ftZFEcxv3fagCWtkpjCKe7Dgeo5zQBpx6e+3ebO5DE/L59yj8+uMlz7ZpGjgnV/KtUldTmSXyvO2H0JxgHtjPFSmz3lBJG8kJXIk1C6VUA7/J9fSrJMBQLDumz90xyMka8Yxg4GPoDmgDnr/Sl2gwaXcyyjlmICKv/fRx9MVhxwI2pLLqdufssYDSJJJAcr245x/jWvr9/ALqCyAEVuzBS8SrNuJ6AFuPx7VHbWS6Ut3E1u2oLdkcwhXcAD+LHXFAH1je/EnRdP8Ah5HqukPC0qWkbwWI/eMoOFClV9OfTp2rK8JfFyLWfENnZXdrPbRXG2NXaNdpdvuc7ieeePpXzfFFf2elS28EUf2MIoZG+QEg5xgHJ/H6Gtb4daRfa94i06F7FId99C4kgdlwEYMW4GB0xQB9ka1qdto+mT3t5IiRRLn5mC7j2UZ7muO8K/Eix1Lw2L2/2xXscvky26Ohbk/KwG7HIx365FZ/7QXkN4Nt47lpVR7oDMUgVgdrc8g5x7V8sWNzYG9v1eO33RsVMslw/O3pwB1x+dAH2f4i8VaHauul3WorHcXg8n9y4LxbhgMcHI5I5+lfF3i7Qb/w342v9G/tS4W4t5GVHmR381T90nBPJXBqydVmulmmkSZbkD/j5jIPl4Awdp7dOe1ZV/dyT+IIbuae4uvLVBc3JkLF37uV7jtQBu2F3rk9jNp8+oyvFOqxyQLBIFlCnIBJIzg4xmoY9O1KOcZvL6IKfmVrdCGH4k/jXQtbtIoeIWzKyg+XKQmAcc4Pb2zTI7G8t5HMUkgRyDtz5iZ/XOPb8aAKiTx27RW9wgglYfKWcQq5xyPTd+FAis2aRS7AsADiWRiff5Tj86j120eexmtprxYbjI2tLFtEbA8NwMj8etcLPNPBayEXIa63eW6l2IY+o7j2oA7C+1vSNL3BnhZ1PCIEJB9mPOa5GbxPb/a5Z00u2nlk4L3ilmx7FeB+FYaRzSMx8rzt3/TMSMP++jmmjzEBLtOitwcxHAH+6P8AGgC1eanPdsxaKCBSflEKlufYlutRrLdOuxLu9IHHIUgY9s1RH2VnJ8yN24yHjYAj0yORUkUEUw/dRbsdljZwfx4x+NAE0N28YZVvTtb5mjfEf8weaWNZpjviInxy2yTeR7nI/wAaiZEtwpzdo39x49p/AjIP41Dv859rES+zqNw/Ec0AWpUu4sFoypIBx5Kqxz7gEfjRA0xcmC3u1fk8S4z+HH6VGkrwljGt1ESQPklYEH2Pf8aSW5aRBHJPOycf6x84x068YoAsq18v/Lq2dp5JOcfXPWk86eIAPGyIRuLoUYD35zj86ZBFKiMsaRSllBKm2DZ/4Een4VLCroH82BFDDOIoiv4ZA4oAki1FoIiRcyoEUtm3cgZ7AgfKRkfQ16x+xfI83xY1eSRi0j6PMzE9yZ4K8R1OcCBI0Lbn+8dxHGehHTr9Ole1/sVf8lT1X/sCy/8Ao+CgD7UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8A/bV/5JZpX/AGGov/RE9fGFrIkU6PLGJUB+ZCcZFfZ/7a3/ACSzSv8AsNRf+iJ6+KqAOrkjhYGR7e2IPI33QG4DptUDn8qeJ3kIktbazXaSCXiLAcY5z39sGqvhm4LwywRP5dwBncVTaU75LEHj6gfWr8rEySKbkSYBJMMkWz6Z4H+e9AFBxmQ/aBG0hBKpHuUjj/PFTRReXATHb3bQvyfn8tCPU9z+JFKtyI2c2qxKpBUsrIoJP+1jOfpSfeaNg8fmd3uJld2PoFx0/wAmgBj3MwY7hbLtwRmVX2j2GeTTB9lbcZHdi2MjZ5rHHQYGAPzNSXMs8jjdfBVX7oQA4/2flGM/jxUTyyEBp7m4yw4EbbSfcknpQBJLaH7y2twYz/fCQ4/3QM/yNaOl311pwQGErHECds8zFBnswwM5/SsV/J3kC3lckhVPnMc/jjmmP9nCqRaBQeSwdix+men5UAeu2F1ZawsU4uVgkX/lmqAMPXrkkD1xVqI24ZHF9Gsu3CyTBmAHrtyAPr+VeRQ3MNs4V4JlBOflmMT49M/T1rb0zWomuFke0tbnClW8psThfYt8pP0/CgD0G3ksY0YnU7aYMSX27jk+pwMD271JcX9nbxMLW5jXHy7bbdHvHu2NxOaoaTe6TqNuTGyNID1ly7px90r6gfgPWrUc0fkARS2sKkExqbdi23PqeD/OgDmri/t3kaG4liE8qEKrcunPH498dfU13fwHhgvPHFpNczujW0nnyhJjjIBC5HQDnJ5rkdZWwidZp5rZdoABRVjyD6k8k0vhi5mjvLnVJYRHbPF5MAecxrt7nBPzAn270AfRvx81m3TQdPa2eGdlnZiAQdo2lc57DnrXzZp16WuLh2tljllTDJ5G8YJyGBGM9OtdJ4q1e+fTfLjtlMTPGp2urox7qcnjj86yP7J1FLhJkF6tmVAjVsMAMZ+UjoOp9s0ATW9g2pwhb2W4lyMrCuYhjpgjqf1p93oNh9nktIrN7Z2XjazbiB7Z/p0ptvYW1xOBcRKJFOWZiwbd7c5/GtFLeEElRO3OziUjP1Hc/lQBVsY4LO2SGO5VgjYYSQsrAY5HzZyPSrFlIZIAZWfALYUQbwo7bRnio5TGQscEySKMqqm3BIz1FZOq6ollHJHMGCx5UFbTyzx2OSRtoA2Furob9jwSgcqiW+0DPHzbs4Ht+VeZeJdR+13kqRSIYQSZHDZ3k9wuM1LrWvveq8Vqbi2t1HIjVfm47gc/nWA84JwboMMcFlIK/l79aAGwxscHezKOeT3q5cSQGNGWNFf+LBwR9Rk5PuKpBQ2MyIzZ4YgbcfTFPCqcfvARno8iKuaAH75pdo8wOy9cxgMPwzzQ0Uj4EihgBkiVAB+DA/1pXjOSu+IIDtHlSrx7E7eTUfkEdH25ycAr/IGgAKCBcJNGhztykp6+4OQKsfaJzGY576OVMf8ALSATKR6lgCahikuIzkXMSH1V8YH4A8fWnedNvDy3CoBxnBAJ/wCAgZoAesxBICRyRdQYGYL+CnOfypsMgLqYpbgKvP8AqV4Podv9aRZZ5AGFtZ3QxkvGnzD8Rg0pMTFi9qztxncxwPocEj8aAEC27oGM8e8klkePbz+Q/SnIkCKQ8xjUHqjiRD7jnilSFJTja5Ur6O4A+q8fj1rP1V0iCxRSOxblsnIHpg4B/OgCleTtc3DSOSc8AkDOB0zivef2Kf8Akqeq/wDYFl/9HwV8/wBfQH7FP/JU9V/7Asv/AKPgoA+1KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPAP21v+SWaV/wBhqL/0RPXxVX2r+2t/ySzSv+w1F/6Inr4qoAcpKsCOo5rqrcxTWv2m302OZCPmZjJMYj6tnA3fnxXJ1c068NpNkgNE3DKckc98Z5NAG625v3rSTsRwHfZGPoOrH04xUbOdyCa5QOxwNiebJjP3Rk1JJNZsQ0k8DtgHc7FiB2GBxx6CoxcxRISl9EFwA21QrewGBn8cj60ASYjYsc3xdTgK2z5effjP0FRCZUlOxvKfpudQze2WIOPw/Comnhj6NC+MDc0m8gegBzj9ag+0RhCN64PGd45PbIAzigC6zRpuKzyS8HcwBGW/2ec4pRLIr8M67zkRqV3E+pxkj+dUROi/P5qLnByCMj8B29qcsyj7sirxz+9Az9cfyFAFwuyxsGuTHGxyyCEYYj0Lck1EXuJCqKQ7cYUr82PU4HH4Gi3u4lcgyxAEbcl/1wAK0oZbSIKzXFqQclmafLHJ9AT+RoA1dJa/jgMkwBKY8ryYhlV75bGQPx+tbP8Ab9/AgW6unRSS7grye3c9fT865n+14YpAovINoPA3sw/TGPX8Kq3WqWsxG653R91TC4A6Yz0oA3bjxLNMH+yhEkKkCR1EpUeu5hxnsKw57y4uJ1lnVppFYcY+XHvxwKrNqSNEADB5XJXfJkrx0wDn/wCvmoBc28RB8xBkZID7uePTigDYju0S9uEuIoriyusCSMud6+mMdG98V02lXVpcBo4ZB5Y5KyKUkTrjkHBbt0xXDTTW8gzJfqgb5sR4+XvThNb/APLK8jUMRkswz+P/AOugD1GTUtLgG2SSQuhILLOrkHHPTgCsLV/FNtsEWnEtgBfOnIBx1yFU54PvXHTpbxqB9stpQDwVlXpj3NVluLeT70sa56qcAD6YoA2ZNeuFWRY7q5LOvLgqiNx3XnH41jTzm4cPJNMw5wQflXnpj+tRG4RQvlzxkE4JYr39u4pm+Pc2+5i2gHA65/I9fx7UATBQy4Lu+3IG1Mjj8aiYrHjF0FB7eWTj+lKJ4cjM0bAcABygX+tM+0IpPlSRgZPDNuz9c0ALEYwSFkJJ4UhMK3tz0qTy2zhmiL9CiAcfnVcTxswG8IPZhj8snpTkulbaDNHJ82Rv+XB9aALE8bpjY0rIRglWUj6DHNQssm7JErPnoyFWqMspYlXtmB4PmMOvrnr+NOEkYVgZEyMZy4bP0P8A9Y0ASZdSCklwEHJ8wlSpPqRnP1xSrLIH3A3Wf7ysJOPTIpgePqk8RZRwzEAj9af5iGXP2i3UZzvGAR6YxQAhkM6/OIJB13AlWB6f54qUccmRQCcAs7fKfbHINMW4jYHL27MDkNvw36/41LutlQb54jkb85RiMdhzkfSgAuJ44YWlIjYgjAWUNz9CAa5+eVppnkf7zHJqS9uWuJSSzFF4QMegqvQAV9AfsU/8lT1X/sCy/wDo+Cvn+voD9in/AJKnqv8A2BZf/R8FAH2pRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    52-year-old woman with disconnected Roux-en-O misconstruction.",
"    <br>",
"     (A-C) Axial reconstruction CT scans show levels of gastric pouch (A), descending duodenum (B), and distal anastomosis (C). Enteric contrast medium administered orally opacifies markedly dilated gastric pouch (black asterisk, A), alimentary limb (short arrows, B and C), and extruded stomach and biliary limb (white asterisks). Common limb, beginning at supposed distal anastomosis (long arrow, C), distal small bowel, and colon (arrowheads, B and C) are collapsed and gasless. At surgery, biliary limb was found to have been incorrectly anastomosed to gastric pouch, forming Roux-en-O loop that ran from gastric pouch to end blindly in excluded distal stomach. Distal portion of bowel is collapsed and gasless because common limb was completely disconnected from Roux loop.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reprinted with the permission of the American Journal of Roentgenology. Mitchell MT, Gasparaitis AE, Alverdy JC. Imaging findings in roux-en-o and other misconstructions: Rare but serious complications of roux-en-y gastric bypass surgery. AJR Am J Roentgenol 2008; 190:367. Copyright &copy; 2008 American Roentgen Ray Society.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18664=[""].join("\n");
var outline_f18_14_18664=null;
var title_f18_14_18665="Preinvasive and invasive cervical neoplasia in HIV-infected women";
var content_f18_14_18665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preinvasive and invasive cervical neoplasia in HIV-infected women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/14/18665/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/14/18665/contributors\">",
"     William R Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/14/18665/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/14/18665/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/14/18665/contributors\">",
"     Bruce J Dezube, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/14/18665/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/14/18665/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/14/18665/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between human immunodeficiency virus (HIV) infection and cervical neoplasia was first suspected in 1988 when it was noted that the prevalence of HIV infection was fivefold higher among women attending a colposcopy clinic than among those attending an obstetric clinic serving the same general population (10 versus 2 percent). Two years later, the same investigators described a group of HIV-infected women with invasive cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/1\">",
"     1",
"    </a>",
"    ]. The series was remarkable because of the young age of the patients and because of the severity of the disease: the youngest was a 16 year-old girl with stage IIIB disease. Cervical cancer persisted or recurred in all of the HIV-infected patients despite therapy, but in only 37 percent of HIV-negative women. All of the HIV-infected patients died of cervical cancer, with a mean survival of only 10 months.",
"   </p>",
"   <p>",
"    As a result of these and other observations, in 1993 the Centers for Disease Control and Prevention (CDC) designated moderate and severe cervical intraepithelial neoplasia as conditions defining a stage of early symptomatic HIV infection (category B), and invasive cervical cancer as an acquired immunodeficiency (AIDS)-defining condition (category C) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    .) Cervical cancer is now the most common AIDS-related malignancy in women at some centers in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of cervical intraepithelial neoplasia (CIN) (as confirmed by colposcopy) is four to five times higher among HIV-infected compared to HIV-negative women or adolescents with high risk sexual behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased incidence of CIN in this population was illustrated in a prospective cohort study of 328 HIV-infected and 325 HIV-negative women with no evidence of CIN by Papanicolaou (Pap) smear or colposcopy at study entry [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/6\">",
"     6",
"    </a>",
"    ]. Biopsy confirmed CIN was significantly more likely to develop in HIV-infected women over 30 months follow-up (prevalence of infection: 20 versus 5 percent); most lesions were low grade, and no invasive cancers were noted. Of note, only 54 percent of these women took one or more antiretroviral medications, none were on protease inhibitors, and the mean CD4 cell count for the HIV-infected women was 429 X",
"    <span class=\"nowrap\">",
"     10(6)/L.",
"    </span>",
"   </p>",
"   <p>",
"    The risk of cervical cancer among HIV-infected women is five- to eightfold the risk for HIV-negative women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/7-11\">",
"     7-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of the female genital tract with human papillomavirus (HPV) is generally felt to be necessary but not sufficient for the development of cervical cancer. Additional factors are critical in pathogenesis of cervical abnormalities since only a small percentage of young women infected with HPV develop cervical cancer. The most important of these factors are viral subtype (",
"    <a class=\"graphic graphic_table graphicRef76394 \" href=\"UTD.htm?0/27/443\">",
"     table 1",
"    </a>",
"    ) and persistence of infection. An overview of the role of HPV in the pathogenesis of CIN and cervical cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link&amp;anchor=H3#H3\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\", section on 'Role of human papillomavirus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV infected women are at risk of immune system impairment. Immunosuppression is an important risk factor for development of CIN, probably because the weakened response of the immune system allows HPV to persist. The contribution of the impaired immune status of these women to the pathogenesis of cervical abnormalities is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with low CD4+ cell counts (eg, CD4 count",
"      <span class=\"nowrap\">",
"       &lt;200/mcL",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       &gt;500/mcL)",
"      </span>",
"      have the highest prevalence of HPV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women with low CD4+ cell counts more commonly harbor high risk HPV types [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women with low CD4+ cell counts are at high risk for persistence of cervical HPV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. Some data suggest that HPV infection is likely to recur after a latent phase in HIV-infected women, which is rarely seen in other women [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree of immunosuppression in HIV infected women predicts the occurrence and severity of cervical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. For example, a multicenter series of 485 HIV-infected women found that those with CD4 counts",
"    <span class=\"nowrap\">",
"     &lt;200/mcL",
"    </span>",
"    had a twofold increase in CIN, and a lower rate of regression of untreated low grade disease compared to women with CD4 counts above",
"    <span class=\"nowrap\">",
"     500/mcL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, a case-control series of HIV infected women observed that those diagnosed with invasive cervical cancer had lower median CD4 counts and higher median viral loads than those without cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV infection may directly promote HPV-associated oncogenesis at the molecular level. In vitro studies have suggested that the HIV-encoded Tat protein can enhance expression of viral oncogenes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for cervical cancer in HIV infected women is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36934?source=see_link\">",
"     \"Screening for cervical cancer in HIV infected women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION OF ABNORMAL CYTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal cervical cytology is more common in HIV-infected than HIV-uninfected women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/21\">",
"     21",
"    </a>",
"    ]. Colposcopy is performed for evaluation of all abnormal cytological screening, except atypical cells of undetermined significance (ASC-US), which is evaluated as in HIV-negative women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although HIV-infected women with ASC-US and negative colposcopy are at higher risk of developing CIN 2 or greater than HIV-negative controls with these findings, the absolute risk of progression is low. In one study with a four year follow-up, progression to high grade disease occurred in 47 of 391 (12 percent) of HIV-infected women with",
"    <span class=\"nowrap\">",
"     ASC/LSIL",
"    </span>",
"    plus negative colposcopy versus 4 of 103 (4 percent) of HIV-negative controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/23\">",
"     23",
"    </a>",
"    ]. However, most of the excess risk of progression could be attributed to a higher prevalence of oncogenic HPV types in the HIV-infected women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate management of CIN, including optimal ablative therapy, role of postablative treatment with topical agents, and timing and method of follow-up, is still largely unknown. Close follow-up by a provider with experience in HIV-related cervical disease is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Low grade lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In HIV-negative women, regression of low grade lesions is common (&gt;70 percent); therefore, many of these women are monitored at 6 to 12 month intervals without ablative or excisional treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link&amp;anchor=H6#H6\">",
"     \"Cervical intraepithelial neoplasia: Management\", section on 'Low grade lesions: CIN 1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An understanding of the natural history of low grade lesions in HIV infected women is necessary in order to determine whether this approach is also appropriate in these women. It appears that at least one-third of HIV positive women with a histologic diagnosis of CIN I show regression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/18,24\">",
"     18,24",
"    </a>",
"    ]; however, the risk of progression is less clear. Two studies reported progression in 4 to 7 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], while others reported higher rates of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/27-30\">",
"     27-30",
"    </a>",
"    ], which could occur rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/31\">",
"     31",
"    </a>",
"    ]. Given this uncertainty and lack of data to define subgroups of women who may be at higher or lower risk of progression, we recommend following ASCCP consensus guidelines for expectant management of women with biopsy confirmed CIN I and satisfactory colposcopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link&amp;anchor=H6#H6\">",
"     \"Cervical intraepithelial neoplasia: Management\", section on 'Low grade lesions: CIN 1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A lesion that persists after one to two years or any progression during the follow-up period should generally be treated. However, follow-up of HIV-negative women with CIN I beyond 24 months has shown an overall reduction in disease persistence, although a few women had progression of CIN during the extended follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/3\">",
"     3",
"    </a>",
"    ]. There are no data to suggest that it is unsafe, even in HIV-infected women, to continue close clinical follow-up (cytology, colposcopy) of a compliant patient with persistent CIN I, with treatment planned if there is evidence of disease progression.",
"   </p>",
"   <p>",
"    The use of highly active antiretroviral therapy (HAART) has been associated with increased rates of regression and decreased rates of recurrence in HIV infected women. Based on this, HIV infected women using HAART with low viral loads and stable CD4 levels may be managed similar to non-HIV infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/30,32\">",
"     30,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Excision or ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ablation and excision are both acceptable treatment modalities for HIV-infected women with satisfactory colposcopic examinations and biopsy proven CIN",
"    <span class=\"nowrap\">",
"     II/III",
"    </span>",
"    or persistent CIN I. Endocervical sampling is recommended before ablation.",
"   </p>",
"   <p>",
"    If colposcopy is not satisfactory, then ablative treatment is unacceptable because histopathological examination of the nonvisualized tissue is required to exclude the presence of occult cancer. A diagnostic and therapeutic excisional procedure should be performed in these cases. Excision is also recommended for patients with recurrent disease after ablation.",
"   </p>",
"   <p>",
"    Therapeutic techniques include cryosurgery, loop electrosurgical excision procedure (LEEP), excision, and cone biopsy. The success rate for these approaches in HIV-negative women is over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Procedures for cervical conization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44343?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Ablative therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the success rate is lower in HIV-infected women. Persistence and recurrence of CIN after treatment is more common in these patients, as illustrated by the following representative studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 19 women with CIN I who were followed for one year,",
"      <span class=\"nowrap\">",
"       recurrent/persistent",
"      </span>",
"      disease developed in three of six who underwent excision, compared to seven of thirteen who were observed [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/34\">",
"       34",
"      </a>",
"      ]. No cases of invasive cancer developed in either group.",
"     </li>",
"     <li>",
"      Another series compared 44 HIV-positive women to 125 HIV-negative women, all of whom were treated for CIN with cryotherapy, laser therapy, or cone biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/35\">",
"       35",
"      </a>",
"      ]. Biopsy proven recurrence was more common in the HIV-infected patients (39 versus 9 percent). A similar difference in recurrence rate was noted in a series of 114 women treated with LEEP (56 versus 10 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study including 127 HIV-infected women treated for CIN of all grades reported recurrence in 62 percent after one treatment, 42 percent (14 of 33) after two treatments, and 50 percent (three of six) after three treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another series of 136 HIV-infected women who underwent excisional treatment reported a recurrence rate of 51 to 55 percent. Risk factors for recurrence were positive margins (sixfold increased risk) and LEEP (compared with cold knife conization; 1.7-fold increased risk) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One factor that contributes to the poorer treatment outcome in HIV-infected women is incomplete excision or ablation of CIN. As an example, in two studies of LEEP, CIN was at the margins in all (11 of 11) tissue specimens of HIV-positive patients but in only 32 percent (86 of 265) of tissue specimens from HIV-negative women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. It is not known why positive margins occurred more often among HIV positive women. In both groups of patients with disease remaining at the margins, recurrence was more likely in HIV-infected compared to HIV-negative women. This suggests that in addition to margin status, other factors, such as immunosuppression, are important in disease recurrence. In two of the reports described above, recurrence in the HIV group was more common in patients with a CD4 count below",
"    <span class=\"nowrap\">",
"     500/mcL",
"    </span>",
"    (45 versus 18 percent and 61 versus 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since results of standard excisional therapy are better in HIV-negative than in HIV-infected women, use of primary or adjuvant medical therapy to improve treatment outcomes has been investigated. Results have been mixed. Little or no effect was seen with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/41,42\">",
"     41,42",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/43\">",
"     43",
"    </a>",
"    ], or systemic or intralesional interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], but use of the agents described below has shown some benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Topical 5-fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical 5-fluorouracil (5-FU) is an effective prophylactic agent for immunosuppressed women with CIN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The value of this agent in HIV-infected women was illustrated in a phase III trial supported by the ACTG (ACTG 200) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/46\">",
"     46",
"    </a>",
"    ]. In this trial, 101 HIV-infected women with CIN II or CIN III who had undergone excisional or ablative therapy were randomly assigned to six months of prophylaxis with 5-FU (topical application of 2 g of 5 percent cream biweekly) or to observation alone. Pap smears and colposcopy were scheduled at regular intervals during the ensuing 18 months, with the primary end point being recurrence of any grade of CIN. The 5-FU therapy was associated with significant reductions in the rate of any recurrence (28 versus 47 percent) and the rate of high-grade recurrence (8 versus 31 percent). Thus, topical vaginal 5-FU cream is recommended as adjunctive therapy to",
"    <span class=\"nowrap\">",
"     excision/ablation",
"    </span>",
"    procedures for CIN",
"    <span class=\"nowrap\">",
"     II/III.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Highly active antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    introduction of HAART has improved the prognosis in patients with HIV infection and reduced the incidence of many neoplastic complications of AIDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HAART treatment is associated with beneficial effects in HIV-infected patients regarding CD4 count and HIV RNA load; improvements in these measures are also associated with a lower risk of CIN and cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. This indirectly suggests that HAART may reduce the incidence and recurrence of CIN in HIV-infected women.",
"   </p>",
"   <p>",
"    HAART appears to be associated with regression of CIN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/32\">",
"     32",
"    </a>",
"    ]. This would also suggest that these therapeutic regimens decrease the risk of developing cervical cancer in HIV-infected women; however, there are insufficient data regarding this question.",
"   </p>",
"   <p>",
"    Initially, studies of the effect of HAART on CIN were limited and conflicting because of small numbers of study participants and differences in study design [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/18,30,32,48-53\">",
"     18,30,32,48-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The highest quality information on the effect of HAART on CIN in HIV-infected women comes from a large, multicenter prospective cohort study by the Women's Interagency HIV Study (WIHS) Group [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/32\">",
"     32",
"    </a>",
"    ]. In HIV-infected women receiving HAART, the rates of regression of incident CIN (299 LSIL, 13 HSIL) were compared before and after the initiating therapy. Major findings from this study were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No incident CIN lesions regressed pre-HAART; the overall rate of regression was 12.5 percent per year post-HAART.",
"     </li>",
"     <li>",
"      Among the 312 women, 141 (45 percent) had lesions that regressed to normal cytology, with a median time to regression of 2.7 years. The incidence of regression increased over time after HAART was introduced. Prior to HAART, the regression rate was 0 percent; after HAART, the regression rate increased to 12.5 percent. By comparison, regression to normal cytology occurred in 16 of 27 (59 percent) of HIV-negative women.",
"     </li>",
"     <li>",
"      A higher rate of regression in HIV-infected women taking HAART was observed in women with higher CD4+ counts and low grade incident CIN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study suggests that the benefit of HAART is due, at least in part, to improvement in CD4+ counts. It also lends support to the recommendation that CIN is a relative indication for HAART.",
"   </p>",
"   <p>",
"    These results were supported by a subsequent prospective cohort study (n = 537) that compared HIV-positive women who did or did not take HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/54\">",
"     54",
"    </a>",
"    ]. Women on HAART were more likely to have CIN regression, although this approached, but did not reach, statistical significance. Also, women with CIN who did versus did not take HAART were more likely to show clearance of HPV infection (high and low risk subtypes); this effect was not seen in women with normal or ASC-US cervical cytology.",
"   </p>",
"   <p>",
"    Another study suggested that adherence to and effectiveness of HAART regimens is associated with a reduced burden of HPV infection and squamous intraepithelial lesions (SIL). In this report, 286 HIV-infected women were prescribed HAART and followed prospectively. Those who used HAART appropriately greater than 95 percent of the time and those who had effective suppression of HIV replication had significantly decreased prevalence of new HPV infections, as well as increased clearance of existing SIL [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccines have been demonstrated to be effective in the prevention of HPV infections, the necessary precursor to cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/56\">",
"     56",
"    </a>",
"    ]. A quadrivalent vaccine has been approved in the United States for prophylaxis of HPV infection and prevention of cervical cancer.",
"   </p>",
"   <p>",
"    Several factors may affect the use of HPV vaccines in HIV-infected women. The distribution of HPV subtypes seen in HIV-infected women is typically different from that seen in HIV-negative women, so vaccines designed for the HIV-negative population may be less useful [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/57\">",
"     57",
"    </a>",
"    ]. Also, the effect of HIV-induced immunosuppression on vaccine response is unknown. Finally, since the most common source of HIV infection in women is via sexual contact, nearly all HIV-infected women are likely to already be infected with HPV as well [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/58\">",
"     58",
"    </a>",
"    ]. Minimal objective information on the use of HPV vaccines in HIV-infected women is currently available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected women with CIN should be advised that recurrence is more frequent than in the general population and the risk of recurrence correlates inversely with the degree of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/35-37,59\">",
"     35-37,59",
"    </a>",
"    ]. Recurrence rates are as high as 56 percent, and up to 87 percent in severely immunocompromised (CD4 lymphocyte count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mL)",
"    </span>",
"    women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/4,37,60\">",
"     4,37,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, cancer can develop rapidly in HIV-infected women. A large study matching AIDS and cancer registries found that the average interval between diagnosis of CIS and development of invasive disease was considerably shorter in HIV-infected than in HIV-negative women (3.2 versus 15.7 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/7\">",
"     7",
"    </a>",
"    ]. However, these data were largely obtained before widespread use of antiviral therapy. Therefore, these women require close monitoring after treatment. Hysterectomy is an option for recurrent CIN in women not desirous of fertility.",
"   </p>",
"   <p>",
"    We recommend monitoring with both cervical cytology and colposcopy, with liberal use of biopsy, at least three month intervals for an indefinite period of time. There are no long-term data on the progression of CIN after therapy in HIV-infected women. When such data are available, it may be possible to determine criteria for women who can be followed safely with less frequent and intensive surveillance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF INVASIVE CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although preinvasive cervical disease is asymptomatic, women with invasive squamous cell carcinoma often have symptoms. The most frequent presenting complaint is irregular vaginal bleeding; postcoital bleeding is the classic symptom of cervical cancer, but is relatively uncommon. Vaginal discharge also can occur. Biopsy of a visible cervical lesion is required to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical carcinoma in HIV-infected women tends to be more advanced at diagnosis, and patients are frequently more debilitated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The cancer spreads locally by extension to the corpus, parametria, and vagina. Metastases are common and occur at unexpected sites [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Some patients with cervical cancer are diagnosed while hospitalized for other manifestations of AIDS. Since some symptoms of AIDS are similar to those of advanced cancer (eg, weight loss, fatigue, and lymphadenopathy), the presence of cervical cancer may be masked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT OF INVASIVE CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard therapy for invasive cervical cancer consists of surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    .) Surgical excision is most appropriate for early stage disease, while radiation therapy is beneficial in almost all stages. Chemotherapy improves the outcome of patients treated with radiation therapy (ie, chemoradiotherapy), while chemotherapy alone has generally been reserved for palliation.",
"   </p>",
"   <p>",
"    Therapy of invasive cervical cancer in HIV-infected women must take into consideration several additional factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with HIV-associated cervical cancer are usually younger than HIV-negative women.",
"     </li>",
"     <li>",
"      In most women (26 of 28 in one report), invasive cervical cancer is the initial AIDS-defining diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV-infected women with cervical cancer tend to be less immunosuppressed (as assessed by the CD4 count) than HIV-infected patients with other AIDS-defining illnesses [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast to CIN and some other malignancies associated with HIV infection (eg, Kaposi's sarcoma, central nervous system non-Hodgkin lymphoma), the introduction of HAART has not decreased the incidence of invasive cervical cancer in infected women [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/65\">",
"       65",
"      </a>",
"      ]. This is because cervical cancer, unlike Kaposi's sarcoma, was not a rare disease prior to the AIDS era and the vast majority of American women with cervical cancer are not HIV-infected. Therefore, any reduction in risk of cervical neoplasia in HIV infected women has a minimal impact on the overall incidence of cervical cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"       \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"      </a>",
"      .) However, HAART may have a positive impact on prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, aggressive therapy should be offered to most HIV-infected women with cervical cancer. The patient should be informed that the prognosis in general is worse than in HIV-negative women (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64747 \" href=\"UTD.htm?27/28/28108\">",
"     table 3",
"    </a>",
"    ), although this information is derived largely from women not on HAART and that prognosis associated with concomitant antiviral therapy is not known. Some women will be unwilling to tolerate the side effects associated with aggressive therapy if there is only a small chance of survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is typically reserved for stage I tumors. The choice of procedure varies with the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local excision by cold knife conization or LEEP may be adequate for microinvasive lesions (&lt;3 mm depth of invasion) in women who wish to maintain fertility. If future fertility is not an issue, simple hysterectomy is preferred. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=see_link\">",
"       \"Cervical intraepithelial neoplasia: Procedures for cervical conization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radical hysterectomy is appropriate for grossly visible tumors that are confined to the cervix (up to and including stage IIA). Advantages of surgery over radiation in such women include preservation of the ovaries and of vaginal function. Although there is an increase in early morbidity with surgery (eg, anesthesia, blood loss, infection), overall morbidity from elective gynecology surgery does not appear to be increased in otherwise asymptomatic HIV-infected women [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/67\">",
"       67",
"      </a>",
"      ]. The addition of postoperative chemoradiotherapy should be considered for women at increased risk of recurrent or persistent disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H546745501#H546745501\">",
"       \"Management of early stage cervical cancer\", section on 'Adjuvant therapy indications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoradiation with curative intent is applicable to most stages of cervical cancer, except stage IVB disease. Although the method of delivery and total dose of radiation are tailored to the extent of the lesion, the most common regimen is external beam radiation to the whole pelvis, followed by intracavitary therapy with implanted cesium or radium. Randomized clinical trials have documented the survival benefit of concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    during radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H10523862#H10523862\">",
"     \"Management of locally advanced cervical cancer\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major advantage of radiation compared to surgical therapy for cervical cancer is less immediate morbidity. However, pelvic chemoradiation in HIV-infected women is not without adverse effects. Recovery from myelosuppression may be slower than in HIV-negative women; depending upon its severity, temporary cessation of therapy may be required. It is not known if pelvic chemoradiation therapy can potentiate the immunosuppressive effects of HIV infection. However, one study suggests that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    to radiotherapy does not enhance radiation-induced immunosuppression, at least in HIV-negative women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiation proctitis is a potential complication of pelvic radiation that may be exacerbated by concomitant chemotherapy. It is usually treated symptomatically and, if available, topical butyrate enemas may accelerate healing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18665/abstract/69\">",
"     69",
"    </a>",
"    ]. If this is ineffective, radiation and chemotherapy should be withheld until the diarrhea resolves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    .) The diarrhea must be distinguished from other forms of diarrhea associated with HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with diarrhea\"",
"    </a>",
"    .) Late complications of pelvic chemoradiotherapy, such as bowel obstruction and bowel and bladder fistulas, are uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy alone can provide palliative benefit for women with cervical cancer. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    has been shown to improve survival in women with advanced or metastatic cervical cancer, and is currently considered the standard regimen for patients. There are limited data concerning the efficacy of chemotherapy in advanced cervical cancer in HIV-infected women; a significant tumor response appears to be rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link\">",
"     \"Management of recurrent or metastatic cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of uncertainties remain in the management of women with HIV infection and cervical neoplasia. Although cervical neoplasia appears to be more aggressive in HIV-infected patients, there is no consensus on appropriate management. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV testing should be recommended to women with abnormal cervical cytology. This is of particular importance to young women from high seroprevalence areas. HIV testing should also be recommended to women with newly diagnosed cervical cancer under age 50, particularly in women under age 30 or with widely advanced disease or unusual sites of metastases. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the high frequency of development of CIN in HIV-infected women, these women should, at a minimum, undergo a thorough annual examination including visual inspection of the anus, vulva, and vagina, as well as cervical cytology and a screening colposcopy (as long as cervical cytology is normal). More frequent evaluation may be appropriate in patients with CD4 counts below",
"      <span class=\"nowrap\">",
"       500/mcL",
"      </span>",
"      and is necessary in those with abnormalities on cervical cytology, biopsy, or colposcopy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We perform cervical cancer screening twice in the first year after diagnosis of HIV infection and then annually, provided the test results are normal. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of highly active retroviral therapy in HIV-infected women is associated with a lower risk of CIN and cervical cancer. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Highly active antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary treatment of CIN in HIV-infected women is generally similar to the approach used in HIV-negative women. LEEP excision of the cervix appears to be most appropriate for patients with CIN II or CIN III or persistent CIN I, and topical vaginal 5-FU cream is recommended as adjunctive therapy in this setting. The patient should be counseled that recurrence is more frequent than in the general population. As a result, monitoring with cervical cytology, colposcopy, and liberal use of biopsy should be performed at three month intervals or less. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of invasive cervical cancer in HIV-infected women is also generally based upon the approach used in HIV-negative women. Treatment should not be withheld because of concern for comorbidity, since these patients are more likely to die from the cervical cancer than from other AIDS-related illnesses. Elective gynecologic surgery may be undertaken in the otherwise asymptomatic HIV-infected woman with no increase in risk. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment of invasive cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/1\">",
"      Maiman M, Fruchter RG, Serur E, et al. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 1990; 38:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/2\">",
"      From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/3\">",
"      Maiman M, Fruchter RG, Clark M, et al. Cervical cancer as an AIDS-defining illness. Obstet Gynecol 1997; 89:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/4\">",
"      Wright TC Jr, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/5\">",
"      Moscicki AB, Ellenberg JH, Crowley-Nowick P, et al. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 2004; 190:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/6\">",
"      Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/7\">",
"      Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/8\">",
"      Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/9\">",
"      Franceschi S, Dal Maso L, Arniani S, et al. Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer 1998; 78:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/10\">",
"      Serraino D, Carrieri P, Pradier C, et al. Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int J Cancer 1999; 82:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/11\">",
"      Serraino D, Dal Maso L, La Vecchia C, Franceschi S. Invasive cervical cancer as an AIDS-defining illness in Europe. AIDS 2002; 16:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/12\">",
"      Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/13\">",
"      Denny L, Boa R, Williamson AL, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 2008; 111:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/14\">",
"      Ahdieh L, Mu&ntilde;oz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000; 151:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/15\">",
"      Theiler RN, Farr SL, Karon JM, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010; 115:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/16\">",
"      Maiman M, Tarricone N, Vieira J, et al. Colposcopic evaluation of human immunodeficiency virus-seropositive women. Obstet Gynecol 1991; 78:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/17\">",
"      Sch&auml;fer A, Friedmann W, Mielke M, et al. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 1991; 164:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/18\">",
"      Delmas MC, Larsen C, van Benthem B, et al. Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression. European Study Group on Natural History of HIV Infection in Women. AIDS 2000; 14:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/19\">",
"      Leitao MM Jr, White P, Cracchiolo B. Cervical cancer in patients infected with the human immunodeficiency virus. Cancer 2008; 112:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/20\">",
"      Vernon SD, Hart CE, Reeves WC, Icenogle JP. The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res 1993; 27:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/21\">",
"      Massad LS, Seaberg EC, Wright RL, et al. Squamous cervical lesions in women with human immunodeficiency virus: long-term follow-up. Obstet Gynecol 2008; 111:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/22\">",
"      Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/23\">",
"      Massad LS, Evans CT, Strickler HD, et al. Outcome after negative colposcopy among human immunodeficiency virus-infected women with borderline cytologic abnormalities. Obstet Gynecol 2005; 106:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/24\">",
"      Belafsky P, Clark RA, Kissinger P, Torres J. Natural history of low-grade squamous intraepithelial lesions in women infected with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/25\">",
"      Massad LS, Evans CT, Minkoff H, et al. Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus. Obstet Gynecol 2004; 104:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/26\">",
"      Del Mistro A, Bertorelle R, Franzetti M, et al. Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. Clin Infect Dis 2004; 38:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/27\">",
"      Robinson WR, Luck MB, Kendall MA, Darragh TM. The predictive value of cytologic testing in women with the human immunodeficiency virus who have low-grade squamous cervical lesions: a substudy of a randomized, phase III chemoprevention trial. Am J Obstet Gynecol 2003; 188:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/28\">",
"      Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 92:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/29\">",
"      Massad LS, Schneider M, Watts H, et al. Correlating Papanicolaou Smear, Colposcopic Impression, and Biopsy: Results from the Women's Interagency HIV Study. J Low Genit Tract Dis 2001; 5:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/30\">",
"      Robinson WR, Hamilton CA, Michaels SH, Kissinger P. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol 2001; 184:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/31\">",
"      Holcomb K, Maiman M, Dimaio T, Gates J. Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus. Obstet Gynecol 1998; 91:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/32\">",
"      Ahdieh-Grant L, Li R, Levine AM, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004; 96:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/33\">",
"      Burghardt E, Holzer E. Treatment of carcinoma in situ: evaluation of 1609 cases. Obstet Gynecol 1980; 55:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/34\">",
"      Heard I, Bergeron C, Jeannel D, et al. Papanicolaou smears in human immunodeficiency virus-seropositive women during follow-up. Obstet Gynecol 1995; 86:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/35\">",
"      Maiman M, Fruchter RG, Serur E, et al. Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. Obstet Gynecol 1993; 82:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/36\">",
"      Wright TC Jr, Koulos J, Schnoll F, et al. Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision. Gynecol Oncol 1994; 55:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/37\">",
"      Fruchter RG, Maiman M, Sedlis A, et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996; 87:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/38\">",
"      Reimers LL, Sotardi S, Daniel D, et al. Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women. Gynecol Oncol 2010; 119:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/39\">",
"      Robinson, WR, Tirpack, JS. The predictive value of LEEP specimens with involved margins for residual dysplasia. Int J Gynecol Cancer 1996; 6:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/40\">",
"      Robinson, WR, Lund, ED, Adams, J. The predictive value of LEEP specimen margin status for residual/recurrent cervical intraepithelial neoplasia. Int J Gynecol Oncol 1998; 8:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/41\">",
"      Mackerras D, Irwig L, Simpson JM, et al. Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Br J Cancer 1999; 79:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/42\">",
"      Romney SL, Ho GY, Palan PR, et al. Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 1997; 65:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/43\">",
"      Robinson WR, Andersen J, Darragh TM, et al. Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women. Obstet Gynecol 2002; 99:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/44\">",
"      Frost L, Skajaa K, Hvidman LE, et al. No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1990; 97:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/45\">",
"      Yliskoski M, Syrj&auml;nen K, Syrj&auml;nen S, et al. Systemic alpha-interferon (Wellferon) treatment of genital human papillomavirus (HPV) type 6, 11, 16, and 18 infections: double-blind, placebo-controlled trial. Gynecol Oncol 1991; 43:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/46\">",
"      Maiman M, Watts DH, Andersen J, et al. Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial. Obstet Gynecol 1999; 94:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/47\">",
"      Sillman FH, Sedlis A. Anogenital papillomavirus infection and neoplasia in immunodeficient women. Obstet Gynecol Clin North Am 1987; 14:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/48\">",
"      Heard I, Schmitz V, Costagliola D, et al. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/49\">",
"      Heard I, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 2002; 16:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/50\">",
"      Minkoff H, Ahdieh L, Massad LS, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001; 15:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/51\">",
"      Orlando G, Fasolo MM, Schiavini M, et al. Role of highly active antiretroviral therapy in human papillomavirus-induced genital dysplasia in HIV-1-infected patients. AIDS 1999; 13:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/52\">",
"      Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/53\">",
"      Schuman P, Ohmit SE, Klein RS, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003; 188:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/54\">",
"      Paramsothy P, Jamieson DJ, Heilig CM, et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009; 113:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/55\">",
"      Gravitt PE, Kirk GD. Progress and pitfalls in defining the influence of highly active antiretroviral therapy on human papillomavirus-associated cervical disease. J Infect Dis 2010; 201:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/56\">",
"      Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/57\">",
"      De Vuyst H, Franceschi S. Human papillomavirus vaccines in HIV-positive men and women. Curr Opin Oncol 2007; 19:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/58\">",
"      Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006; 24 Suppl 3:S3/140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/59\">",
"      Gilles C, Manigart Y, Konopnicki D, et al. Management and outcome of cervical intraepithelial neoplasia lesions: a study of matched cases according to HIV status. Gynecol Oncol 2005; 96:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/60\">",
"      Heard I, Potard V, Foulot H, et al. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr 2005; 39:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/61\">",
"      Maiman M, Fruchter RG, Guy L, et al. Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer 1993; 71:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/62\">",
"      Schwartz LB, Carcangiu ML, Bradham L, Schwartz PE. Rapidly progressive squamous cell carcinoma of the cervix coexisting with human immunodeficiency virus infection: clinical opinion. Gynecol Oncol 1991; 41:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/63\">",
"      Singh GS, Aikins JK, Deger R, et al. Metastatic cervical cancer and pelvic inflammatory disease in an AIDS patient. Gynecol Oncol 1994; 54:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/64\">",
"      Klevens RM, Fleming PL, Mays MA, Frey R. Characteristics of women with AIDS and invasive cervical cancer. Obstet Gynecol 1996; 88:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/65\">",
"      International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/66\">",
"      Robinson WR, Freeman D. Improved outcome of cervical neoplasia in HIV-infected women in the era of highly active antiretroviral therapy. AIDS Patient Care STDS 2002; 16:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/67\">",
"      Devito JR, Robinson WR. Gynecological surgical outcomes among asymptomatic human immunodeficiency virus-infected women and uninfected control subjects. J La State Med Soc 1995; 147:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/68\">",
"      Santin AD, Hermonat PL, Ravaggi A, et al. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 2000; 48:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18665/abstract/69\">",
"      Vernia P, Fracasso PL, Casale V, et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet 2000; 356:1232.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3245 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18665=[""].join("\n");
var outline_f18_14_18665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION OF ABNORMAL CYTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Low grade lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Excision or ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Topical 5-fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Highly active antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS OF INVASIVE CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT OF INVASIVE CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3245\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3245|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/27/443\" title=\"table 1\">",
"      Risk of cervical CA with HPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/6/33902\" title=\"table 2\">",
"      Staging cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/28/28108\" title=\"table 3\">",
"      Cervical cancer survival",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44343?source=related_link\">",
"      Cervical intraepithelial neoplasia: Ablative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=related_link\">",
"      Cervical intraepithelial neoplasia: Procedures for cervical conization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=related_link\">",
"      Evaluation of the HIV-infected patient with diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=related_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=related_link\">",
"      Management of recurrent or metastatic cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36934?source=related_link\">",
"      Screening for cervical cancer in HIV infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_14_18666="Overview of treatment of uterine leiomyomas (fibroids)";
var content_f18_14_18666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of treatment of uterine leiomyomas (fibroids)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/14/18666/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/14/18666/contributors\">",
"     Elizabeth A Stewart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/14/18666/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/14/18666/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/14/18666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/14/18666/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/14/18666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine leiomyomas are benign tumors. Since histological confirmation of the clinical diagnosis is not necessary in most cases, asymptomatic uterine leiomyomas can usually be followed without intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/1\">",
"     1",
"    </a>",
"    ]. Women with leiomyomas whose physicians prescribed \"watchful waiting\" experienced no significant change in symptoms or decline in quality of life, thereby providing some reassurance to women who are asymptomatic or have mild symptoms and choose to avoid intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylactic therapy to avoid potential future complications from myomas or their treatment is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/3\">",
"     3",
"    </a>",
"    ]. Possible exceptions include women with significant submucosal leiomyomas who are contemplating pregnancy and women with ureteral compression leading to moderate or severe hydronephrosis. In these women, prophylactic treatment may prevent miscarriage or urinary tract obstruction.",
"   </p>",
"   <p>",
"    Relief of symptoms (eg, abnormal uterine bleeding, pain, pressure) is the major goal in management of women with significant symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/4\">",
"     4",
"    </a>",
"    ]. The type and timing of any intervention should be individualized, based upon factors such as [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type and severity of symptoms",
"     </li>",
"     <li>",
"      Size of the myoma(s)",
"     </li>",
"     <li>",
"      Location of the myoma(s)",
"     </li>",
"     <li>",
"      Patient age",
"     </li>",
"     <li>",
"      Reproductive plans and obstetrical history",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overview of the treatment of uterine leiomyomas will be presented here. The clinical manifestations, diagnosis, and natural history of these tumors are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXPECTANT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no high quality data regarding follow-up of fibroids in patients who are asymptomatic or who decline medical or surgical treatment. However, given data that fibroids can shrink substantially and that there is substantial regression during the postpartum period, expectant management appears to be a reasonable option for some women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. We order an initial imaging study (usually an ultrasound) to confirm that a pelvic mass is a fibroid and not an ovarian mass. After an initial evaluation, we perform annual pelvic exams and, in patients with anemia or menorrhagia, check a complete blood count. If symptoms or uterine size are increasing, we proceed with further evaluation and patient counseling regarding treatment options. We also screen women with menorrhagia for hypothyroidism, a disease that is common in reproductive age women, and refer women with heavy menstrual bleeding and a history suggestive of a bleeding disorder for hematologic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive evidence-based report noted \"a remarkable lack of randomized trial data demonstrating the effectiveness of medical therapies in the management of women with symptomatic fibroids\" [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/8\">",
"     8",
"    </a>",
"    ]. Given the high prevalence of both leiomyomas and the use of gonadal steroid preparations (eg, contraception, management of menstrual cycle abnormalities), it is difficult to isolate the effect of these drugs on mild leiomyoma-related symptoms.",
"   </p>",
"   <p>",
"    Anecdotal data suggest medical therapy provides adequate symptom relief in some women, primarily in situations where bleeding is the dominant or only symptom. In general, 75 percent of women get some improvement over one year of therapy, but long-term failure rates are high [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/9\">",
"     9",
"    </a>",
"    ]. A systematic review observed that in trials where women were randomly assigned to oral medical therapy, almost 60 percent had undergone surgery by two years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A trial of medical therapy in premenopausal women with mild symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mildly enlarged uteri can also be useful for helping to distinguish symptoms primarily related to leiomyomas from those primarily due to a concurrent problem, such as oligoovulation, which may be contributing to abnormal uterine bleeding or infertility. However, in postmenopausal women, caution should be exercised when raising the level of steroid hormones from the physiologic baseline, as there is indirect evidence that taking hormone therapy causes leiomyomas to grow in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hormonal therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined hormonal contraceptives and progestational agents are commonly prescribed to regulate abnormal uterine bleeding, but appear to have limited efficacy in the treatment of uterine leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. These drugs can be useful in some women with heavy menstrual bleeding, particularly those with coexisting problems (eg, dysmenorrhea or oligoovulation); but they do not appear to be effective in decreasing bulk symptoms. There is also evidence that, in some women, contraceptive steroids may be associated with a decreased risk of uterine fibroids; however, it is not clear that these agents are useful for either primary or secondary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. There is one study that suggests that oral contraceptives started before age 16 may be associated with an increased risk of fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Steroid hormones influence the pathogenesis of leiomyomas, but the relationship is complex. As an example, although there are high levels of both estrogen and progesterone during pregnancy and with estrogen-progestin contraceptive use, both decrease the risk of developing new leiomyomas but may lead to leiomyoma growth. The specific hormonal compound, the timing and duration of exposure, the delivery method (endogenous, oral, transdermal, depot, local) and other factors may all be important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Estrogen-progestin contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many texts continue to suggest that estrogen-progestin contraceptive pills (OC) are contraindicated in women with uterine leiomyomas. However, clinical experience suggests some women with heavy menstrual bleeding associated with leiomyomas respond to OC therapy. This, plus data that OCs are associated with a decreased risk of leiomyomas and reduced symptoms from other concurrent gynecologic conditions, suggests that a therapeutic trial may be appropriate before proceeding to more invasive therapies. The purported mechanism of action is via endometrial atrophy.",
"   </p>",
"   <p>",
"    This approach should be reassessed if a woman has exacerbation of bulk-related symptoms on OCs. Since most formulations appear to work similarly, switching to other formulations does not appear to be effective in the woman who does not respond to a short trial of one formulation.",
"   </p>",
"   <p>",
"    Data are not available regarding treatment using newer methods of contraceptive steroid delivery (eg, ring, patch). However, with vaginal administration (NuvaRing), the uterus is likely to receive a higher dose of medication than other systemic tissues, which could affect how leiomyomas respond to hormone therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Levonorgestrel-releasing intrauterine system",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials evaluating the use of levonorgestrel-releasing intrauterine system (IUS) for the treatment of menorrhagia related to uterine leiomyomas. Observational studies and systematic reviews have shown a reduction in uterine volume and bleeding, and an increase in hematocrit after placement of this IUS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/10,19-22\">",
"     10,19-22",
"    </a>",
"    ]. The device is widely used for control of heavy menstrual bleeding and is now approved by the United States Food and Drug Administration (FDA) for this indication. The presence of intracavitary leiomyomas amenable to hysteroscopic resection is a strong relative contraindication to use. A second advantage of this treatment is that it provides contraception for women who do not desire pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Progestin implants, injections, and pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with OCs, it is difficult to discern the effectiveness of progestin-only contraceptive steroids specifically for treatment of leiomyomas. As with the breast, progesterone is a growth factor for myomas and may even be more critical than estrogen. That being said, progestin-only contraceptives cause endometrial atrophy and thus provide relief of menstrual bleeding-related symptoms. They can be considered for treatment of mild symptoms, especially for women who need contraception. There is also consistent evidence from cohort studies that these agents are associated with a decreased risk of leiomyoma formation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/18,23\">",
"     18,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to gonadotropin-releasing agonists and antagonists, most of these \"contraceptives\" provide continuous exposure to low doses of hormones, which should minimize deleterious effects (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Gonadotropin-releasing hormone agonists'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Gonadotropin-releasing hormone antagonists'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Gonadotropin-releasing hormone agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotropin-releasing hormone (GnRH) agonists are the most effective medical therapy for uterine myomas. These drugs work by initially increasing the release of gonadotropins, followed by desensitization and downregulation to a hypogonadotropic, hypogonadal state that clinically resembles menopause. Most women will develop amenorrhea, improvement in anemia (if present), and a significant reduction (35 to 60 percent) in uterine size within three months of initiating this therapy, thus achieving improvement in both categories of myoma symptomatology [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/15,16,24\">",
"     15,16,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is rapid resumption of menses and pretreatment uterine volume after discontinuation of GnRH agonists. In addition, significant symptoms can result from the severe hypoestrogenism that accompanies such therapy, including hot flashes, sleep disturbance, vaginal dryness, myalgias and arthralgias, and possible impairment of mood and cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/15\">",
"     15",
"    </a>",
"    ]. Bone loss leading to osteoporosis after long-term (12+ months) use is the most serious complication and most often limits therapy. A rule of thumb for women with endometriosis is that approximately 6 percent of bone is lost over 12 months of therapy and 3 percent is regained following the cessation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/25\">",
"     25",
"    </a>",
"    ]. However, women with leiomyomas tend to be older and heavier than women with endometriosis, thus they may have less bone loss.",
"   </p>",
"   <p>",
"    Because of the rapid rebound in symptoms and side effects, GnRH agonists are primarily used as preoperative therapy. GnRH agonists are approved for administration for three to six months prior to leiomyoma-related surgery in conjunction with iron supplementation to facilitate the procedure and enable correction of anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/26\">",
"     26",
"    </a>",
"    ]. Reduction in uterine size can facilitate subsequent surgery by reducing intraoperative blood loss and by increasing the number of women who are candidates for a vaginal procedure, a transverse (rather than vertical) abdominal incision, or a minimally-invasive procedure. Since oral iron supplementation alone will improve the preoperative hematocrit in a significant number of patients, the cost and adverse effects of GnRH agonists must be weighed against their efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H623653#H623653\">",
"     \"Abdominal myomectomy\", section on 'Reducing uterine size with GnRH agonists'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GnRH agonists should not be used preoperatively for every myoma surgery, but with a particular endpoint in mind (volume reduction, resolution of anemia, or both). Although many physicians reflexively plan three or six months of treatment, interval assessment of goals is optimal because of the variability of response. Continuing GnRH agonist for six months prior to abdominal myomectomy to effect volume reduction is not optimal treatment if there is no volume reduction by two to three months. Likewise, treatment of a 2.8 cm leiomyoma prior to surgery is not helpful if the hysteroscopic surgeon can easily resect a 3-centimeter leiomyoma.",
"   </p>",
"   <p>",
"    The side effects of long-term GnRH agonist administration can be minimized during therapy by giving add-back therapy with low dose estrogen-progestin after the initial phase of downregulation. A phase of downregulation is necessary to achieve shrinkage of leiomyomas even though simultaneous administration of a GnRH agonist and steroids can work for other diseases, such as endometriosis. Low dose estrogen-progestin therapy, such as used for menopausal replacement (equivalent to 0.625 mg of conjugated estrogen and 2.5 of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    or 5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    ) maintains amenorrhea and the reduction in uterine volume, while preventing significant hypoestrogenic side effects (eg, osteoporosis, vasomotor symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/28\">",
"     28",
"    </a>",
"    ]. Using OC add-back for leiomyomas is not indicated.",
"   </p>",
"   <p>",
"    Rarely, GnRH-agonists are used to provide short-term relief to women close to menopause or with acute medical contraindications to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/29\">",
"     29",
"    </a>",
"    ]. The United States Food and Drug Administration has approved use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    and iron preoperatively in women with leiomyomas, but not for medical management of these tumors. Therapeutically equivalent options include leuprolide acetate depot (intramuscularly 3.75",
"    <span class=\"nowrap\">",
"     mg/month",
"    </span>",
"    or 11.25",
"    <span class=\"nowrap\">",
"     mg/three",
"    </span>",
"    months),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    acetate (3.6",
"    <span class=\"nowrap\">",
"     mg/month",
"    </span>",
"    subcutaneously or 10.6 mg subcutaneous implant every three months) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26580?source=see_link\">",
"     nafarelin",
"    </a>",
"    acetate (administered as a twice daily intranasal spray). However, the fact that these agents are best administered at specific times in the menstrual cycle (late luteal if no chance of pregnancy or with onset of menses), cause an increase in estrogen prior to downregulation and take a minimum of three weeks to reach this down-regulated state means that some women who might benefit are not candidates for therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gonadotropin-releasing hormone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar clinical results have been achieved with GnRH antagonists, which compete with endogenous GnRH for pituitary binding sites [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. The advantage of antagonists over agonists is the rapid onset of clinical effects without the characteristic initial flare-up observed with GnRH agonist treatment. However, in the United States, these agents are marketed at doses used for ovulation induction and long-acting preparations are not available. Thus, treatment of leiomyomas is cumbersome due to the need for daily injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Antiprogestins and progesterone receptor modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone appears to be capable of stimulating growth in uterine fibroids. The primary clinical concern with antiprogestins and progesterone receptor modulators (PRM) is the potential for an increased risk of endometrial hyperplasia or cancer. The association with endometrial hyperplasia was inconsistent across studies in which endometrial sampling was performed at baseline and then after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. The reported rate of hyperplasia varied widely from 0 to 63 percent and did not appear to correlate with dose; there were no cases of hyperplasia with atypia or cancer.",
"   </p>",
"   <p>",
"    An expert panel of pathologists, convened by the United States National Institutes of Health, reported that a novel pattern of changes that resemble hyperplasia is found in endometrial tissue following treatment with PRMs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/39\">",
"     39",
"    </a>",
"    ]. They term this new pattern PRM-associated endometrial changes and suggest that long-term follow-up is indicated to define the natural history of these changes. Recent molecular studies suggest that endometrium exposed to PRMs do not appear to express the typical molecular signatures of endometrial malignant progression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential complication of these agents is transient elevations in serum aminotransferases, which has been reported with high dose regimens; this appears to be a rare occurrence with low dose regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24356551\">",
"    <span class=\"h4\">",
"     Mifepristone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiprogestin",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (RU-486) is the most widely studied PRM and reduces uterine volume by 26 to 74 percent in women with leiomyomas, comparable to the reduction observed with GnRH agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/34\">",
"     34",
"    </a>",
"    ]. Regrowth occurs slowly following cessation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/41\">",
"     41",
"    </a>",
"    ]. Data from randomized trials and prospective studies have shown that high dose regimens (&gt;10 to 50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    give comparable rates of amenorrhea to GnRH agonists, while lower doses (5 to 10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    achieve an amenorrhea rate of 40 to 70 percent and, in other women, produce a reduction in menstrual flow [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/34-38,41,42\">",
"     34-38,41,42",
"    </a>",
"    ]. There is accumulating evidence that mifepristone provides symptomatic relief and improved quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/35,41\">",
"     35,41",
"    </a>",
"    ]. There is also a small randomized clinical trial utilizing the PRM CDB-2914 and a pilot study utilizing asoprisnil, both of which may have similar effects to mifepristone for leiomyoma treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    is not approved by the United States Food and Drug Association (FDA) for the treatment of uterine myomas. An impediment to use of mifepristone for treatment of leiomyomas is that currently available doses are not appropriate (200 mg once for termination of pregnancy versus 5 to 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three to six months for myoma reduction). Use of a compounding pharmacy is required and many are reluctant to provide this compound due to political, rather than medical, concerns for this off-label treatment indication [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/45\">",
"     45",
"    </a>",
"    ]. Other PRMs are still investigational agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24356925\">",
"    <span class=\"h4\">",
"     Ulipristal acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39412?source=see_link\">",
"     Ulipristal",
"    </a>",
"    acetate is a PRM that inhibits ovulation, but has little impact on serum estradiol levels. Ulipristal acetate (oral, 5 mg or 10 mg once daily for 13 weeks) was compared with placebo in one randomized trial of 242 women with menorrhagia, fibroid-associated anemia, and a uterus that was &le;16 weeks of gestation size [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/46\">",
"     46",
"    </a>",
"    ]. Ulipristal acetate resulted in a significantly higher rate of resolution of menorrhagia (5 mg: 91 percent; 10 mg: 92 percent; placebo: 19 percent) and a significant, but only slightly higher increase in hemoglobin (5 mg: 4.3",
"    <span class=\"nowrap\">",
"     g/dl;",
"    </span>",
"    10 mg: 4.2",
"    <span class=\"nowrap\">",
"     g/dl;",
"    </span>",
"    placebo: 3.1",
"    <span class=\"nowrap\">",
"     g/dl).",
"    </span>",
"    Significant reductions in fibroid volume occurred in women treated with ulipristal acetate (5 mg: -21 percent volume; 10 mg: -12 percent; placebo: +3 percent). There were no findings of endometrial hyperplasia or cancer. Approximately half of patients in each group chose to undergo surgical treatment of fibroids at the completion of the study.",
"   </p>",
"   <p>",
"    Another randomized trial by the same group included 307 women with menorrhagia and a uterus that was &le;16 weeks of gestation size [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/47\">",
"     47",
"    </a>",
"    ]. Participants were assigned to 13 weeks of therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39412?source=see_link\">",
"     ulipristal",
"    </a>",
"    acetate (oral, 5 mg or 10 mg per day) or the GnRH-agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate (intramuscular, 3.75 mg monthly).&nbsp;All groups had comparable rates of resolution of menorrhagia. Resolution of menorrhagia was achieved more quickly in the ulipristal groups (approximately six days compared with 30 days for leuprolide). Women treated with ulipristal had a significantly lower frequency of moderate to severe hot flashes (in the ulipristal acetate groups, 5 mg: 11 percent; 10 mg: 10 percent versus leuprolide: 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/47\">",
"     47",
"    </a>",
"    ]. The reduction in uterine size was significantly lower for the ulipristal groups (5 mg: 20 percent; 10 mg: 22 percent; leuprolide: 47 percent).",
"   </p>",
"   <p>",
"    Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    , the available dose is an impediment to off-label treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39412?source=see_link\">",
"     ulipristal",
"    </a>",
"    acetate. Ulipristal acetate is sold in the United States as a single 30 mg dose, as opposed to 5 to 10 mg per day evaluated for fibroid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Additionally, while supplementary data for the aforementioned studies suggest that there is reversal of the PRM-associated endometrial changes with a drug free-interval, and endometrial safety with long-term therapy is still uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Raloxifene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of selective estrogen receptor modulators for treatment of leiomyomas is unclear; while preclinical testing in animal models and treatment of postmenopausal women has been encouraging, clinical trials in reproductive age women have been less convincing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/49\">",
"     49",
"    </a>",
"    ]. A possible increased risk of venous thrombosis when high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    are used is an additional concern.",
"   </p>",
"   <p>",
"    By comparison, studies in premenopausal women have been conflicting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial in which 100 symptomatic premenopausal women were randomly assigned to receive a GnRH analog with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      or placebo, the raloxifene group achieved a greater reduction in leiomyoma size than the placebo group, but this did not result in a greater reduction in leiomyoma-related symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/50\">",
"       50",
"      </a>",
"      ]. This trial did not address the efficacy of raloxifene alone. Another trial by the same authors in asymptomatic premenopausal women found no significant effect of raloxifene alone (60 to 180",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three to six months) on leiomyoma size or uterine bleeding compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A smaller trial (25 patients) found",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      (180",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three months) inhibited leiomyoma growth in premenopausal women compared to untreated controls, in whom leiomyomas continued to enlarge [",
"      <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger controlled trials over extended treatment intervals should be performed to better ascertain the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    on leiomyomas in premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small series and one randomized clinical trial have described shrinkage of symptomatic leiomyomas and a decrease in leiomyoma symptoms in women in the menopausal transition given aromatase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Although these agents have fewer side effects than many of the hormonal therapies discussed above, their potential role in management of uterine myomas requires further study to establish the duration of response, risks, and cost-effectiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antifibrinolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifibrinolytic agents, which are useful in the treatment of idiopathic menorrhagia, have not been well studied in leiomyoma&ndash;related menorrhagia. One drug (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    ) is now available in the United States and FDA-approved for the treatment of heavy menstrual bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/58\">",
"     58",
"    </a>",
"    ]. Women with fibroids made up approximately 35 percent of the women enrolled in the pivotal trial leading to approval of this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) have not been extensively studied in leiomyoma-related menorrhagia. NSAIDs do not appear to reduce blood loss in women with myomas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], but because they decrease painful menses, they can be useful in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12332980\">",
"    <span class=\"h2\">",
"     Danazol and gestrinone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgenic steroids may be an effective treatment of leiomyoma symptoms in some women, but are associated with frequent side effects.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     Danazol",
"    </a>",
"    is a 19-nortestosterone derivative with androgenic and progestin-like effects. Its mechanisms of action include inhibition of pituitary gonadotropin secretion and direct inhibition of endometriotic implant growth, and direct inhibition of ovarian enzymes responsible for estrogen production. Since it induces amenorrhea and has been shown to have a direct effect on endometriosis implants, danazol likely inhibits autologous endometrium. Danazol may control anemia related to leiomyoma-related menorrhagia, but it does not appear to reduce uterine volume. Side effects are common (eg, weight gain, muscle cramps, decreased breast size, acne, hirsutism, oily skin, decreased high density lipoprotein levels, increased liver enzymes, hot flashes, mood changes, depression).",
"   </p>",
"   <p>",
"    Another androgenic steroid, gestrinone, decreases myoma volume and induces amenorrhea in women with leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/62\">",
"     62",
"    </a>",
"    ]. An advantage of this drug is that there is a carry-over effect after it is discontinued. In one study, as an example, uterine volume remained lower than pretreatment values 18 months after discontinuation of therapy in 89 percent of women treated for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/62\">",
"     62",
"    </a>",
"    ]. Gestrinone is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biology of uterine leiomyomas has traditionally been explained in terms of steroid hormones; thus, virtually all current medical therapies are based upon manipulation of these hormones. However, an expanded view of the biology of this benign tumor (eg, the specific genes that are dysregulated) may open new avenues of pharmaceutical intervention and ultimately lead to new strategies for prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25143?source=see_link\">",
"     \"Histology and pathogenesis of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regulation of growth factor pathways is one area of innovative treatment. There is evidence that interferons can reverse the proliferative effects of basic fibroblast growth factor on leiomyoma cells in culture [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/65\">",
"     65",
"    </a>",
"    ]. In a case report, a woman undergoing treatment with interferon-alfa for hepatitis C had dramatic and sustained shrinkage of a uterine leiomyoma after seven months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the mainstay of therapy for leiomyomas. Hysterectomy is the definitive procedure; myomectomy by various techniques, endometrial ablation, uterine artery embolization (UAE), magnetic resonance-guided focused-ultrasound surgery (MRgFUS), and myolysis are alternative procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=see_link\">",
"     \"Prolapsed uterine leiomyoma (fibroid)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link\">",
"     \"An overview of endometrial ablation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link\">",
"     \"Abdominal myomectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are indications for surgical therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal uterine bleeding or bulk-related symptoms (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H4#H4\">",
"       \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infertility or recurrent pregnancy loss (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=see_link\">",
"       \"Reproductive issues in women with uterine leiomyomas (fibroids)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation for malignancy is not an indication for surgery in most women with leiomyomas. Examples of this are women in whom a leiomyomatous uterus limits the evaluation of the adnexa or who have a large or rapidly growing uterine mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link&amp;anchor=H23337512#H23337512\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\", section on 'Should hysterectomy be performed to exclude uterine sarcoma?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H7945374#H7945374\">",
"     \"Abdominal myomectomy\", section on 'Evaluation of pelvic malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest hysterectomy for (1) women with acute hemorrhage who do not respond to other therapies; (2) women who have completed childbearing and have current or increased future risk of other diseases (cervical intraepithelial neoplasia, endometriosis, adenomyosis, endometrial hyperplasia, or increased risk of uterine or ovarian cancer) that would be eliminated or decreased by hysterectomy; (3) women who have failed prior minimally invasive therapy for leiomyomas; and (4) women who have completed childbearing and have significant symptoms, multiple leiomyomas, and a desire for a definitive end to symptomatology.",
"   </p>",
"   <p>",
"    Leiomyomas are the most common indication for hysterectomy, accounting for 30 percent of hysterectomies in white and over 50 percent of hysterectomies in black women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/67\">",
"     67",
"    </a>",
"    ]. The cumulative risk of a hysterectomy for leiomyomas for all women between ages 25 and 45 is 7 percent, but is 20 percent in black women.",
"   </p>",
"   <p>",
"    The main advantage of hysterectomy over other invasive interventions is that it eliminates both current symptoms and the chance of recurrent problems from leiomyomas. For many women who have completed childbearing, this freedom from future problems makes hysterectomy an attractive option.",
"   </p>",
"   <p>",
"    The morbidity associated with hysterectomy may outweigh the benefits when there is a solitary subserous myoma, a pedunculated myoma, or a submucosal myoma readily excised via laparoscopy or hysteroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/68\">",
"     68",
"    </a>",
"    ]. In these cases, an endoscopic myomectomy is a less morbid option. Avoiding the morbidity of hysterectomy should also be considered by women whose only symptom is bleeding, or who are in the menopausal transition; these women are often effectively treated with either a levonorgestrel-releasing IUS or endometrial ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Myomectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy is an option for women who have not completed childbearing or otherwise wish to retain their uterus. Although myomectomy is an effective therapy for menorrhagia and pelvic pressure, the disadvantage of this procedure is the risk that more leiomyomas will develop from new clones of abnormal myocytes.",
"   </p>",
"   <p>",
"    The classic approach to removing subserosal or intramural myomas has been through a laparotomy incision, laparoscopic and robotic-assisted procedures are becoming more common. However, there is a small number of reports of pregnancy following robotic-assisted myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Hysteroscopic myomectomy is the procedure of choice for removing intracavitary myomas (submucosal and intramural myomas that protrude into the uterine cavity). When a fibroid prolapses through the cervix, myomectomy can be performed vaginally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link\">",
"     \"Abdominal myomectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=see_link\">",
"     \"Hysteroscopic myomectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=see_link\">",
"     \"Prolapsed uterine leiomyoma (fibroid)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Endometrial ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women who have completed childbearing, endometrial ablation, either alone or in combination with hysteroscopic myomectomy, is an option for management of bleeding abnormalities. Since intramural and subserosal leiomyomas are not affected by this procedure, bulk or pressure symptoms are unlikely to improve.",
"   </p>",
"   <p>",
"    Some devices for endometrial ablation are designed only for use in a normal size cavity and cannot conform to an irregular cavity. When a submucous leiomyoma is present, microwave ablation is possible if the leiomyoma is less than 3 cm and leiomyoma resection with rollerball ablation is indicated if the leiomyoma is greater than 3 cm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link\">",
"     \"An overview of endometrial ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a recent population based study of outcomes of endometrial ablation, a decrease in the rate of amenorrhea was found with an enlarged uterine cavity (uterine length greater than 9 cm), but not with the presence of either submucous or intramural fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most case series of endometrial ablation have excluded women with significant myomas, one study that examined endometrial ablation with hysteroscopic myomectomy reported only an 8 percent risk for a second surgery after a mean of six years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Myolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myolysis refers to laparoscopic thermal coagulation or cryoablation (cryomyolysis) of leiomyoma tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. This technique is easier to master than myomectomy, which requires suturing. However, localized tissue destruction without repair may increase the chance of subsequent adhesion formation or rupture during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/76\">",
"     76",
"    </a>",
"    ]. It is used infrequently in current practice, however, a new device utilizing radiofrequency ablation has recently been published [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link&amp;anchor=H432924#H432924\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\", section on 'Myolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Uterine artery occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occlusion of uterine vessels either via laparoscopy or a vaginally-placed clamp has been proposed as an alternative to uterine artery embolization (UAE), but experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/78-83\">",
"     78-83",
"    </a>",
"    ]. Currently, it appears that UAE is preferable to laparoscopic uterine artery occlusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link&amp;anchor=H432917#H432917\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\", section on 'Uterine artery occlusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     INTERVENTIONAL RADIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Uterine artery embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine artery embolization (UAE), or uterine fibroid embolization (UFE), is a minimally invasive option for management of leiomyoma-related symptoms; excellent technical and clinical success has been reported. It is an effective option for women who wish to preserve their uterus and are not interested in optimizing future fertility. UFE results in shrinkage of myomas of approximately 30 to 46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/84\">",
"     84",
"    </a>",
"    ]. UFE is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=see_link\">",
"     \"Uterine leiomyoma (fibroid) embolization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systematic review of randomized trials concluded that women undergoing UAE have a shortened hospital stay, less pain than following surgery and a quicker return to work than those undergoing hysterectomy or myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. However, they have more complications, unscheduled visits, and readmissions. Data also suggest that women with larger uteri",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more leiomyomas at baseline are at greater risk of failure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Like the situation with endometrial ablation, there appears to be a relatively high rate of reintervention for treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/88\">",
"     88",
"    </a>",
"    ]. Research is needed to see if better patient selection can minimize this risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=see_link\">",
"     \"Uterine leiomyoma (fibroid) embolization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Magnetic resonance guided focused ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance guided focused ultrasound surgery (MRgFUS) (eg, ExAblate 2000) is a more recent option for the treatment of uterine leiomyomas in premenopausal women who have completed childbearing. This noninvasive thermoablative technique converges multiple waves of ultrasound energy on a small volume of tissue, which leads to its thermal destruction, and can be performed as an outpatient procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. The maximum size of a leiomyoma for this procedure is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. It is not typically size alone that limits treatment, but size, vascularity, access and other factors.",
"   </p>",
"   <p>",
"    This system is not indicated for leiomyomas which are resectable with a hysteroscope, heavily calcified, or when intervening bowel of bladder could be damaged by treatment. While desire for future pregnancy was originally a contraindication for this therapy, labeling for the device now allows treatment in women considering future pregnancy following counseling.",
"   </p>",
"   <p>",
"    The maximum size of fibroids that can be treated with this method is uncertain. In a case series, 50 women with leiomyomas exceeding 10 cm were pretreated with a GnRH agonist and were then successfully treated with MRgFUS, but individual fibroid measurements before and after pretreatment were not reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/92\">",
"     92",
"    </a>",
"    ]. According to a survey, MRgFUS practitioners consider a fibroid &gt;10 cm to be somewhat of an impediment, but not an absolute contraindication to the procedure. Factors reported as the most important contraindications included severe adenomyosis, five or more fibroids, and nonenhancement with gadolinium [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/95\">",
"     95",
"    </a>",
"    ]. Further study is needed to determine the optimal fibroid size threshold for MRgFUS. It appears that MRgFUS results in a reduction in myoma volume of approximately 37 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance imaging gives good visualization of the anatomic structures and provides real-time thermal monitoring to optimize tissue destruction. Symptomatic improvement is observed within the first three months postprocedure, and this improvement has been maintained at least through 24 to 36 months follow-up, with more complete ablation leading to better outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/97-101\">",
"     97-101",
"    </a>",
"    ]. Adverse event rates appear to be decreased with increased experience, despite more extensive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/98\">",
"     98",
"    </a>",
"    ]. The procedure is time consuming and costly, but short-term morbidity is low and recovery is rapid. However, analyses based on quality of life measures have found the procedure to be cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/102,103\">",
"     102,103",
"    </a>",
"    ] and a recent evidence based review from the United Kingdom National Health Service suggests the data support clinical use of this modality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies are needed to determine long-term outcome and optimal candidates for this procedure; comparative studies are also needed.",
"   </p>",
"   <p>",
"    There are several case reports and one case series of pregnancy following MRgFUS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/105-109\">",
"     105-109",
"    </a>",
"    ]. The case series is drawn from all sites performing MRgFUS and describes 54 pregnancies in 51 women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/109\">",
"     109",
"    </a>",
"    ]. Mean birth weight was 3.3 kgs and there was a 64 percent vaginal delivery rate. There was no specific pattern of complications. Nine percent of women had placentation problems, but in this series, all had prior uterine surgery as a risk factor for this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?18/14/18666/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=see_link\">",
"       \"Patient information: Uterine fibroids (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/21/2386?source=see_link\">",
"       \"Patient information: Uterine artery embolization (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"       \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Asymptomatic women",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest expectant management of asymptomatic women, except in the case of a woman with moderate or severe hydronephrosis or a woman with a hysteroscopically-resectable submucous leiomyoma who is pursuing pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Expectant management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of postmenopausal hormonal therapy, leiomyomas generally become smaller and asymptomatic in postmenopausal women; therefore, intervention is not usually indicated. We suggest evaluation to exclude sarcoma in a postmenopausal woman with a new or enlarging pelvic mass (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The incidence of sarcoma is 1 to 2 percent in women with a new or enlarging pelvic mass, abnormal uterine bleeding, and pelvic pain. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Submucosal leiomyomas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend hysteroscopic myomectomy for women with appropriate submucosal leiomyomas that are symptomatic (eg, bleeding, miscarriage) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). This procedure allows future childbearing, usually without compromising the integrity of the myometrium, but is also an appropriate option in women who have completed childbearing since it is minimally invasive. Abdominal myomectomy is performed in women with significant symptoms and a submucous leiomyoma(s) not amenable to hysteroscopic resection. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Myomectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Women who desire fertility",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the lack of information about the safety of pregnancy after other invasive procedures, we recommend abdominal myomectomy for treatment of symptomatic intramural and subserosal leiomyomas in women who wish to preserve their childbearing potential and who have no major contraindications to a surgical approach (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Hysteroscopic myomectomy is the preferred approach to submucosal leiomyomas. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Myomectomy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, for women for whom risk of intraoperative conversion to hysterectomy is high, or women who are considering a future pregnancy but will accept impaired fertility in exchange for an expedited recovery phase, other options such as uterine artery embolization and magnetic resonance guided focused ultrasound may be considered appropriate treatment options. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Uterine artery embolization'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Magnetic resonance guided focused ultrasound'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Laparoscopic myomectomy is an option for women with a uterus less than 17 weeks' size or with a small number of subserosal or intramural leiomyomas. Future childbearing is possible; however, the integrity of the uterine incision during pregnancy has not been evaluated adequately and may be inferior to abdominal myomectomy. Due to reports of uterine rupture in pregnancy following some laparoscopic myomectomies, surgeons should discuss the risks and benefits of each option with patients, including possible risk of uterine rupture, as well as provide information regarding their experience with laparoscopic suturing. While robotic assistance may alleviate these problems, there are currently little data to support this contention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Women who do not desire fertility",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hysterectomy is the definitive procedure for relief of symptoms and prevention of recurrent leiomyoma-related problems. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Hysterectomy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We suggest use of GnRH agonists prior to a potentially complicated hysterectomy (or myomectomy) if the surgeon feels reduction in",
"      <span class=\"nowrap\">",
"       uterine/myoma",
"      </span>",
"      volume will significantly facilitate the procedure or if there is significant anemia which has not responded to iron therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gonadotropin-releasing hormone agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with abnormal uterine bleeding related to leiomyomas who wish to undergo the least invasive procedure, we suggest a trial of placement of a levonorgestrel-releasing intrauterine contraception over other drug therapies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Medical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Levonorgestrel-releasing intrauterine system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several more invasive options, both surgical and using interventional radiology, are available to symptomatic women (bleeding, pain, pressure) who have completed childbearing but wish to retain their uterus. There is no high quality evidence to recommend one procedure over another. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Interventional radiology'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Since fertility and pregnancy outcome may be adversely affected after many of these procedures, we suggest not performing these procedures (other than myomectomy) for women wishing to optimize future pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/1\">",
"      Parker WH. Uterine myomas: management. Fertil Steril 2007; 88:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/2\">",
"      Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study: I. Outcomes of hysterectomy. Obstet Gynecol 1994; 83:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/3\">",
"      Lefebvre G, Vilos G, Allaire C, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can 2003; 25:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/4\">",
"      Alternatives to Hysterectomy in the Management of Leiomyomas. ACOG Practice Bulletin No. 96. American College of Obstetricians and Gynecologists. Obstet Gynecol 2008; 112: 201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/5\">",
"      Stewart EA. Uterine fibroids. Lancet 2001; 357:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/6\">",
"      Peddada SD, Laughlin SK, Miner K, et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci U S A 2008; 105:19887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/7\">",
"      Laughlin SK, Hartmann KE, Baird DD. Postpartum factors and natural fibroid regression. Am J Obstet Gynecol 2011; 204:496.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/8\">",
"      Viswanathan M, Hartmann K, McKoy N, et al. Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep) 2007; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/9\">",
"      Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. Obstet Gynecol 1994; 83:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/10\">",
"      Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006; :CD003855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/11\">",
"      Sener AB, Se&ccedil;kin NC, Ozmen S, et al. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril 1996; 65:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/12\">",
"      Polatti F, Viazzo F, Colleoni R, Nappi RE. Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. Maturitas 2000; 37:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/13\">",
"      Fedele L, Bianchi S, Raffaelli R, Zanconato G. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol 2000; 88:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/14\">",
"      Palomba S, Sena T, Morelli M, et al. Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2002; 102:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/15\">",
"      Friedman AJ, Barbieri RL, Doubilet PM, et al. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/16\">",
"      Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993; 76:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/17\">",
"      Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/18\">",
"      Wise LA, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004; 159:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/19\">",
"      Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003; 79:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/20\">",
"      Starczewski A, Iwanicki M. [Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids]. Ginekol Pol 2000; 71:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/21\">",
"      Magalh&atilde;es J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception 2007; 75:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/22\">",
"      Zapata LB, Whiteman MK, Tepper NK, et al. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010; 82:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/23\">",
"      Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol 2004; 24:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/24\">",
"      Minaguchi H, Wong JM, Snabes MC. Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature. J Reprod Med 2000; 45:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/25\">",
"      Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002; 99:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/26\">",
"      Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG 2002; 109:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/27\">",
"      Stovall TG, Muneyyirci-Delale O, Summitt RL Jr, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol 1995; 86:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/28\">",
"      Thomas EJ. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids. Br J Obstet Gynaecol 1996; 103 Suppl 14:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/29\">",
"      de Aloysio D, Altieri P, Pretolani G, et al. The combined effect of a GnRH analog in premenopause plus postmenopausal estrogen deficiency for the treatment of uterine leiomyomas in perimenopausal women. Gynecol Obstet Invest 1995; 39:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/30\">",
"      Felberbaum RE, Germer U, Ludwig M, et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod 1998; 13:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/31\">",
"      Gonzalez-Barcena D, Alvarez RB, Ochoa EP, et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 1997; 12:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/32\">",
"      Flierman PA, Obery&eacute; JJ, van der Hulst VP, de Blok S. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. BJOG 2005; 112:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/33\">",
"      Felberbaum RE, K&uuml;pker W, Krapp M, et al. Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide). Reprod Biomed Online 2001; 3:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/34\">",
"      Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004; 103:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/35\">",
"      Fiscella K, Eisinger SH, Meldrum S, et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006; 108:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/36\">",
"      Carbonell Esteve JL, Acosta R, Heredia B, et al. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008; 112:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/37\">",
"      Engman M, Granberg S, Williams AR, et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 2009; 24:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/38\">",
"      Bagaria M, Suneja A, Vaid NB, et al. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol 2009; 49:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/39\">",
"      Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/40\">",
"      Wilkens J, Williams AR, Chwalisz K, et al. Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Hum Reprod 2009; 24:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/41\">",
"      Eisinger SH, Bonfiglio T, Fiscella K, et al. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005; 12:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/42\">",
"      Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993; 76:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/43\">",
"      Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008; 111:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/44\">",
"      Wilkens J, Chwalisz K, Han C, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008; 93:4664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/45\">",
"      Hodgen GD. Antiprogestins: the political chemistry of RU486. Fertil Steril 1991; 56:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/46\">",
"      Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/47\">",
"      Donnez J, Tomaszewski J, V&aacute;zquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/48\">",
"      Stewart EA. Uterine fibroids and evidence-based medicine--not an oxymoron. N Engl J Med 2012; 366:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/49\">",
"      Palomba S, Sammartino A, Di Carlo C, et al. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril 2001; 76:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/50\">",
"      Palomba S, Russo T, Orio F Jr, et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod 2002; 17:3213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/51\">",
"      Palomba S, Orio F Jr, Morelli M, et al. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 2002; 87:3603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/52\">",
"      Jirecek S, Lee A, Pavo I, et al. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 2004; 81:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/53\">",
"      Lingxia X, Taixiang W, Xiaoyan C. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev 2007; :CD005287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/54\">",
"      Shozu M, Murakami K, Segawa T, et al. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil Steril 2003; 79:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/55\">",
"      Varelas FK, Papanicolaou AN, Vavatsi-Christaki N, et al. The effect of anastrazole on symptomatic uterine leiomyomata. Obstet Gynecol 2007; 110:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/56\">",
"      Hil&aacute;rio SG, Bozzini N, Borsari R, Baracat EC. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil Steril 2009; 91:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/57\">",
"      Parsanezhad ME, Azmoon M, Alborzi S, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril 2010; 93:192.",
"     </a>",
"    </li>",
"    <li>",
"     Lethaby, A, Farquhar, C, Cooke, I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000:CD000249.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/59\">",
"      Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010; 116:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/60\">",
"      M&auml;k&auml;r&auml;inen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol 1986; 93:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/61\">",
"      Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol 1986; 68:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/62\">",
"      Coutinho EM, Gon&ccedil;alves MT. Long-term treatment of leiomyomas with gestrinone. Fertil Steril 1989; 51:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/63\">",
"      Niu H, Simari RD, Zimmermann EM, Christman GM. Nonviral vector-mediated thymidine kinase gene transfer and ganciclovir treatment in leiomyoma cells. Obstet Gynecol 1998; 91:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/64\">",
"      Al-Hendy A, Lee EJ, Wang HQ, Copland JA. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol 2004; 191:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/65\">",
"      Lee BS, Stewart EA, Sahakian M, Nowak RA. Interferon-alpha is a potent inhibitor of basic fibroblast growth factor-stimulated cell proliferation in human uterine cells. Am J Reprod Immunol 1998; 40:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/66\">",
"      Minakuchi K, Kawamura N, Tsujimura A, Ogita S. Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon alfa treatment for hepatitis. Lancet 1999; 353:2127.",
"     </a>",
"    </li>",
"    <li>",
"     Management of Uterine Fibroids. Summary, Evidence Report/Technology Assessment: Number 34. AHRQ Publication No. 01-E051, January 2001. Agency for Healthcare Research and Quality, Rockville, MD. www.ahrq.gov/clinic/epcsums/utersumm.htm (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/68\">",
"      Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004; 104:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/69\">",
"      Bocca S, Stadtmauer L, Oehninger S. Uncomplicated full term pregnancy after da Vinci-assisted laparoscopic myomectomy. Reprod Biomed Online 2007; 14:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/70\">",
"      L&ouml;nnerfors C, Persson J. Pregnancy following robot-assisted laparoscopic myomectomy in women with deep intramural myomas. Acta Obstet Gynecol Scand 2011; 90:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/71\">",
"      El-Nashar SA, Hopkins MR, Creedon DJ, et al. Prediction of treatment outcomes after global endometrial ablation. Obstet Gynecol 2009; 113:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/72\">",
"      Derman SG, Rehnstrom J, Neuwirth RS. The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol 1991; 77:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/73\">",
"      Goldfarb HA. Laparoscopic coagulation of myoma (myolysis). Obstet Gynecol Clin North Am 1995; 22:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/74\">",
"      Zupi E, Piredda A, Marconi D, et al. Directed laparoscopic cryomyolysis: a possible alternative to myomectomy and/or hysterectomy for symptomatic leiomyomas. Am J Obstet Gynecol 2004; 190:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/75\">",
"      Visvanathan D, Connell R, Hall-Craggs MA, et al. Interstitial laser photocoagulation for uterine myomas. Am J Obstet Gynecol 2002; 187:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/76\">",
"      Arcangeli S, Pasquarette MM. Gravid uterine rupture after myolysis. Obstet Gynecol 1997; 89:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/77\">",
"      Garza Leal JG, Hernandez Leon I, Castillo Saenz L, Lee BB. Laparoscopic ultrasound-guided radiofrequency volumetric thermal ablation of symptomatic uterine leiomyomas: feasibility study using the Halt 2000 Ablation System. J Minim Invasive Gynecol 2011; 18:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/78\">",
"      Hald K, Langebrekke A, Kl&oslash;w NE, et al. Laparoscopic occlusion of uterine vessels for the treatment of symptomatic fibroids: Initial experience and comparison to uterine artery embolization. Am J Obstet Gynecol 2004; 190:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/79\">",
"      Yen YK, Liu WM, Yuan CC, Ng HT. Laparoscopic bipolar coagulation of uterine vessels to treat symptomatic myomas in women with elevated Ca 125. J Am Assoc Gynecol Laparosc 2001; 8:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/80\">",
"      Lichtinger M, Hallson L, Calvo P, Adeboyejo G. Laparoscopic uterine artery occlusion for symptomatic leiomyomas. J Am Assoc Gynecol Laparosc 2002; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/81\">",
"      Lichtinger M, Herbert S, Memmolo A. Temporary, transvaginal occlusion of the uterine arteries: a feasibility and safety study. J Minim Invasive Gynecol 2005; 12:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/82\">",
"      Hald K, Kl&oslash;w NE, Qvigstad E, Istre O. Laparoscopic occlusion compared with embolization of uterine vessels: a randomized controlled trial. Obstet Gynecol 2007; 109:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/83\">",
"      Vilos GA, Vilos EC, Romano W, Abu-Rafea B. Temporary uterine artery occlusion for treatment of menorrhagia and uterine fibroids using an incisionless Doppler-guided transvaginal clamp: case report. Hum Reprod 2006; 21:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/84\">",
"      Gupta JK, Sinha AS, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev 2006; :CD005073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/85\">",
"      van der Kooij SM, Bipat S, Hehenkamp WJ, et al. Uterine artery embolization versus surgery in the treatment of symptomatic fibroids: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 205:317.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/86\">",
"      Spies JB, Bruno J, Czeyda-Pommersheim F, et al. Long-term outcome of uterine artery embolization of leiomyomata. Obstet Gynecol 2005; 106:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/87\">",
"      Marret H, Cottier JP, Alonso AM, et al. Predictive factors for fibroids recurrence after uterine artery embolisation. BJOG 2005; 112:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/88\">",
"      Edwards RD, Moss JG, Lumsden MA, et al. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med 2007; 356:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/89\">",
"      Stewart EA, Gedroyc WM, Tempany CM, et al. Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. Am J Obstet Gynecol 2003; 189:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/90\">",
"      Hindley J, Gedroyc WM, Regan L, et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol 2004; 183:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/91\">",
"      Hesley GK, Felmlee JP, Gebhart JB, et al. Noninvasive treatment of uterine fibroids: early Mayo Clinic experience with magnetic resonance imaging-guided focused ultrasound. Mayo Clin Proc 2006; 81:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/92\">",
"      Smart OC, Hindley JT, Regan L, Gedroyc WG. Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol 2006; 108:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/93\">",
"      Hesley GK, Gorny KR, Henrichsen TL, et al. A clinical review of focused ultrasound ablation with magnetic resonance guidance: an option for treating uterine fibroids. Ultrasound Q 2008; 24:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/94\">",
"      Yoon SW, Lee C, Cha SH, et al. Patient selection guidelines in MR-guided focused ultrasound surgery of uterine fibroids: a pictorial guide to relevant findings in screening pelvic MRI. Eur Radiol 2008; 18:2997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/95\">",
"      Taran FA, Weaver AL, Coddington CC, Stewart EA. Understanding adenomyosis: a case control study. Fertil Steril 2010; 94:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/96\">",
"      Funaki K, Fukunishi H, Sawada K. Clinical outcomes of magnetic resonance-guided focused ultrasound surgery for uterine myomas: 24-month follow-up. Ultrasound Obstet Gynecol 2009; 34:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/97\">",
"      Stewart EA, Rabinovici J, Tempany CM, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006; 85:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/98\">",
"      Fennessy FM, Tempany CM, McDannold NJ, et al. Uterine leiomyomas: MR imaging-guided focused ultrasound surgery--results of different treatment protocols. Radiology 2007; 243:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/99\">",
"      Stewart EA, Gostout B, Rabinovici J, et al. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol 2007; 110:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/100\">",
"      Gorny KR, Woodrum DA, Brown DL, et al. Magnetic resonance-guided focused ultrasound of uterine leiomyomas: review of a 12-month outcome of 130 clinical patients. J Vasc Interv Radiol 2011; 22:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/101\">",
"      Kim HS, Baik JH, Pham LD, Jacobs MA. MR-guided high-intensity focused ultrasound treatment for symptomatic uterine leiomyomata: long-term outcomes. Acad Radiol 2011; 18:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/102\">",
"      O'Sullivan AK, Thompson D, Chu P, et al. Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids. Int J Technol Assess Health Care 2009; 25:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/103\">",
"      Zowall H, Cairns JA, Brewer C, et al. Cost-effectiveness of magnetic resonance-guided focused ultrasound surgery for treatment of uterine fibroids. BJOG 2008; 115:653.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nice.org.uk/nicemedia/live/11349/57237/57237.pdf. (Accessed on January 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/105\">",
"      Gavrilova-Jordan LP, Rose CH, Traynor KD, et al. Successful term pregnancy following MR-guided focused ultrasound treatment of uterine leiomyoma. J Perinatol 2007; 27:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/106\">",
"      Morita Y, Ito N, Ohashi H. Pregnancy following MR-guided focused ultrasound surgery for a uterine fibroid. Int J Gynaecol Obstet 2007; 99:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/107\">",
"      Rabinovici J, Inbar Y, Eylon SC, et al. Pregnancy and live birth after focused ultrasound surgery for symptomatic focal adenomyosis: a case report. Hum Reprod 2006; 21:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/108\">",
"      Hanstede MM, Tempany CM, Stewart EA. Focused ultrasound surgery of intramural leiomyomas may facilitate fertility: a case report. Fertil Steril 2007; 88:497.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/14/18666/abstract/109\">",
"      Rabinovici J, David M, Fukunishi H, et al. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil Steril 2010; 93:199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5478 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18666=[""].join("\n");
var outline_f18_14_18666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXPECTANT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hormonal therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Levonorgestrel-releasing intrauterine system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Progestin implants, injections, and pills",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Gonadotropin-releasing hormone agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gonadotropin-releasing hormone antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Antiprogestins and progesterone receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24356551\">",
"      Mifepristone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24356925\">",
"      Ulipristal acetate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Raloxifene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antifibrinolytic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12332980\">",
"      Danazol and gestrinone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Myomectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Myolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Uterine artery occlusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      INTERVENTIONAL RADIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Uterine artery embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Magnetic resonance guided focused ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Asymptomatic women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Submucosal leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Women who desire fertility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Women who do not desire fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=related_link\">",
"      Abdominal myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=related_link\">",
"      An overview of endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=related_link\">",
"      Differentiating uterine leiomyomas (fibroids) from uterine sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25143?source=related_link\">",
"      Histology and pathogenesis of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=related_link\">",
"      Hysteroscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=related_link\">",
"      Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/21/2386?source=related_link\">",
"      Patient information: Uterine artery embolization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=related_link\">",
"      Patient information: Uterine fibroids (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=related_link\">",
"      Prolapsed uterine leiomyoma (fibroid)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=related_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=related_link\">",
"      Techniques to reduce blood loss during abdominal or laparoscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=related_link\">",
"      Uterine leiomyoma (fibroid) embolization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_14_18667="Slit lamp materials";
var content_f18_14_18667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Materials and equipment that facilitate the SLE and their uses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Item",
"       </td>",
"       <td class=\"subtitle1\">",
"        Function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluorescein strip*",
"       </td>",
"       <td>",
"        Identification of corneal epithelial defect (small amount) or micro perforation (Seidel test)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anesthetic drops*",
"       </td>",
"       <td>",
"        Corneal anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cotton tipped applicator*",
"       </td>",
"       <td>",
"        Movement of lids, lid eversion, FB or contact lens removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cotton pledgette",
"       </td>",
"       <td>",
"        Removal of tight fitting contact lens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burr drill",
"       </td>",
"       <td>",
"        FB removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18G needle",
"       </td>",
"       <td>",
"        FB removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gauze or tissue*",
"       </td>",
"       <td>",
"        Wiping tears, secretions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eye rinse solution*",
"       </td>",
"       <td>",
"        Rinsing fluorescein, eye irrigation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contact lens removal device",
"       </td>",
"       <td>",
"        Contact lens removal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Have available for every SLE.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18667=[""].join("\n");
var outline_f18_14_18667=null;
var title_f18_14_18668="Vulnerable elders surv 13 scale";
var content_f18_14_18668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The Vulnerable Elders Survey (VES) 13 scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Domain",
"      </td>",
"      <td class=\"subtitle1\">",
"       Score",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       75-85",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &gt;85",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Self-rated health",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Good, very good, and excellent",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fair and poor",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Activities of daily living (ADL)/instrumental activities of daily living (IADL)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"2\" rowspan=\"1\">",
"       Needs assistance with",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Bathing or showering",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Shopping",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Money management",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Transfer",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Light housework",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Difficulty in special activities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Kneeling, bending, and stooping",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Performance of housework (example: scrubbing the floor)",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Reaching out and lifting upper extremities above the shoulder",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lifting and carrying 10 pounds",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Walking 1/4 of a mile",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Writing or handling and grasping small objects",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Score &ge;3: Vulnerable elderly",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001; 49:1691.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18668=[""].join("\n");
var outline_f18_14_18668=null;
var title_f18_14_18669="Tracheomalacia FV loop";
var content_f18_14_18669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flow-volume loop classic for tracheomalacia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 352px; background-image: url(data:image/gif;base64,R0lGODlhLgFgAdUAAP///wAAAAAzmf9/f7/M5T9msn+ZzN/l8r+/v5+y2H9/fz8/P/+/v/9fX+/v78/Pz8/Y6+/y+A8PDy9ZrA8/n09PT2+MxU9yuG9vb9/f3x9Mpff4+19/v6+/3+fr9S8vL5+fn6+vrx8fH/+fn4+l0o+Pj/8/P/9vb19fX//f3//Pz/9PT/+Pj//v7/8fHwATOf8AAP8vLwAGEwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAuAWABAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVAAgKGUMOJQsLIEUOGAsVIZanqFIZGBIBCEIOHwEoCqBECwEYsq+pvb5HDwutvCUBCggPRRkBIgAgs0eYCtPTv9aRuLy4rQElRAgBC5fh0dTTAdfpjdlC2Q8BEt/k4OJM6Or4iOwAKAGmAegcIMiwrNkzFE3u5VsYKIMCEbNAgftQIdc4BQBw6XKVkKHHP8E8LcAgJESFBRgBBAMlipSpjh9jplMos2YqmjZzUsKps+cj/54+gyoCKrRoIaJGkwJCqrTpHqZOo9qBKrVqHKpWs7LBqrXrGa5ew4oBK7ZsF7Jm02JBq7btFLZu4zqBK7duErp28xLBq1cv3752/wKWK3iw28KG1SJObHYxY7GOH3uNLFkr5cpWL2OWqnmz086elYIObXQ0aaGmT/tMrVon69Y2X8OWKXv2x9q2GeLOnW83b3W+f18LLvwX8eK9jiNHpXy5pebOHUmjBj06o+nnrKetrv1n97LcvzMKL35o+cnnu5JPb2g9e0Lu3wuKL39pfc73o9LPz2c/fz3+/YdHgAJOVWBpBxZFYIJyLMggHA4+6EaEEm5VoWsX5kRhhmhsyP+hGR5+SEaIIo5V4m12JWDAigYQcACLBiQAwIswGkYiIQUIoKMALe4oQAEAEOCjADbalSMBQwgJZJI/EmFBARYIMAEBGgggIwRVSglBBBdcMCOU+NWV4wQFFACBkBSUKSOaZVoAQI4cXCCABgZQQAEAELSYgABediCABRNQEEGYco1Z5pkCpFnAmom2+SaRQhrwKAARcJDlkgboiCShcR3J5JJCKElEjkHyOKmcHQDQJACZCrCpfka6yqSiboo6BKmRnvonB036CSgFB3Dq1pMQDAFBmY4e6+YQT+K5KADNclmAAVBy6eUBYMJ6om7bctttPi8kkIAHQog7brnikgv/gLnqsovuueum+2678sYLr7v20ntvvfj2y++/+was78DzFpyvwf4KjDDABB/ssCUyHHDABkJIPHHFElM8Y8YYX7yxxxZrHHLHInP8cckgmzzyySS3zPLLK8es8swp14zyzS7LbHPONON8yo3fbgF00FkMTfQVRh9dRdJKv9V0IAgg4MARAiUz19N+PMCNBC8N8QxAH0xtTxYREGD22WeLcYDZJeISQgjkENGKKN3AdIWQQ+7YRI479rgjkHjrTcKOEwzKt6ZrZDsYBgF8wLgtQtAzTj1FYKdAYYHnvbcAHKxo9pwrMkrnivESMIEAJDzauQHBDrF2BCSQMCilJBiQ/yqeSG45Y+23E2AACcGWfUAHLeIpJQGz9+XA1lZHPk/clZtzeRaZD7k5CWaXfbyLpU5JQLHMoq4660VkqsGYeFKgwelujumqn+e7ymsBdq6d6I4EHP6qXhBxAo884pDc2LBQPR9tDn+Zk1TmQBUBOxmuAKcTAPiEkCkk8QoCvOoAle6UIw1GQAOCwh2ffIc6IXEAAIOT1KoG04oHvCMeKwHA3BjnjQHeLW96Y0KOsIc8IXkvWD40G/ggEKgJCiFKkhpCBVnlqhwhC0ikEsIKhXQ+NeUqVysEzNfgIRFjOAMgjRPbEjCHQx1t7lVB/F6pQBUkO2GvWBzoQAdOJyMluv8qAqeLQJRSFwEZRREARUShD4N1piuaSkqUMoxAeAEAgWiikch4AhnLeEYm/W2No/IRkCiwoxMSoVU6klEEDsdBIgkBSzuCQAI4qSPsmSpXfNtfdCaJwyacKXllO1uxymbEQgoxVNwrnwA02LqKsQ13RThTMc0WPO4JD5jioaXm4rBErAmhMLlEW9ri8DprXtObNwEnc8T5M3I+x5yVYBo6kaDOdRqhne7cSzwjAc95AqCe88RnPPXpTn6u05/oBKhwQIALeFSAkWoQaG4eIAvHKQADEKmAGDtkzywo4AMIdYYEMgqiimIhBBMdggvXoFDeCMQBD8jEhDyaBbhloBX/H1gpS6+ggAWA43LNS+hMafqByzmAIxbaaRXewYx35DQNJeVNJx5QggrIVKiHSCpsHvDIBkFVCpcrhVXxUEZZvcchEBEBBqoa1Dt0VZbsMQlAPtGG+JwVCdqMwNrORki0HSCbaqSUihKQPMBwAiKUQ2oe3nqEIZGwb4/q2wKFcDr0qSFXHkFADXXK1TKiVYquyl6mOMDMR/HQft4rlp+8hCoiqCh/HJhdAsqUuhcRoAMyOsCTLpCqA3CgABwoloo60CU4/iiJ+HAIWQVbWRxeVlU8Il2mpkU+OK3IfmniQLAyJSnqZpIDUfJSlCwgJ1dysgANpIABbnsACkygTqVc/9+cADknNqYDHBz9ymAtiwTrgVJWh3MVBqmFSOta91amPB0A1LeiHwlpWYOr4wEG17kjRVHAkM0HfNs6X+PW15QUNBWAL2vGwblpj5kUAqlAFzrIVpOJq2NdFHGlYWtIrx/x7Whx83ZcM9qRuUjyFAUvwF8gHWBOVBJAMR9FgMGRlkcEOK2GIXC8BFyAyRPQoAWOZUoW03Y4YARjjMsQHxh5echEsHGGEatjAHQgSxdQbZU0UEcAVwm8lOIAJ8Ub4TnqSFJ2lhK2qsznO7lYeiota0/+yB+pWoHQZQEpMI4q46s+4aIZBcFGSepoKDC0cRh4aERD2uhKO4GgAJHAQf8p7Ok+WM7QQTt1qQeB6qe1WjUO4LSgV60EcFQABMOlLK2XkIGCNi7X8t21E4oBVEoLWwkZQAFMMSDrTh/bCOAQgQKaHexnUy0Eyg4HsJ1t7egNg9TdLgJRmcFscANgAOG+xAdKwGhdnzvddFBICk4AbxBA5APtrvYA6B3uaAtDAtQe0RAGgO5wXxQWxdY1wdNdAhFoAhz55vLAC97tl4IxpuBeeLofgIKRBFzgQtA4vK8y8W5fLssA2TLIz03xYxNUJCKJ+MpF/uyBzOEeKWhAy49tjAm/4R4DYMDOhd3zhAcV3UPfddFV3tGcv1sSXoYRmCvm5XVJnVVSVxGL1gT/o+OOoZt/QHnKKRz0p0eCsEWoXmIRZ9j8Aum+wEXDifsgdqNTtOBJZwTaiWArEXsVs0fIUXVbXATcygnOVKaAm1abAA7IyABrTlWdtPSmOM0JAqicwLIQhPdJ7H1WjjLUknSErFkNCpQFAPOciPenAU8pg+Zb1J44u6LBkaAD5lWV4uV0gT07XjRPz/siPh+qRoFJ9Jgtvd+T+FoC8L4IqzJwe09X4E3lKHlOpB+Rov/2v3M+5J6nrxH6TuQwY7j4IZyREPzk3iZFgE9MvgBdqymn2R0AVWnjPhO9jqHOS4L4mARgZGImyFUEVQJcBRA/wwR9dHI6qXI6ncNj1eQn/+c1LfBjABagAaoyekBiZKmTFAHQAg0Afv8nfsmkONDyRMVSJnxXAGk2BLzlgrcTZhpwAQVwO7BTJrm1WhNEALf1ZEFyWwWQOtkCJpUyLaLBACxAgmdngmqQRZ4RAAzAAEwICQBoBigYhVNYhSM3IVtodl3ohVQIhmG4FV+IbiMgfGU4BlI4hkhHcVMYh2vIhmfIACZAcQ0Qh3nIACowh1/QhiGHdEKQhkOQAlNIb3zoh0JzhuhGbwMwgiy3cOjWAPymiGvBiO9GcQVHiSswACNAiJaINJgoiABgh0PAAHkoBDoHiaH4Fl94AiuQiVwIADoXdA1whwNgAmPYinPBAv9jqAJ9qAKd2AKoiAQNkIcFl3O7yItjxAAtUAQqAIsr4ItLkIYjAAA5lwLWllIK0G4hoAAlsG3vdAQr0IePSHAEd41IMAInoAIpoIZXBTciABFdIwSM8wESIAHiKE9GsInLWIvoGJCPqHO4KJABqY4zJQsu1DhE8FPxUAwkYUNE4H9OsIUmoIonYJCgOFMAcU00ITkCVAQnV3ckWZImeZIomZIquZIs2ZIu+ZIwGZMkGVjxdg8dOQQgCT1KwBOaCAVbWHAjwIoTmQQIQJNPJQdFSQdJeQdz45BE8A4xBTdOJZFCoIuzqAQ/eZVk+A1GaW5xsJRI2ZVx0A/ngBA3BQD/9FgRkLOTR0CRTZCVWwkAJoCQ0CaWxjYHYPmVdvkGDlARASBRF6ESsiABEUmVJAiPRBCUVOiWA1dre0lcePmYaZCXkgAUjKkEubiYV6mGlHmUeqmUkjkUfQgA7niYTzAAMaCZccmZocltb9CZbgCbP8FvGWmaThB0xHiRtNiWzHhPnshyVXmNd3ibTJh0iNmF6PCGjRmXvPl0DUCXy8mLyYmOQ/CczNmPABCUWnmcofEANhcNTHcUValzQ3mcj2h2xsmdmBELYJQSIsU8jnAPF9lyb6iNmFmKurmaxXE5zHaTQ1ARb/OX8bmKwKmK6PaFSUCKm1kccCMBxYAQe2GT/+0EdFV4oCzwjEmwAuQZnUNZHL62lvckofEZiGAYdEqoc/Y5kQPgAsuon8LRDyGAAC0UoR45ouDXAClqiJ04Aqiojml4nlZ5bifAAkNHc7lRESXgABDhQmwFoFJpo+8mdEegc6hIcPkpl1RoipSIncWhNWBEEmfppfAgc/CxnMKXd7rodAAAA6PZocgRNWLjSDgZnmUaciN4nlPaokKgoUGqp9fphzRxmUJQpQF5btCJBOo5coGqlf1oik2QqPBGE7SZokpgiJWoBEHamzRhnSqgnubZm0OAE5t4qIj6qKD6TUSwoce5oUsAqZHajwp6n6Z6qpb5p3baBNZJq7yJi/+yygSu+qr9qI4mSqnZ+ZuzqqvNaYioKIcqcKVIoALOKKWnek9IcALOeIpTOIKXmgQZyQIsQKzMSBSdqqcMsAIuYKTQaK2ZiqxtmZH0uYS0SKpC0I7TWgRUAZC56KZcWq+hagXoKJTvKJT8WhjaOah+Oq2IAZCpyK/8yLAm4rAPC7Fg8GpKQ7FHY7FEg7FBo7HfwrHd4rHbArInIrIlQrIiYrIPomoSqwUqu7JegLIcArMZIrMXQrMVYrMSgrMPorMMwrMJ4rMHArQFIrQCQrT/YbSF5rJ/qLQvy7Rn4bRcgLT5IbX3QbX1YbXygbXvobXswbXp4bXnAbblIbbRBLX/QmO2WkC236G23cG22uG21gG3s4S2RUO3a2G3SIO3ViC3zsG3y+G3yAG4xSG4wkG4v2G4vIG4uaG4tsG4s+G4ZdEJKBFSLaFVdiOxjFMBFQGhQ6ARu3C5EIsLJWBrRFAQX8S5bJkIcAoLkWQEo/AFNZUM3ilGBFWPYeGdUaMSrZCPE5WTXTmSYKQIaikEzzBZt0AZZ5kRCVcBAGcWvgYAEAkRqOu7qPAMGIcLmmASC1BDuAAADvEK3wsAtVBTIPAAmis2CHAS5XYLzdAOCbcM7qkYAdGRjmS6B5EKrUAQAiqVjEMS3XuWZwk2rSACsoAQ/Cugm+BF7ptRC4BxbYELvZr7PBjhuXY3CYwDjv4AABUxNfiovIEZwOJwOa9ADhUxDRAhD4y0D0MwPW7REts7NTFUubZbCe8wj/HgwR78v14EwuLLEeSAC+aAwp1rdCz8bLJgEdBrDE/avS9UU15EDiJ8T+JQDAeFbaVbN+5LC4FWAe37bF9TVazwl1PTvQDAOCJAllLcwyNcDw8BEFM5BCJAOb7GEcuDunrrNRmMBJezj3YrDO32DPF7x4I8yIRcyIZ8yIicyIq8yEobBAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Maximal expiratory flow declines rapidly after a sharp peak associated with the collapse of central airways as a result of negative transmural pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carl O'Donnell.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18669=[""].join("\n");
var outline_f18_14_18669=null;
var title_f18_14_18670="Nasal CPAP in nocturnal asthma";
var content_f18_14_18670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Nasal CPAP improves PEFR in nocturnal asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 226px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with nocturnal asthma studied before (blue columns), during (red columns), and after (green columns) nasal continuous positive airway pressure. Nasal CPAP led to a statistically significant increase in peak expiratory flow rate (PEFR) in the morning and evening, and before and after bronchodilators.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Chan CS, Woolcock AJ, Sullivan CE, Am Rev Respir Dis 1988; 137:1502.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18670=[""].join("\n");
var outline_f18_14_18670=null;
var title_f18_14_18671="Baumann angle";
var content_f18_14_18671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anteroposterior radiograph angles of the elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Baumann's angle (&alpha;).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow region: General concepts in the pediatric patient. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_14_18671=[""].join("\n");
var outline_f18_14_18671=null;
